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Summary 
 
Across the developing world peste des petits ruminants virus (PPRV) places a huge 
disease burden on small ruminant agriculture. PPR is mainly controlled by 
vaccinating animals with live attenuated vaccines. However, the current PPR 
vaccines and companion serological tests do not enable serological differentiation 
between naturally infected and vaccinated animals (DIVA), therefore a meaningful 
serological assessment of vaccine coverage and epidemiological surveillance is not 
possible. Therefore, the main objective of this PhD study was to establish a reverse 
genetics system for PPRV, so that a marker vaccine could be developed to enable the 
serological differentiation between vaccination and infection, alongside developing 
proof of concept for increasing the valency of the existing vaccines. 
 
Initially, as a prerequisite to full genome synthesis the full genome sequence for a 
PPRV vaccine strain was confirmed. An efficient reverse genetics system for the 
PPRV Nigeria75/1 vaccine strain was established in this study and 3 recombinant 
PPRVs were rescued including a faithful clone of the vaccine strain (rPPRV 
Nigeria75/1), a clone expressing GFP as a heterologous protein (rPPRV+GFP 
Nigeria75/1) and a negatively marked vaccine containing mutations to the 
haemagglutinin (H) gene (rPPRV-C77 Nigeria75/1). All 3 rescued viruses showed 
similar growth characteristics in vitro when compared to the parental vaccine strain 
and, following in vivo assessment the H mutant provided full protection in goats 
upon virulent virus challenge. Although the mutations made to H abrogated in vitro 
binding of C77, the mutations made were not sufficient to enable DIVA in vivo. 
 
Finally proof of concept was developed for the segmentation of PPRV and 
expression of heterologous proteins in an effort to generate a multivalent vaccine. A 
recombinant two-segmented version of PPRV was successfully rescued that 
expressed GFP from one segment and the bluetongue virus VP2 from the other. This 
virus was partially characterised in vitro and demonstrates the potential for this 
approach in the development of multivalent vaccines for small ruminants. 
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Chapter 1 General introduction 
1.1 Background information 
Peste des petits ruminants (PPR) is also known as ‘goat plague’, ‘Kata’, ‘syndrome 
of stomatitis-pneumoenteritis’ or ‘ovine rinderpest’. PPR is an important infectious 
viral disease of domestic and wild small ruminants that threatens the food security 
and sustainable livelihood of farmers across Africa, the Middle East and Asia 
(Banyard et al., 2010; Dhar et al., 2002; Libeau et al., 2014; Parida et al., 2007). 
PPR is emerging in new regions of the world and is causing great economic losses 
(Perry et al., 2002; Singh et al., 2014; Stem, 1993). The causative agent, peste des 
petits ruminants virus (PPRV) belongs to the family Paramyxoviridae, genus 
Morbillivirus alongside other important viral pathogens such as rinderpest virus 
(RPV), measles virus (MV) and canine distemper virus (CDV). The live attenuated 
PPRV vaccine strains Nigeria 75/1 and Sungri 96 have been used successfully in the 
field for decades (Diallo et al., 2007; Sen et al., 2010). The commercially available 
diagnostic ELISAs are targeted against the nucleoprotein (N) and haemagglutinin 
(H) proteins and detect antibodies in vaccinated as well as naturally infected animals. 
No tools currently exist that allow serological Differentiation between Infected and 
Vaccinated Animals (DIVA). To this end, marker vaccines are a potential solution to 
the DIVA concept that may play an important role in the reduction of PPRV in 
endemic regions. 
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1.2 Taxonomy 
PPRV belongs to the genus Morbillivirus, sub family Paramyxovirinae, family 
Paramyxoviridae, and order Mononegavirales. A detailed classification including 
other members of the order is provided in Table 1.1. 
 
Table 1.1 Classification of the order Mononegavirales  
Order Family Subfamily Genus 
Mononegavirales Bornaviridae  Bornavirus 
Filoviridae  Cuevavirus 
Ebolavirus 
Marburgvirus 
Nyamiviridae  Nyavirus 
Rhabdoviridae  Cytorhabdovirus 
Ephemerovirus 
Lyssavirus 
Novirhabdovirus 
Nucleorhabdovirus 
Perhabdovirus 
Sigmavirus 
Sprivivirus 
Tibrovirus 
Tupavirus 
Vesiculovirus 
Paramyxoviridae Pneumovirinae Metapneumovirus 
Pneumovirus 
Paramyxovirinae Aquaparamyxovirus 
Avulavirus 
Ferlavirus 
Henipavirus 
Respirovirus 
Rubulavirus 
Morbillivirus 
 
The morbillivirus genus contains seven species including PPRV (Figure 1.1) with 
classification being based on the requirements of the International Classification and 
Taxonomy of Viruses (ICTV). 
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Figure 1.1 Un-rooted neighbour-joining tree showing the relationships between 
the different morbilliviruses. The phylogenetic tree was constructed using partial 
nucleoprotein gene sequences of 230 nucleotides (accession no NC_006383, peste 
des petits ruminants virus; NC_001498, measles virus; AB547189, rinderpest virus; 
NC_001921, canine distemper virus; KC802221, phocine distemper virus; 
JQ411016, Feline morbillivirus; AY949833, porpoise morbillivirus; NC_005283, 
dolphin morbillivirus and AF200818, pilot whale morbillivirus) with 1000 bootstrap 
replicates and the Kimura 2-parameter model in MEGA 5.2. The scale bar indicates 
nucleotide substitutions per site. Three virus strains, porpoise morbillivirus, dolphin 
morbillivirus, and pilot whale morbillivirus have been isolated from cetaceans are 
considered part of the species cetacean morbillivirus. 
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Three well characterised strains porpoise morbillivirus (PMV), dolphin morbillivirus 
(DMV) and pilot whale morbillivirus (PWMV) are considered part of the species 
cetacean morbillivirus (CMV) were isolated from different marine mammals. 
(Barrett et al., 1993b; Taubenberger et al., 2000). Historically measles virus (MV) 
and rinderpest (RPV) have been recorded for centuries as the cause of severe 
epidemics in humans or cattle, respectively, although the latter has been successfully 
controlled and globally eradicated. Canine distemper virus (CDV) was initially 
thought to be restricted to the infection of dogs although the virus has since been 
recorded in a number of terrestrial carnivore species including tigers, lions, hyena 
and non-human primates alongside infection of aquatic mammals (Buczkowski et 
al., 2014). Recently, a completely new morbillivirus, feline morbillivirus (FmoPV), 
has been reported in domestic cats (Woo et al., 2012). 
 
Morbilliviruses are largely characterised at the molecular level through studies with 
the prototype virus, MV and to some extent CDV and RPV. PPRV is largely 
unexplored for virus replication and transcription. However, the morbilliviruses are 
known to be conserved across genus and family sharing similar characteristics. The 
description of PPRV in the sections below are generalised for morbilliviruses or 
paramyxoviruses with the inclusion of specific literature available to PPRV. 
 
1.3 Virology 
1.3.1 Virus structure 
The viral genome for all members of the Mononegavirales consists of a single-strand 
of non-segmented negative-sense RNA encapsidated by N as a helical nucleocapsid. 
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The N-RNA complex, along with the RNA-dependent RNA polymerase (RdRP, 
large polymerase; L) and the co-factor phosphoprotein (P) forms a complex as 
ribonucleoprotein (RNP) complex (Figure 1.2). RNPs are contained within the virus 
envelope and appear as helical structures with a ‘herring-bone’ appearance. During 
the viral budding process, the viral envelope is derived from the infected cell 
membrane and is embedded with protruding viral fusion (F) and H glycoproteins 
(Figure 1.2). The matrix (M) protein is located on the inner surface of the envelope 
and bridges the RNPs and cytoplasmic tails of the membrane glycoproteins. 
Structurally, the morbilliviruses are pleomorphic (200-700 nm) enveloped particles 
as determined using negative-stain electron microscopy (EM) (Plowright et al., 
1962). No good EM structure for PPR virion is available to determine its structure 
and size. Morbillivirus particles contain more than one RNP and are therefore 
functionally polyploid in nature (Rager et al., 2002). 
  
26 
 
 
Figure 1.2 A schematic diagram of the PPR virion structure. The PPRV 
glycoproteins (F and H proteins) are embedded within the viral envelope. The M 
protein lines the inner surface of virus envelope. The ribonucleoprotein complex is 
composed of N, P and L proteins in association with the RNA genome. 
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1.3.2 PPRV genome organisation 
The PPRV genome is a non-segmented, single-stranded, negative-sense RNA 
molecule of 15,948 nucleotides in length (Bailey et al., 2005). The genome length of 
PPRV conforms to the ‘rule of six’ (multiple of six) like several other 
paramyxoviruses (Calain and Roux, 1993), as required for efficient genome 
replication and virus propagation (Bailey et al., 2007) assuming that each N protein 
is bound to six nucleotides of genome or anti-genome RNA to form the RNP 
complex. The genome organisation of PPRV is presented in Figure 1.3. 
 
The PPRV genome consists of six transcriptional units located in the order 3’ N, P, 
M, F, H and L 5’ that encode for the corresponding six structural proteins, N, P, M, 
F, H and L (Bailey et al., 2005; Chard et al., 2008) and two additional non-structural 
proteins, C and V that are translated via alternative mechanisms from the P mRNA 
(Mahapatra et al., 2003). A breakdown of the PPRV genome sequence and its 
component parts, including their position and length, is presented in Table 1.2. 
Transcriptional units are separated from each other by an intergenic (IG) 
trinucleotide sequence that for the morbilliviruses consist of the sequence, CTT. The 
region upstream of the IG region includes a polyadenylation signal for the upstream 
gene and the sequence after the IG region marks the 5’ transcriptional start site of the 
next transcriptional unit. The IG trinucleotides are not transcribed during the 
transcription of individual genes but are incorporated by the RdRP into the positive 
strand replicative intermediate during the replicative stage of the viral life cycle. 
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Figure 1.3 A schematic representation of the PPRV genome organisation. The 
PPRV genome is a non-segmented, single-stranded negative sense RNA molecule. 
The genome consists of six transcriptional units (encoding the nucleoprotein (N), 
phosphoprotein (P), matrix (M), fusion (F), hemagglutinin (H) and large/ polymerase 
(L) proteins) that are flanked by a 3’ genome promoter (GP) and a 5’ anti-genome 
promoter (AGP). The P transcriptional unit also encodes for additional C and V non-
structural proteins. The V protein is produced by co-transcriptional P mRNA editing 
by insertion of a non-template G residue and the C protein is produced from the 
alternative reading frame in P mRNA by leaky scanning during translation. 
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A 3’ leader and a 5’ trailer terminal sequence are present at the genome termini. 
These are largely complementary over the first 20 nucleotides and contain conserved 
binding sites for the RdRP. As such these short untranslated regions play an 
important role as regulatory elements in replication, transcription and packaging of 
RNA genome during virus propagation (Bailey et al., 2007). For RPV, mutations 
introduced into the 3’ genome promoter region greatly affected the promoter activity 
in a minigenome assay (Mioulet et al., 2001) and exchange of the genome promoter 
(GP) and anti-genome promoter (AGP) regions between virulent and avirulent 
strains of recombinant RPV affected the replicative ability of the virus with a 
virulent strain of RPV containing vaccine GP and AGP being strongly attenuated 
(Banyard et al., 2005). 
 
Untranslated regions between transcriptional units can be of a variable length. In 
particular the 3’ untranslated region (UTR) of the M gene (444 nucleotides) and 5’ 
UTR of the F gene (633 nucleotides) are considerably longer in length than the other 
UTRs in the viral genome. The UTR between the M and F genes is rich in GC 
nucleotides (68 - 72%). Generally, between isolates the PPRV genome is relatively 
conserved with a maximum divergence reported of 12% at the nucleotide level and 
7% at the amino acid sequence level. 
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Table 1.2 The genome organisation of PPRV  
Sequence 
components 
Nucleotide 
Position 
on 
genome 
Total 
length 
5’UTR CDS 3’UTR Intergenic 
region, 
nucleotide 
Protein 
Size, 
amino 
acid 
Deduced 
MW, 
KDa 
Leader 1-52 52 NA NA NA (CTT) NA NA 
N mRNA 55-1744 1689 52 1578 59 CTT 525 58  
P mRNA 1748-3402 1655 59 1530 66 CTT 509 55  
V (P) mRNA 1748-3402 1656 59 897 700 CTT 298 31  
C (P) mRNA 1748-3402 1655 81 534 1040 CTT 177 20 
M mRNA 3406-4888 1484 32 1008 444 CTT 335 38 
F mRNA 4892-7302 2410 633 1641 136 CTT 546 59  
H mRNA 7306-9262 1957 20 1830 107 CTT 609 69  
L mRNA 9266-
15908 
6643 22 6552 69 (CTA) 2183 247  
Trailer 15912-
15948 
37 NA NA NA NA NA NA  
 
* CDS, coding sequence; UTR, untranslated region; ORF, open reading frame; NA, not applicable. 
 
1.3.3 PPRV entry, replication cycle and packaging 
The replication cycles of all paramyxoviruses are similar and the first step is the 
attachment of the virus to a cell surface and membrane fusion to release a genome 
into a cell cytoplasm in a pH-independent manner (Figure 1.4). Like other 
morbilliviruses, PPRV has an established lymphatic and epithelial tropism (Birch et 
al., 2013; Couacy-Hymann et al., 2007b). The H protein is responsible for the 
attachment of a virus to the cell surface through the recognition of host cell receptor 
molecules such as sialic acid, immune cell marker signalling lymphocyte activation 
molecule (SLAM)/ CD150 (Adombi et al., 2011; Seki et al., 2003) or the recently 
reported epithelial cell receptor Nectin-4 (Birch et al., 2013). 
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Figure 1.4 A schematic replication of life cycle of a morbillivirus. Adapted from 
(Moss and Griffin, 2006). The first step in virus infection is the attachment of a 
virion to a host cell surface receptor which leads to the fusion of viral and cellular 
membrane. The negative sense RNA genome is released into the cell cytoplasm and 
transcription initiates to produce viral gene transcripts. Later, following the 
production of viral proteins a switch to a replicative mode occurs that results in the 
production of a positive sense anti-genome RNA, a replicative intermediate which as 
a template for the generation of nascent genome RNA. The viral transcripts are 
translated using host cell translational machinery and later viral components are 
assembled and budded in to new virion. 
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For binding to SLAM, an interaction between the V domain of SLAM and the β-
sheet 5 quartet of the H protein leads to conformational changes in the H protein 
(Navaratnarajah et al., 2008). The H protein conformational change upon receptor 
binding triggers the F protein to initiate membrane fusion. It has been postulated that 
the morbillivirus H and F proteins are associated (the H dimer with the F1-F2 trimer) 
prior to receptor attachment thus preventing premature fusion by the F protein. 
Attachment of the H protein to receptors creates a scaffold and later activates the F 
protein to function and drive fusion of the viral envelope with the host cell 
membrane and release the RNP complex into the cell cytoplasm (Ludwig et al., 
2008; Plemper et al., 2002). Morbilliviruses replicate exclusively in the cytoplasm of 
host cells although it is not clear whether replication occurs diffusely throughout the 
cell cytoplasm or whether there are dedicated intracellular sites within cytoplasm 
where replication occurs (Duprex et al., 1999). The genomes of morbilliviruses are 
never found as naked RNA and are always bound to N protein to form helical RNP 
complex, an interaction that confers resistance to host cell RNases. The RNP consists 
of the negative sense (–) genome or a positive sense anti-genome (+) RNA. The RNP 
complex containing the RNA, with the N, P and L proteins makes up the minimal 
replicative unit of these viruses that is required for the initiation of the transcription 
and replication processes. The L protein contains RdRP activity and with the co-
factor P protein, functions in both transcription and replication of the genome. The 
RdRP uses the RNP as a template and cannot act on naked RNA (Rozenblatt et al., 
1979). The interaction of the RdRP with RNA is mediated by the P protein which 
has both L and P binding sites (Kingston et al., 2004; Longhi et al., 2003). A viral 
genome as a negative sense RNP is released into the cell cytoplasm following fusion 
of the viral and cellular membrane and is acted upon by viral polymerase complex 
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that enters at GP and transcribes the viral genes (Horikami and Moyer, 1991). 
During the transcriptional mode, it is not clear whether the RdRP always produces a 
3’ leader (52 nucleotide) sequence or whether it directly transcribes the capped 
mRNA of the N gene. As the polymerase reaches the IG regions it may fall off the 
template or continue to transcribe the next gene. If the polymerase detaches from the 
template it can only reinitiate at the GP and as such a transcriptional gradient is 
produced whereby the 3’ proximal genes are produced in abundance with a reduction 
in gene expression along the genome (Rennick et al., 2007). Thus, the fine control in 
producing required relative amounts of each viral protein is achieved through the 
transcriptional gradient. The viral mRNAs produced are 5’ methylated and 3’ poly-
adenylated by the viral polymerase and are translated by host cell translation 
machinery (Banerjee, 1987). 
 
Post-translational modification of the viral glycoproteins (H and F) is carried out on 
the endoplasmic reticulum (ER) as proteins are transported to the cell membrane via 
the Golgi apparatus. At a later stage following infection, the polymerase switches 
from a transcriptive to replicative state and its been hypothesised that the switch is 
mainly due to the accumulation of a sufficient intracellular concentration of the N 
and P proteins required for encapsidation of genomic RNA (Banerjee, 1987; Lamb 
and Kolakofsky, 2001). During the replication mode the signals of the gene start, IG 
and gene stop regions are ignored and a full-length anti-genome RNA is produced 
including a leader sequence. Later, to generate a nascent genome strand RNA, the 
polymerase enters the AGP in the newly synthesised positive sense anti-genome 
RNA template to produce genome RNA. Unlike the mRNA, the nascent genome or 
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anti-genome RNA molecules produced are not capped or polyadenylated and are 
immediately encapsidated by the N protein. 
 
Synthesis of nascent genomes and viral components to a sufficient amount in the 
host cell leads to the assembly and budding of virus particles. The interaction 
between the various viral components during transportation to the cell membrane for 
assembly and packaging into new virus particles is not well understood. The M 
protein is believed to play a role in the assembly of the viral RNA and protein 
components into a host cell membrane, and packaging, budding and release of new 
virion particles (Takimoto and Portner, 2004). The M protein interacts with both 
RNPs and the cytoplasmic domains of the glycoproteins at the plasma membrane 
and thus forms the bridge between them. The interaction between the M protein and 
glycoproteins is specific to each virus. Where studies have attempted to examine 
these interactions are requirement for homologous interactions have been reported. 
For example, a chimeric RPV with the glycoproteins replaced from PPRV was 
viable but grew to a low titre (Das et al., 2000) and it was found that the addition of 
the homologous M protein from PPRV improved the titre of the rescued virus 
(Mahapatra et al., 2006). Functionally, the M protein has been shown to inhibit RNA 
transcription and interact with the N protein to assemble into RNPs and transport to 
the cell membrane (Iwasaki et al., 2009; Runkler et al., 2007). 
 
1.3.4 PPRV proteins 
1.3.4.1 Nucleoprotein (N) 
The N gene is the first to be transcribed and being located at 3’ proximal end of the 
genome expresses the most abundantly produced mRNA. The N protein of PPRV is 
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525 amino acids in length (58 KDa) and consists of a conserved N-terminal 
structural core domain (NCORE) and a highly variable C-terminal domain (NTAIL) 
(Bodjo et al., 2008; Diallo et al., 1994). The primary function of the N protein is to 
encapsidate the genomic RNA to form a helical nucleocapsid structure, resistant to 
RNase degradation (Lamb and Kolakofsky, 2001). The nucleocapsid structure 
appears to be a ‘herringbone’ structure by negative-stain EM (Barrett et al., 1993a; 
Bodjo et al., 2008). 
 
Each N protein binds and encapsidates exactly six nucleotides of RNA (Calain and 
Roux, 1993; Kolakofsky et al., 1998) and therefore 2658 (=15948/6) N proteins are 
required per genome of PPRV for complete encapsidation. The large amount of N 
protein required for encapsidation is likely the reason for its 3’ terminal genome 
location. N protein monomers, aided by P (serving as a molecular chaperone) 
prevent N-N aggregates from self-assembling and this soluble form of N-P is the 
substrate for encapsidation of nascent RNA. The encapsidated RNA retains 
considerable conformational flexibility to allow transcription and replication (Figure 
1.5). The association of N and P is also essential for the functioning of the L protein 
in RNA synthesis in MV (Buchholz et al., 1994; Ryan and Portner, 1990). 
The N protein of the morbilliviruses is also highly antigenic in nature and induces an 
N protein specific immunity that does not confer protection (Lamb and Kolakofsky, 
2001). 
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Figure 1.5 The structural proteins of paramyxoviruses. Crystal structures of 
measles virus H (Hashiguchi et al., 2007) and parainfluenza virus 5 F (Yin et al., 
2006) proteins attached to cell membrane are shown as a space-filled model. The 
ribbon plot model (left side of H dimer) of a six-bladed β-propeller sheet H-protein 
head structure and location in the H protein of measles virus is shown at the top 
(Navaratnarajah et al., 2011). The M protein, located on the inner side of virus 
envelope, bridges with ribonucleoprotein complex containing the N, P and L proteins 
with the polymerase activity being shown below (Griffin and Oldstone, 2009). The 
figure has been generated with elements adapted from the various sources as cited 
within the caption. 
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1.3.4.2 Phosphoprotein (P) 
The P protein is encoded by the second gene and consists of 509 amino acids with a 
predicted size of 55 KDa. It is genetically the least conserved protein with short 
interspersed conserved domains (Barrett and Underwood, 1985). The P protein is 
heavily phosphorylated, in a process mediated by cellular kinases. The active form of 
P protein is a tetramer and it is a multi-functional protein which interacts with both 
the N and L protein as N-P and P-L complexes (Longhi et al. 2003; Kingston et al. 
2004). As described, P protein plays a chaperone role preventing excessive N protein 
self-assembly, maintaining its soluble state and helping in the formation of the 
nucleocapsid structure. The P protein acts as co-factor for the L protein in the 
progression of the RdRP complex on the RNA template during replication. 
 
1.3.4.3 Matrix (M) protein 
The M protein is 335 amino acids (38 KDa) in length and is the most conserved 
protein among PPRV isolates. The M protein is believed to be involved in assembly 
and transport of viral components to the apical surface of host cell membrane and 
budding of virions (Takimoto and Portner, 2004). Within the virion it is located on 
the inner surface of the virus envelope, where it interacts with the RNP and the 
cytoplasmic domains of H and F glycoproteins embedded in the envelope (Baron et 
al., 1994) (Figure 1.5). Recombinant viruses lacking the M protein are unable to 
assemble and bud efficiently reiterating its role in these elements of the viral life 
cycle (Pantua et al., 2006). Recently, the co-expression of the PPRV M, H and N 
proteins in Sf9 insect cells has been reported to enable generation of PPRV virus-like 
particles (Liu et al., 2014a; Liu et al., 2014b). 
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The extended UTR between the M and subsequent F gene described earlier is 
proposed to play a role in regulating translation by forming secondary structures in 
M and F mRNAs (Bailey et al., 2005; Dhar et al., 2006; Meyer and Diallo, 1995). A 
recombinant MV lacking the long M/F UTR demonstrated that the deleted region 
was not essential for viral replication, although its absence altered the viral 
phenotype (Takeda et al., 2005). In addition, the nine-nucleotide sequence in the 5’ 
UTR of PPRV F gene was found to be complementary to the 18S ribosomal RNA 
(Chulakasian et al., 2013). 
 
1.3.4.4 Fusion (F) protein 
The F protein consists of 456 amino acids and is a type I transmembrane 
glycoprotein/ fusion protein, and is responsible for virus-host cell fusion and infected 
cell-cell fusion. Fusion activation needs the synergistic effect of the H protein 
(Figure 1.5) (Lamb, 1993; Morrison, 2003). The F protein is synthesised as an 
inactive precursor polypeptide (F0) with a cleavable N-terminal 28 amino acid signal 
peptide. The signal peptide directs the transport of protein to the endoplasmic 
reticulum for trimerisation (Plemper at al., 2001). The F0 trimers are cleaved by 
cellular furin in the trans-Golgi at a conserved R-X-R/ K-R site (Chard et al., 2008). 
Cleavage results in the generation of large (F1) and small (F2) protein components 
that form an active heterodimer a linked by disulphide bonds. The un-cleaved F0 
trimers transported to the virus envelope may also be cleaved by extracellular host 
cell enzymes. The new N-terminus of the F1 protein (20-25 amino acids) is 
hydrophobic, and acts as a fusion peptide. This peptide is inserted into the target 
membrane during the fusion process. The C-terminal ends of the F1 and F2 peptides 
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have transmembrane domain functions in membrane anchoring (Meyer and Diallo, 
1995; Rahaman et al., 2003).  
 
1.3.4.5 Haemagglutinin (H) protein 
The H protein consists of 609 amino acids and is a type II glycoprotein, where the C-
terminus of the H protein extends outside the cell membrane and the N-terminal 
transmembrane domain extends towards the cytoplasmic milieu. Unlike other 
morbillivirus H proteins, the PPRV H displays both haemagglutination activity 
(agglutination of erythrocytes) and neuraminidase activity (cleaves sialic acid 
residues from the carbohydrate moieties of glycoproteins) (Dhar et al., 2006; Seth 
and Shaila, 2001) and as such is often termed the HN protein. The MV H protein 
shows haemagglutination activity but lacks neuraminidase activity (Varsanyi et al., 
1984) whilst the RPV H protein lacks both haemagglutination and neuraminidase 
activity (Langedijk et al., 1997). 
 
The H protein displays a high degree of antigenic variability among the 
morbilliviruses due to immunological pressure as it carries B cell epitopes that 
generate neutralising antibodies (Renukaradhya et al., 2002). The cell surface 
receptor, SLAM (CD150), binding site was mapped for the H protein of PPRV 
(Vongpunsawad et al., 2004). The crystal structure of the MV H protein has been 
determined (Hashiguchi et al., 2007) and has shown that each monomer of a dimer 
of H protein exhibits a six-bladed β-propeller head structure and a connecting 
membrane stalk (Figure 1.5). The H protein binding to the receptor molecule 
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transmits the fusion-triggering signal to the F protein to initiate membrane fusion for 
MV entry (Navaratnarajah et al., 2011). 
 
1.3.4.6 Large (L) / polymerase protein 
The L protein is the largest PPRV protein (247 KDa) and is encoded by a gene 
(2,183 amino acids) located at the 5’ proximal end of the genome. The L gene 
accounts for 40% of the total genome length. The L protein is the least abundant 
protein produced as it is required in catalytic amounts due to its polymerase 
enzymatic activity. The L protein, and its RdRP activity, is essential in both the 
replication and transcription of genes including the capping and polyadenylation of 
viral mRNAs (Hammond et al., 1992; Hercyk et al., 1988; Horikami et al., 1992). 
The P protein is an essential co-factor of the L protein during polymerase activity. L 
protein sequences and their different functions are highly conserved across the 
paramyxoviruses with clearly identified protein domains (McIlhatton et al., 1997). 
The L protein consists of three large conserved domains connected by variable hinge 
regions (McIlhatton et al., 1997). The first N-terminal domain is involved in 
interactions with both the N and P proteins whilst the second domain carries out 
phosphodiester bond formation during polymerase activity. Finally the third domain 
has an ATP binding function facilitating kinase activity (Blumberg et al., 1988). 
Studies have shown that the green fluorescent protein (GFP) ORF can be inserted 
into the second variable hinge region of the L protein of recombinant MV, CDV and 
RPV without significantly disrupting the function of the L protein (Brown et al., 
2005; Duprex et al., 2002). These recombinant viruses were used to study virus 
pathogenesis and suggested inclusion of a heterologous protein into the L ORF as a 
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means of functional attenuation of these viruses (Brown et al., 2005; Duprex et al., 
2002; Silin et al., 2007). 
 
1.3.4.7 Non-structural V and C proteins 
The C and V proteins are non-structural or accessory proteins produced from the P 
ORF by alternative translational and transcriptional mechanisms (Figure 1.3). The V 
protein is encoded from an overlapping ORF within the P mRNA. The P mRNA 
transcription initiates normally and at position 751, a pseudo-template addition of 
one G nucleotide residue occurs due to viral RdRP slippage at the editing site 
complex. During translation, this leads to frame shift downstream of the mRNA 
editing site to produce the V protein of 298 amino acids (Mahapatra et al., 2003). An 
identical RNA editing mechanism has been reported in other morbilliviruses (Barrett 
et al., 1993a; Cattaneo et al., 1989) and although less frequent, the generation of V 
transcripts accounts for one third of the total mRNA generated from the P gene start 
codon in MV (Cattaneo et al., 1989). The V/ P proteins share identical amino-
terminus sequences but have a different C-terminal region due to the frame shift. 
Surprisingly, the common V/ P N-terminus is poorly conserved whereas the 
carboxyl-terminal region of V protein is highly conserved and rich in cysteine 
residues with zinc binding motifs (Mahapatra et al., 2003). 
 
The C protein is encoded by the P mRNA through utilisation of an alternative 
reading frame (+1); beginning 23 nucleotides downstream of the P protein start 
codon (Figure 1.3). The C protein is produced by leaky ribosomal scanning of P 
mRNA during the translational process. The C protein of PPRV consists of 177 
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amino acids and has a molecular weight of 20 KDa (smaller than V protein). C is the 
least conserved protein across all of the morbilliviruses. 
 
The V and C proteins of morbillivirus have been reported to act as virulence factors 
modulating the host cell innate immune response (Patterson et al., 2000). The V and 
C proteins are also required for normal virus propagation as they regulate 
transcription and replication during virus infection. The V protein of RPV has been 
reported to interact with both the N and L proteins, and is therefore involved in both 
transcription and replication (Sweetman et al., 2001). A recombinant knockout RPV 
that lacked the expression of either V or C proteins individually or in tandem had 
impaired growth in vitro in B95a cells (Baron and Barrett, 2000). The V knockout 
RPV had an increased level of genome and anti-genome synthesis that led to change 
in cytopathic effect (CPE) to a more syncytium-forming phenotype (Baron and 
Barrett, 2000). The C knockout RPV was attenuated with a measurable reduction in 
viral mRNA synthesis. RPV lacking both V and C protein expression had a 
cumulative effect with severe growth defects (Baron and Barrett, 2000). Similarly, a 
C and V deficient wild-type MV was found to be attenuated in monkeys (Devaux et 
al., 2008). Overall, paramyxovirus accessory proteins are involved in the modulation 
of the host cell mediated immune response generally through limiting the cellular 
interferon (IFN) response (section 1.7). A recent study with PPRV demonstrated that 
the V protein blocks type I IFN action and partially blocks type II INF action 
(Chinnakannan et al., 2013). 
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1.4 Disease  
1.4.1 Clinical signs 
Goats and sheep are the primary host for PPRV. Goats are more susceptible to 
disease than sheep (Nanda et al., 1996). As described in the OIE (world organisation 
for animal health/ Office International des Epizooties) manual (OIE, 2012), the 
incubation period is typically 4 to 6 days although it may range between 3 and 10 
days. At the acute stage of disease, animals show pyrexia up to 41°C lasting for 3 to 
5 days, depression, anorexia and dryness in the muzzle. Watery nasal and lachrymal 
discharges gradually become mucopurulent with excessive salivation. Erosive 
lesions formed in the oral cavity may become necrotic. In the later stage of infection, 
animals develop diarrhoea, coughing with laboured abdominal breathing. The 
disease condition may last for 14 days before recovery from infection or leads to 
death during the acute stage of infection. The morbidity rate can reach 100% with a 
high case fatality with the acute form of disease. The above described clinical signs 
and mortality can vary considerably depending on the virulence of virus (OIE, 2012). 
 
1.4.2 Pathogenesis 
PPRV pathogenesis is poorly understood and knowledge has been gained mainly by 
comparison with closely related RPV (Brown and Torres, 1994; Wohlsein et al., 
1993). The study of pathogenesis of PPRV has mainly been described through the 
experimental infection of small ruminants with a virulent virus to develop a reliable 
and reproducible animal model (Alcigir et al., 1996; Baron et al., 2014a; Bundza et 
al., 1988; El Harrak et al., 2012; Hammouchi et al., 2012; Pawaiya et al., 2004; Pope 
et al., 2013; Truong et al., 2014). Histological investigation during early infection 
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showed immune cell driven spread of PPRV similar to that seen with other 
morbilliviruses (Pope et al., 2013). The initial site for virus replication was observed 
within the tonsillar tissue and lymph nodes draining the site of inoculation. It has 
been proposed that the virus infected immune cells within the respiratory mucosa 
migrate to the local lymphoid tissue where primary virus amplification occurs and 
from which virus enters the general circulation. Clinical signs usually develop at 3-4 
days post infection (dpi) with pyrexia and anorexia. Anorexia results from the 
presence of lesions in the buccal cavity, tongue and dental jaws which make 
mastication uncomfortable. Leucopoenia is often observed from 4 dpi with a 
considerable reduction of CD4+ T cells (Baron et al., 2014a; Herbert et al., 2014). 
Disease progresses with lacrimal, nasal and mucosal discharges with live virus being 
detected in those excretions as early as 4 dpi. Viral antigens were also observed by 
histochemical staining in lymphoid organs, the respiratory and the gastrointestinal 
tracts (Kumar et al., 2004; Pope et al., 2013). Histopathological assessment of 
infected tissues observed a large number of syncytia in lymphoid tissue between 5 
and 7 dpi that later become necrotic. In the later stage of infection, erosive lesions 
that become necrotic are seen in the oral cavity. The severity of clinical signs peaks 
between 6 and 8 dpi and signs continue for a maximum of 14 days before death or 
recovery from infection. Three visible forms (severe, mild and subclinical) of PPR 
are seen depending on the virulence of the infecting virus and several other 
predisposing factors such as nutritional state of the animal and the presence of 
secondary infections. However, despite the differentiation of PPRV isolates into 
genetically distinct lineages, no lineage specific differences in the pathogenicity of 
the virus were observed following experimental infection (Baron et al., 2014a). 
Goats are considered to be more susceptible to disease with similar pattern of 
45 
 
pathological signs compared to sheep (Truong et al., 2014) and even specific breeds 
of goats may be more susceptible than others (Couacy-Hymann et al., 2007a). 
 
1.5 Epidemiology 
1.5.1 Origin and distribution 
The first report of PPR was made in 1942 in the Ivory Coast (Gargadennec and 
Lalanne, 1942) based on the observation that a disease of small ruminants was not 
transmissible to in-contact cattle. After three decades, the causative agent of PPR 
disease was defined as a distinct viral entity (Gibbs et al., 1979). Before 1942, it is 
likely that PPR would had been confused with rinderpest as they show similar 
clinical symptoms and several reports of epidemic rinderpest-like disease in small-
ruminants in Senegal and French Guinea were published between 1871 and 1927 
(Diallo, 1988). Contrastingly, infections of rinderpest with an absence of clinical 
disease in sheep and goats are well documented in the same regions of Africa 
(Rossiter et al., 1983). The evolution of PPRV and its relationship with RPV has 
been dissected out recently using molecular phylogenetic analysis of virus genome 
sequence data. Bayesian phylogenetic studies found that the RPV is more closely 
related to MV than to PPRV (Furuse et al., 2010; Pomeroy et al., 2008). The origin 
of ancestral PPRV and its relation to other morbilliviruses and evolutionary changes 
are investigated further in this PhD study. 
 
After the first recognition of PPR in Ivory Coast increased awareness led to further 
reports in neighbouring countries in the order, Senegal, Chad, Togo, Benin, Ghana, 
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Nigeria, Oman, Sudan, Saudi Arabia, India, Jordan, Israel, Ethiopia, Kenya, Uganda 
and Pakistan (Sen et al., 2010). This appears to be the geographic spread of disease 
from West Africa to East Africa, and then to the Middle East and Asia. PPRV is 
considered to be endemic across Africa, the Middle East and Asia (Banyard et al., 
2010; Dhar et al., 2002; Kwiatek et al., 2011). 
 
In recent years PPRV has extended its boundaries southwards in Africa as far as 
southern Tanzania (2008) and the Democratic Republic of Congo and Angola 
(2012). PPR outbreaks have also been reported across North Africa including within 
Tunisia (2006), Morocco (2008) and Algeria (2011). Alongside this, within Europe, 
Turkey reported approximately twenty laboratory confirmed PPR outbreaks in sheep 
and goats during 2011-2012. In southwest Asia, the virus spread to Tibet (2007) and 
has recently been reported all over China (2013-2014) (FAO, 2013). 
 
The molecular epidemiology of PPR, based on the sequence comparison of a small 
322 nucleotide (nt) region of the F gene (Forsyth and Barrett, 1995), 255 nt of the N 
gene (Couacy-Hymann et al., 2002) or 298 nt of the H gene (Senthil Kumar et al., 
2014) has defined the existence of four distinct lineages (I-IV) of PPRV (Banyard et 
al., 2010; Dhar et al., 2002; Kwiatek et al., 2011; Shaila et al., 1996). The 
nomenclature of lineages I and II are slightly different for the N and F gene and is 
historically reversed depending on the assay used (lineage II of F gene named as 
lineage I of N gene). However, recently a comparison has been made between the F, 
N and H gene phylogenetic analyses and the partial N gene sequence was shown to 
be a more accurate predictor of viral diversity due to sequence variability across the 
region examined (Senthil Kumar et al., 2014). 
47 
 
Historically, lineages I-III were found in Africa and numbered according to apparent 
spread of virus from West Africa (I and II) to East Africa (III). Lineage IV was 
mainly restricted to the Middle East and Asia with a few exceptions of Lineage III in 
Yemen and Oman and mixed lineages of III and IV in UAE and Qatar. However, 
lineage IV has now established its presence all across the PPR endemic areas with 
frequent outbreaks in Africa (Kwiatek et al., 2011). PPRV lineages circulating in 
Africa (Table 1.3) and the Middle East and Asia (Table 1.4) are shown in Figure 1.6. 
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Table 1.3 Lineages of PPRV circulating in different countries of Africa, based 
on partial N/F gene sequence analysis (taken from Parida et al., 2015). 
Country 
Year of first 
report 
Lineage 
Year of confirmation of 
outbreak through 
sequencing 
NCBI 
submission 
Algeria 2010 IV 2010 Yes 
Angola 2012 IV 2012 No 
Benin 1972 NA NA No 
Burkina Faso NA 
I 1988 Yes 
II 1999 No 
Cameroon NA IV 1997 Yes 
Central African 
Republic 
NA IV 2004 Yes 
Chad 1971 II 1993 No 
Comoros 2010 NA NA No 
Congo NA IV 2006 No 
Democratic 
Republic of the 
Congo 
2012 IV 2012 No 
Egypt 1987 IV 2009, 2010, 2012 Yes 
Eritrea NA IV 2002, 2003, 2005, 2011 Yes 
Ethiopia 1994 
III 1994, 1996 Yes 
IV 2010 Yes 
Gabon NA IV 2011 Yes 
Ghana NA II 1976, 1978, 2010 Yes 
Guinea NA I 1988, 1991 Yes 
Guinea Bissau NA I 1989 Yes 
Ivory Coast 1942 I 1989 Yes 
Kenya 2006 III 2006 Yes 
Libya NA NA NA No 
Mali NA II 1999 Yes 
Mauritania NA II 2012 Yes 
Morocco 2008 IV 2008 Yes 
Niger NA II 2012 No 
Nigeria 1967 
II 
1975, 1976, 2010, 2012, 
2013 
Yes 
IV 
2008, 2009, 2010, 2012, 
2013 
Yes 
Senegal 1955 
I 1964, 1994 Yes 
II 2010, 2013 Yes 
Sierra Leone 2008 II 2009 Yes 
Somalia 2006 III NA No 
Sudan 1971 
III 1971, 1972, 2000 Yes 
IV 2000, 2005, 2008, 2009 Yes 
Tanzania 2008 III 2010, 2011, 2013 Yes 
Togo 1972 NA NA No 
Tunisia NA IV 2012, 2013 Yes 
Uganda 1995 
III 2007 No 
IV 2007, 2008 Yes 
Western Sahara NA IV 2010 No 
 
*Lineages of isolates of PPRV were named by following the classification of lineages based on partial N 
gene sequence phylogenetic analysis; NA, not available. 
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Table 1.4 Lineages of PPRV circulating in different countries of the Middle East and 
Asia, based on partial N/F gene sequence analysis (taken from Parida et al., 2015).  
Country 
Year of first 
report 
Lineage* 
Year of confirmation of PPR 
outbreak through sequencing 
NCBI 
submission 
Turkey 1996 IV 1996,2000, 2006, 2007, 2008, 
2009, 2010, 2011 
Yes 
Iraq  1998  IV 2011, 2012, 2013 Yes 
Iran 1995 IV 1998, 2010, 2011, 2012 Yes 
Saudi Arabia 1980 IV 1999, 2004 Yes 
Israel  1993  IV 1993, 1995,1998, Yes 
Jordan  NA IV NA No 
Kuwait 1999 IV 1999 No 
Oman  1978 III 1983, 1987 Yes 
Yemen 2002 III 2001, 2009 No 
Qatar NA III  
IV 
2010 
2010 
Yes 
Yes 
UAE 1983 III 
IV 
1986 
NA 
Yes 
No 
Lebanon 2006 NA NA No 
Afghanistan 1995 NA NA No 
Kazakhstan 1997 NA NA No 
Tajikistan  2004  NA 2004 Yes 
India 1987 IV 1994, 1995, 1996, 1998, 1999, 
2004, 2002, 2001, 2003, 2005, 
2007, 2008, 2012 
Yes 
Pakistan 1991 IV 1994, 2005, 2006, 2007, 2008, 
2009, 2010, 2012,  
Yes 
Bangladesh  1993  IV 2000, 2008, 2009, 2010, 2011, 
2012 
Yes 
Nepal 1995 IV 1995, 2009 Yes 
China 2007 IV 2007, 2008, 2014 Yes 
Bhutan 2010 IV 2010 Yes 
Vietnam 2007 Serology NA No 
 
* Lineages of isolates of PPRV were named by following the classification of lineages based on partial 
N gene sequence phylogenetic analysis; NA, not available. 
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Figure 1.6 The global spread of PPRV from its first detection in 1942 to 2014. 
(a) depicts global distribution of PPRV from 1942 to 2009, taken from (FAO, 2009) 
and (b) depicts recent circulations of PPRV including lineage distribution in Africa 
and was drawn using smart draw software (USA). 
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1.5.2 Host range 
Sheep and goats are the primary hosts for PPRV with a few reports of disease 
outbreaks in camels (Khalafalla et al., 2010; Kwiatek et al., 2011; Roger et al., 2001; 
Saeed et al., 2004) . Cattle (Anderson and McKay, 1994; Lembo et al., 2013; Sen et 
al., 2014), buffalo (Govindarajan et al., 1997) and pigs (Nawathe and Taylor, 1979) 
develop subclinical infection with PPRV and are not thought to be capable of 
excreting virus and contributing to the disease epidemiology. The infection of 
wildlife, mainly living under semi-free range conditions, has also been reported 
(detailed in Table 1.5). The exact role of wildlife animals in the epidemiology of 
PPR disease remains to be clarified. 
 
Infected animals can transmit PPRV to close in-contact susceptible animals through 
exhaled aerosols, particularly during coughing, or through clinical excretions 
(lachrymal, nasal, saliva and faeces). PPRV is temperature labile and readily 
inactivated outside its host in a dry environment (Rossiter and Taylor, 1994). 
Infected and recovered animals develop life-long protective immunity with no carrier 
state (Hamdy et al., 1976). However, virus can spread in animals as a mild virulent 
form that can later lead to severe disease where transmission occurs to naive 
susceptible populations of small ruminants (Couacy-Hymann et al., 2007a).Other 
host factors like age, sex, breed and season may also play a role in disease outbreaks. 
Sheep and goats are the natural host for PPRV. More frequent outbreaks have been 
reported in goats than in sheep populations suggests that goats are more susceptible 
than sheep to an acute form of the disease (Lefevre and Diallo, 1990). The greater 
susceptibility to infection seen in goat breeds needs to be further investigated. 
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Table 1.5 Reported PPR infections in wildlife species 
Common name Latin name 
Mode of 
detection 
Country Reference 
White-tailed deer 
Odocoileus 
virginianus  
Clinical 
USA (experimental 
infection) 
(Hamdy and 
Dardiri, 1976) 
Laristan sheep Ovis gmelini Clinical 
Al Ain , Arabian 
Gulf 
(Furley et al., 
1987) 
Gemsbok  Oryx gazella  Clinical 
Al Ain , Arabian 
Gulf 
(Furley et al., 
1987) 
Dorcas gazelles Gazella dorcas Clinical 
Al Ain , Arabian 
Gulf 
(Furley et al., 
1987) 
Nubian Ibex Capra nubiana Clinical 
Al Ain , Arabian 
Gulf 
(Furley et al., 
1987) 
African Grey dukier Sylvicapra grimma Serology  Nigeria 
(Ogunsanmi et 
al., 2003) 
Thompson’s gazelle Eudorcas thomsonii Clinical Saudi Arabia 
(Al-Afaleq et al., 
2004) 
Arabian oryx Oryx leukoryx Serology 
 Saudi Arabia and 
UAE 
(Frolich et al., 
2005) 
Bubal hartebeests 
Alcelaphus 
buselaphus 
Serology Ivory Coast 
(Couacy-Hymann 
et al., 2005) 
Buffaloes  Syncerus caffer Serology Ivory Coast 
(Couacy-Hymann 
et al., 2005) 
Defassa waterbuck Kobus defassa Serology Ivory Coast 
(Couacy-Hymann 
et al., 2005) 
Kobs  Kobus kob   Serology Ivory Coast 
(Couacy-Hymann 
et al., 2005) 
Arabian mountain 
gazelles 
Gazella gazella cora 
 Clinical, 
serology and 
genome 
UAE 
(Kinne et al., 
2010) 
Springbuck  
Antidorcas 
marsupialis  
Clinical, 
serology and 
genome 
UAE 
(Kinne et al., 
2010) 
Arabian gazelles Gazella gazelle 
Clinical, 
serology and 
genome 
UAE 
(Kinne et al., 
2010) 
Barbary sheep Ammotragus lervia 
Clinical, 
serology and 
genome 
UAE 
(Kinne et al., 
2010) 
Bushbucks  
Tragelaphus scriptus 
kinne 
Clinical, 
serology and 
genome 
UAE 
(Kinne et al., 
2010) 
Impala  
Aepyceros 
melampus 
Clinical, 
serology and 
genome 
UAE 
(Kinne et al., 
2010) 
Rheem gazelles 
Gazella 
subguttorosa marica 
Clinical, 
serology and 
genome 
UAE 
(Kinne et al., 
2010) 
Afghan Markhor 
goat 
Capra falconeri 
Clinical, 
serology and 
genome 
UAE 
(Kinne et al., 
2010) 
Persian gazelle 
Gazella 
subgutturosa 
Serology Turkey 
(Albayrak and 
Gur, 2010) 
Bharal Pseudois nayaur 
Clinical, 
serology and 
genome 
China (Bao et al., 2011) 
Sindh Ibex 
Capra aegagrus 
blythi 
Clinical, and 
serology 
Pakistan 
(Abubakar et al., 
2011) 
Wild goat Capra aegagrus 
Clinical and 
serology 
Kurdistan 
(Hoffmann et al., 
2012) 
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1.6 Disease diagnosis 
PPR can be confused with other diseases such as rinderpest, bluetongue and 
contagious caprine pleuropneumonia (CCPP) due to similarities in clinical signs. 
PPR identification also becomes complicated by secondary infection specifically due 
to pasteurella infection. Therefore, in addition to clinical observations in the field, 
PPR requires a laboratory based confirmatory test. The laboratory tests currently 
available for PPR diagnosis are grouped into three categories; i) those that detect 
antigen (virus isolation, antigen capture ELISA, lateral flow devices), ii) those that 
detect genetic material (RT-PCR, real-time PCR, LAMP PCR); and iii) those that 
detect antibodies (virus neutralisation test [VNT], competitive ELISA and indirect 
ELISAs). Laboratory test methods for the diagnosis of PPR that are recommended 
by OIE in the manual of diagnostic tests and vaccines for terrestrial animals are 
listed in Table 1.6. Regardless of the test applied, the efficiency of laboratory 
diagnosis is greatly influenced by the integrity of the sample received, with a number 
of factors affecting this during collection and transportation. 
 
The VNT is the OIE gold standard test for PPR diagnosis and is a time-consuming 
method. Competitive ELISA based on H and N proteins of PPRV for detection of 
antibodies and RT-PCR including real-time RT-PCR, are generally used in PPR 
diagnosis. Recently, immunochromatographic lateral flow devices have been 
developed as a pen-side test using a monoclonal antibody (mAb) C77, specific to the 
PPRV H protein (Bruning-Richardson et al., 2011) and validated in field conditions 
that could detect cases as early as 4 dpi, before onset of severe clinical signs (Baron 
et al., 2014b). 
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Table 1.6 OIE listed laboratory test methods available for the diagnosis of PPR  
Method 
Purpose 
Reference 
Populati
on 
freedom 
from 
infection 
Individual 
animal 
freedom 
from 
infection 
Confirmation 
of clinical 
cases 
Prevalence 
of infection-
surveillance 
Immune 
status in 
individual 
animals or 
populations 
post-
vaccination 
Competitive 
ELISA 
++ ++ - +++ +++ c-H ELISA (Anderson 
and 
McKay, 
1994; 
Saliki et 
al., 1993) 
c-N ELISA (Libeau et 
al., 1995) 
Virus 
neutralisation 
+++ +++ - +++ +++   
PCR - - +++ - - RT-PCR 
based on 
F gene 
(Forsyth 
and 
Barrett, 
1995) 
RT-PCR 
based on 
N gene 
(Couacy-
Hymann et 
al., 2002) 
Multiplex 
RT-PCR 
(Balamuru
gan et al., 
2006; 
George et 
al., 2006) 
LAMP (Li et al., 
2010) 
Real-time 
RT-PCR 
(qRT-
PCR) 
(Bao et al., 
2008; 
Batten et 
al., 2011; 
Kwiatek et 
al., 2010) 
Virus isolation in 
cell culture 
- - ++ - - Cells- 
Vero, 
B95a and 
the Vero 
expressing 
dog 
SLAM, 
CV1 
expressing 
goat 
SLAM  
(Adombi et 
al., 2011) 
Immuno-capture 
ELISA  
- - +++ - -  (Libeau et 
al., 1994) 
Agar gel 
immune-
diffusion 
- - + - +  (Durojaiye, 
1987) 
Counter 
immune-
electrophoresis 
 -  - +  -  -  (Majiyagb
e et al., 
1984) 
 
+++, recommended method; ++, suitable method; +, may be used in some situations, but cost, reliability, or other factors 
severely limits its application; -, not appropriate for the purpose. The table adapted from OIE manual (2012) by including 
references.  
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1.7 Immunology  
The immune response to morbillivirus infection involves both the innate and 
adaptive host immune system. Due to the lymphotropic nature of morbilliviruses, a 
profound immunosuppression is often seen following virus infection that allows 
opportunistic secondary infections to develop. The humoral immune response has 
been clearly defined following morbillivirus infection and more recent reports have 
detailed the role of cell-mediated immunity in response to infection. Host innate 
immune responses to virus infection are induced by the detection of pathogen-
associated molecular patterns (PAMPs) by cellular pattern recognition receptors 
(PRRs). A complex network of intracellular signalling pathways are activated and 
resulting in transcription of host defence genes, predominantly pro-inflammatory 
cytokines including IFNs. Several classes of viral PAMP have been identified and 
include dsRNA, uncapped ssRNA and viral proteins (Akira et al., 2006). The PRRs 
include toll-like receptor (TLRs) located at the plasma membrane and endosomal 
compartments. The PRRs located within the cytoplasm of infected cells include the 
retinoic acid-inducible gene I (RIG-I)-like receptor (RLR) family, melanoma 
differentiation-associated protein 5 (MDA5) and dsRNA-dependent protein kinase R 
(PKR). The IFNs elicit distinct antiviral effects and are grouped into three types (I, II 
and III) according to their amino acid sequence (Randall and Goodbourn, 2008). 
 
PPRV is highly lymphotropic, a factor that may leads to severe immunosuppression 
as described for other morbilliviruses (Pope et al., 2013; Rajak et al., 2005b). 
Virulent PPRV isolates cause marked immunosuppression, whereas the PPR vaccine 
induces only transient leukopenia without significantly affecting the immune 
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response (Rajak et al., 2005b). Due to the highly lymphotrophic nature of 
morbilliviruses, dendritic cells (DCs) and/or macrophages are the immune cells most 
commonly targeted by morbillivirus infection. DCs play a role in the transport of 
virus to bronchus-associated lymphoid tissue or local lymph nodes where the virus is 
amplified and subsequently disseminated following an increase in viral load that 
leads to viremia (Lemon et al., 2011). DCs express RIG-I and MDA5, which 
recognise virus and induce type I IFN production (Servet-Delprat et al., 2003). 
Paramyxovirus accessory proteins are involved in limiting IFN production by 
interfering with induction and signalling pathways. The paramyxovirus C protein has 
been shown to inhibit the synthesis of viral mRNA and dsRNA interacting with the 
L protein during the formation of polymerase complex (Curran et al., 1992), thereby 
preventing PKR mediated shut down of host cell protein synthesis (Gainey et al., 
2008). The paramyxovirus V protein has been found to interact with MDA-5 to 
block IFN induction pathway (Childs et al., 2007; Goodbourn and Randall, 2009). 
Morbilliviruses have adapted distinct mechanisms to block the IFN signalling 
pathways, reportedly targeting multiple components. All the morbillivirus V proteins 
can block type I IFN action and to varying abilities can block type II IFN action 
(Chinnakannan et al., 2013). The V protein of PPRV has been shown to inhibit the 
phosphorylation of STAT-1, STAT-2 and interferon-receptor-associated kinase Tyk2 
that are involved in IFN signalling pathways (Chinnakannan et al., 2013). Studies 
with the V protein of RPV showed that the N-terminal domain interacts with STAT-
1, whilst the C-terminal V-specific domain interacts with the IFN receptor associated 
kinase Jak1 and Tyk2 (Chinnakannan et al., 2014). A recombinant MV knockout for 
V protein that was unable to antagonise STAT-1 function and found to be attenuated 
in vivo (Devaux et al., 2011). 
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Virus transfer to T cells is also mediated by the DCs and leads to the induction of T 
cell silencing mechanisms. The H and F proteins of MV have been shown to 
interfere with the proliferation of T cells, causing cell cycle arrest by interfering with 
progression in the S-phase of the cell cycle without inducing apoptosis (Avota et al., 
2010; Engelking et al., 1999; Schlender et al., 1996). Blood from PPRV infected 
goats was analysed for specific immune cell sub-set count and it has been shown that 
no change in the proportion of WC1+ γ/δ T cells and CD14+ monocyte/ macrophage 
cells is seen. However, the CD4+ cells were found to decrease from 4 dpi and the 
CD8+ cells remained unchanged during the initial days and by 7 dpi the proportion of 
CD8+ had slightly increased, although the exact reason for this observation remains 
undefined (Herbert et al., 2014). 
 
The immunosuppressive effect of PPRV infection can have severe outcomes in the 
field depending on the nutritional status of the host and the presence of existing 
infections. In natural infection, immunocompromised animals are prone to secondary 
infections. Leukopenia is often observed from 4 dpi although depending on 
numerous factors the overall outcome of infection may not be sever and recovery 
may occur (Baron et al., 2014a; Herbert et al., 2014; Pope et al., 2013).  
 
From a vaccination perspective, the presence of maternal antibodies that neutralise 
PPRV have been detected in young animals for up to 3-4 months after birth (Libeau 
et al., 1992). Therefore, vaccination in new-borns is not necessary until 3-4 months 
of age (Bodjo et al., 2006). Animals vaccinated with attenuated strains or animals 
infected and recovered will develop protective immunity for life (Boer et al., 1975; 
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Diallo et al., 2007). Cell-mediated and humoral immune responses against PPRV are 
mainly directed against the H, F and N proteins (Sinnathamby et al., 2001). 
However, immunisation with PPRV glycoproteins (H and/or F) induces protective 
humoral immunity whilst anti-N antibodies are not able to neutralise virus (Diallo, 
2003; Sinnathamby et al., 2001). Interestingly, both B cell and T cell epitopes have 
been mapped to the N protein of PPRV (Choi et al., 2005; Mitra-Kaushik et al., 
2001) and a further study verified a B cell epitope at the C-terminus of the N protein 
(Dechamma et al., 2006). A B-cell epitope has also been mapped to the H protein of 
PPRV (Renukaradhya et al., 2002). The CD8+ T and not CD4+ cells were shown to 
be primed upon challenge with virulent PPRV in animals vaccinated with PPRV H 
protein (Herbert et al., 2014). 
 
1.8 Disease control 
Preventive measures employed in an uninfected area include the restriction of animal 
importation from disease-infected regions. Disease can be efficiently controlled by 
the isolation and slaughtering of infected animals, disinfection of the environment 
and the quarantine of infected animals. Prophylactic immunisation in suspected 
animal populations or areas is also recommended. Immunisation is carried out with 
the availability of excellent live attenuated vaccines that elicit protective immunity 
that is maintained for at least three years (Diallo et al., 2007). These vaccines are 
thermolabile and require maintenance of a cold storage chain in the hot tropical 
climate where PPR is endemic. The major obstacle to PPRV control is the 
requirement for frequent immunizations, at least every 3 years, due to the high 
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turnover of small ruminant populations. Vaccination in younger animals of 4 to 6 
months old is recommended (Balamurugan et al., 2012b). 
 
1.8.1 Live attenuated PPRV vaccine 
For many years, in the absence of a homologous vaccine, the ‘Tissue Culture 
Rinderpest Vaccine’ (TCRV) was used as a heterologous PPR vaccine. Its success 
was based on the cross reactivity of neutralising antibodies to the disease (Mariner et 
al., 1993). However the use of the TCRV was prohibited in 1996 by the Food and 
Agriculture Organization (FAO) to enable post-eradication sero-surveillance of any 
remaining circulating RPV. To attempt PPRV vaccine isolation, PPRV was initially 
grown on primary cultures of sheep liver cells (Gilbert and Monnier, 1962). Serial 
passage of PPRV in primary cell culture for attenuation was unsuccessful even after 
65 passages (Benazet, 1984). Later in 1989, Diallo et al. successfully obtained a 
highly attenuated PPRV isolate (Nigeria 75/1) following serial passage in Vero cells 
for 63 passages. The virus was found to have lost its pathogenicity and elicited 
protective immunity (Adu et al., 1990; Diallo et al., 1989). Similarly, at least three 
more vaccine strains Sungri 96, Arasur 87 and Coimbatore 97, were developed in 
India by 75 serial passages of PPRV in Vero cells (Sen et al., 2010; Singh et al., 
2010). Currently, Nigeria 75/1 (lineage II) and Sungri 96 (Lineage IV) are widely 
used in endemic areas for the vaccination of small ruminant populations. whereas 
Arasur 87 is only used regionally in India. Details of these three vaccines are 
provided in Table 1.7. Following further development the PPRV live attenuated 
vaccines were demonstrated to be potent, safe and efficient in inducing a protective 
immunity that is maintained for at least three years in goats and sheep following 
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inoculation of a single dose of vaccine (Diallo et al., 2007; Saravanan et al., 2010). 
The PPRV Nigeria 75/1 vaccine has also been found to protect against challenge by 
virulent virus by providing sterile immunity and thus prevents further spread of 
disease (Couacy-Hymann et al., 1995). These vaccines are manufactured in freeze-
dried form with various chemical stabilizers to make a thermostable product 
(Mariner et al., 1993; Worrall et al., 2000), a critical factor in Africa and Asia. 
 
Table 1.7 Characteristics of the live attenuated PPR vaccines.  
Parameters PPRV Nigeria 75/1 PPRV Sungri 96 PPRV Arasur 87 
Passage and origin LK-6, BK-2, Vero-63 
Nigeria. sheep 
B95a-10, Vero-59 
North India, Goat 
Vero 75 
South India, Sheep 
Complete CPE 3-6 days 3-6 days 2-3 days, rapid 
growing 
Safety in pregnancy Safe in pregnancy 
Lineage II  IV IV 
Usage Extensively used in 
several countries 
Extensively used in 
India (> 20million 
doses) 
Used in some states 
of India 
Virus sequence Full genome 
sequenced 
Full genome 
sequenced 
Not available 
 
1.8.2 Recombinant subunit vaccines 
Initial work carried out with a bivalent capripox virus (CPV) vaccine expressing the 
F and H proteins of RPV has been shown to protect goats against PPRV (Romero et 
al., 1995). CPV expressing the homologous PPRV proteins H (Diallo et al., 2002b) 
or F (Berhe et al., 2003b) were also shown to protect goats against PPRV infection 
and later this was confirmed in both goats and sheep (Chen et al., 2010). The 
concern about the effectiveness of CPV expressing PPRV F and H vaccine in sheep 
and goats with pre-existing immunity against either of the capripox or PPR viruses 
was addressed recently (Caufour et al., 2014). In this experiment, animals were 
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immunised with either with a capripox or a conventional PPR vaccine. These 
animals with pre-existing immunity were inoculated with a recombinant bivalent 
CPV expressing the PPRV F and H glycoproteins. After four weeks of immunisation 
with CPV expressing the F and H proteins, the animals were challenged with a 
virulent CPV strain followed by virulent PPRV three weeks later. Complete 
protection against CPV challenge in animals pre-immunised either with PPRV or the 
CPV vaccine was observed. Unfortunately, only partial protection was obtained 
against PPRV challenge in animals pre-immunised with the CPV expressing PPRV 
glycoproteins. This suggested a limited replication of CPV expressing PPRV F and 
H proteins in the presence of pre-existing antibodies against CPV. The low 
replication led to the poor expression of PPRV F and H proteins and eventually low 
level of antibody response produced against PPRV F and H proteins. 
 
A further subunit vaccine, a vaccinia virus vector (modified vaccinia Ankara) 
expressing PPRV F and H proteins, was also shown to protect goats against PPRV 
infection (Chandran et al., 2010). However, this vaccine required two doses to 
stimulate sufficient neutralising antibodies to protect against PPR, a regimen that is 
not feasible in a PPR disease control programme due to the increase in cost with the 
requirement for multiple vaccinations. Goats immunised with recombinant fowl pox 
(rFP) expressing H or F proteins of PPRV were shown to induce poor antibody 
responses (Herbert et al., 2014). Recombinant adenovirus vectors expressing PPRV 
glycoproteins were developed recently (Herbert et al., 2014; Qin et al., 2012; Rojas 
et al., 2014; Wang et al., 2013a). A recombinant replication-defective human 
adenoviruses serotype 5 incorporating H or F proteins of PPRV was shown to protect 
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goats (Herbert et al., 2014) and sheep (Rojas et al., 2014) against challenge with 
virulent PPRV and induced both humoral and cell mediated immunity.  
 
Subunit vaccines developed based on a baculovirus expression system producing H 
(Sinnathamby et al., 2001) and F proteins (Rahman et al., 2003) or the H protein 
expressed in transgenic peanut plants (Khandelwal et al., 2011) need to be assessed 
further for safety and vaccine potency. Similar assessments are lacking for the 
recently developed suicidal DNA vaccine (based on the Semliki forest virus 
replicon-based expression systems) utilizing the H gene of PPRV (Wang et al., 
2013b) and a virus like particle (VLP) preparation composed of M and H or N 
proteins (Liu et al., 2014a; Liu et al., 2014b). 
 
1.8.3 Reverse genetics techniques to make DIVA and multivalent vaccines 
Reverse genetics is defined as a method in which a live virus is recovered in cell 
culture via a cDNA copy of the RNA genome. In other words, it provides a means to 
manipulate RNA virus genomes through cDNA copies of the RNA genome. This 
technique has been utilised extensively to further the basic understanding of virus 
gene function, virus-cell interaction, and pathogenesis.  
 
The establishment of these techniques for positive strand RNA viruses was rapid as 
it was quickly shown that their genomes acted as mRNA. To recover positive strand 
virus, the cDNA plasmids of virus genome or the RNA transcripts obtained from 
those plasmids are transfected into susceptible cells to recover the virus. Poliovirus 
was the first positive strand RNA virus to be rescued from a cDNA genome plasmid 
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(Racaniello and Baltimore, 1981) and the rescue of other positive stranded RNA 
viruses quickly followed. 
 
Establishment of reverse genetics system for negative stranded RNA viruses took 
longer to develop due to several biological challenges identified when working with 
them. Primarily, the genomes and anti-genomes of negative stranded RNA viruses 
cannot function as mRNA. The realisation that the genome and anti-genome RNA 
must be entirely encapsidated with N protein to form an RNPs that acts as the 
substrate for the RdRP was a breakthrough in our understanding of these viruses. To 
enable virus rescue, a full length genome plasmid cDNA is co-transfected with 
helper plasmids encoding the proteins necessary for the formation of RNPs to initiate 
virus replication. The genome and helper plasmids are often cloned under the 
transcriptional control of a T7 polymerase promoter. The genome and helper 
plasmids are then transfected into a suitable cell line that contain T7 polymerase, 
supplied by either a rFP expressing T7 or through endogenous expression of T7 
polymerase within the cell line used. A further realisation was that the primary 
transcript produced from the full-length genome plasmid should be of positive sense 
(antigenome) otherwise the mRNA generated from the helper plasmids will 
hybridize with negative sense genome transcripts, inhibiting the RNP complex 
formation. 
 
Rabies virus was the first negative-strand RNA virus recovered completely from 
cDNA in 1994 (Schnell et al., 1994). The approach was soon adapted to rescue 
paramyxoviruses including MV (Radecke et al., 1995), RPV (Baron and Barrett, 
1997), Newcastle disease virus (NDV) (Peeters et al., 1999), CDV (Gassen et al., 
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2000), Mumps (Clarke et al., 2000), respiratory syncytial (Collins and Murphy, 
2005), Nipah (Yoneda et al., 2006) and Hendra (Marsh et al., 2013) viruses. A 
reverse genetics system for RPV, a closely related morbillivirus to PPRV, was first 
established in 1997 (Baron and Barrett, 1997) by transfecting the full-length cDNA 
of RPV and helper plasmids (N, P and L) of RPV into B95a cells that were pre-
infected with a recombinant vaccinia virus expressing T7 RNA polymerase (Figure 
1.7). Further, this RPV reverse genetics system with some modifications (using Vero 
cells and rFP expressing T7 polymerase) was used to develop a chimeric RPV-PPRV 
(F/H) virus from a modified cDNA clone. The modified RPV-PPRV (F/H) clone was 
constructed by replacing the F and H genes of RPV with the heterologous PPRV F 
and H genes. However the rescued chimeric virus was severely debilitated in cell 
culture achieving only very low titres (Das et al., 2000). To increase the titre of the 
recombinant virus it was necessary to include the homologous F and H proteins 
alongside the homologous M protein from PPRV (Mahapatra et al., 2006). The new 
RP-PPRV (M/F/H) rescued chimeric virus grew efficiently in cell culture and 
protected goats from challenge with virulent PPRV (Mahapatra et al., 2006). 
Similarly, the N gene of PPRV was swapped into the RPV cDNA clone with the 
objective of developing a marker vaccine for RPV (Parida et al., 2007). This 
chimeric virus protected cattle challenged with virulent RPV. Further, using this 
chimeric virus serological differentiation of vaccinated animals from non-vaccinated 
infected animals was possible using a newly developed ELISA based on variable 
part of RPV N gene (Parida et al., 2007). However, this RPV-PPRV (N) chimeric 
virus was not utilised in field conditions during the final stages of eradication. To 
attempt to develop a positive marker vaccine for RPV, the GFP gene was inserted as 
a separate transcriptional unit in the RPV cDNA clone and was rescued (Walsh et 
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al., 2000a; Walsh et al., 2000b). Using this established reverse genetics method a 
recombinant RPV was rescued that lack C and V proteins of RPV that helped to 
reduce the pathogenicity of the virus (Baron and Barrett, 2000). Similarly, the 
promoter regions of RPV were swapped between vaccine and wild type strain of the 
RP viruses to determine the pathogenicity in cattle (Banyard et al., 2005). 
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Figure 1.7 Schematic representation of the reverse genetics method to generate 
infectious recombinant RPV. The full-length genome (cDNA) plasmid and the 
helper plasmids (N, P and L) were constructed under T7 polymerase promoter. The 
B95a cells were infected with recombinant vaccinia expressing T7 polymerase 
(rV/T7). The genome and helper plasmids were transfected into B95a cells and were 
transcribed by the T7 polymerase. The N, P and L proteins bound to the viral RNA 
anti-genome strand to form the ribonucleocapsid protein (RNP) complex, a 
minimum necessary component required to initiate the replication cycle and produce 
complete virus.  
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Establishment of reverse genetics system for PPRV was unsuccessful despite several 
attempts (Bailey, 2006), although the PPRV mini-genome rescue system was 
successfully developed (Bailey et al., 2007). The reason for being unable to rescue 
PPRV from a full-length PPRV cDNA described were proposed to be associated 
with sequence errors in the final full length cDNA, specifically the presence of 
potentially lethal mutations in the UTR at the M and F gene junction (Bailey, 2006). 
Therefore the main aim of this PhD project was to establish a reverse genetics 
system for PPRV after re-sequencing and confirming the correct sequence in the full 
length genome of PPRV. 
 
Vaccination of small ruminants with the current live attenuated PPRV vaccine 
strains and natural virus infection induces an antibody profile that is 
indistinguishable. Because of this, the development of a marker vaccine with 
companion diagnostic tests is required to fulfil the ‘DIVA’ strategy and enable the 
differentiation between naturally infected and vaccinated animals within a 
population. The availability of a DIVA vaccine would greatly enhance serological 
surveillance during any eradication initiative for PPRV in future (Baron et al., 2011; 
Buczkowski et al., 2014). 
 
Existing DIVA strategies for PPRV have focussed on developing subunit vaccines 
expressing the PPRV F and/or H gene in viral vectors such as poxviruses (vaccinia, 
Capripox and fowl pox) and adenoviruses (canine or human types) as explained in 
Section 1.8.2. The absence of the PPRV N protein in these subunit vaccine 
preparations facilitates serological identification of infected animals using an ELISA 
based on the N protein. However, such subunit vaccines often require multiple doses 
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and may have reduced efficacy due to potential pre-existing immunity to the viral 
vector, reduced antibody induction through an inability to replicate, the potential for 
short lived antibody responses and/or potentially high costs of recombinant vaccine 
production. An alternative strategy is to use the existing live attenuated PPRV 
vaccine by manipulating in a specific region or epitope of a viral protein sequence of 
a cDNA clone using reverse genetics system to obtain positively and or negatively 
marked vaccines. Therefore this PhD study aimed to rescue the widely used vaccine 
strain (Nigeria 75/1) from a cDNA clone. To make it a positive marker vaccine, 
similar to RPV, an extraneous transcriptional unit of GFP was inserted and 
expressed. Alongside this, attempts have been made to negatively mark the vaccine 
by creating a recombinant that is epitope deleted for part of the anti-PPRV H C77 
monoclonal antibody (mAb) binding site, a key component of the current diagnostic 
competitive H ELISA (c-H ELISA). The C77 mAb and the antibody present in the 
test sera compete with each other to bind to the specific epitope on the H protein of 
coated antigen. The assay works on the principle that antibodies to PPRV in the test 
sera can block the binding of the mAb to the antigen. The C77 mAb is detected using 
rabbit anti-mouse IgG conjugated to horseradish peroxidase. Therefore, it is 
hypothesised that the negatively marked vaccine virus with a mutated C77 mAb 
binding epitope would facilitate the c-H ELISA to distinguish serologically 
vaccinated animals from those naturally infected with circulating viruses. Antibodies 
in naturally infected animals could be detected using c-H ELISA whereas the 
protected vaccinated animals will not be detected. 
 
As many diseases in small-ruminants overlap geographically with PPRV (e.g. CPV, 
bluetongue virus [BTV], Rift valley fever virus [RVFV], contagious ecthyma and 
border disease virus) (Malik et al., 2011; Mondal et al., 2009; Ozmen et al., 2009; 
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Saravanan et al., 2007; Toplu et al., 2012) the idea of increased valency was 
investigated using a PPRV vaccine as a vehicle for the expression of heterologous 
proteins. A single vaccination programme covering multiple diseases would greatly 
improve the efficiency of control programmes by increasing productivity of human 
resources through the reduction in the overall cost of vaccine administration. 
Therefore, the final aim of this PhD study was to make a multivalent vaccine using 
PPRV as a viral vector. As the PPRV live attenuated vaccines provide lifelong 
immunity in small ruminants (Diallo et al., 2007; Hamdy et al., 1975; Sen et al., 
2010), using reverse genetics technique immunogens from co-circulating viruses 
(stated above) may be inserted into PPRV genome to make a multivalent vaccine. 
However, insertion of multiple larger insertions as separate transcriptional units in 
full length genome of virus could reduce growth of recombinant virus due to effects 
on the transcriptional gradient. To overcome this polar attenuation recombinant MV 
(Takeda et al., 2006) and NDV (Gao et al., 2008) with genomes divided into two or 
three segments were generated using reverse genetics systems. These tolerated 
multiple larger insertions as separate transcriptional units. A two-segment MV 
genome was obtained by constructing the first plasmid containing N, P, M and F 
genes and second plasmid containing H and L genes. Each gene cassette was 
flanking with the GP and AGP. The transcriptional gradient of expression of genes 
in the segmented virus was not hampered due to a reduction in the total length in 
comparison to the non-segmented genome. The segmented MV and NDV were 
shown to be efficient vectors expressing long and multiple (up to six) transgenes 
(Gao et al., 2008; Takeda et al., 2006). The coding capacity in segmented NDV was 
extended by 30%. A similar strategy could be applied to PPRV in developing 
multivalent vaccines for regionally relevant diseases.  
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1.9 Aims of the project 
In the context of the background literature, the main objectives of this PhD studies 
were: 
1. To re-sequence the whole genome of PPRV Nigeria 75/1 vaccine strain to 
confirm the correctness of existing sequences needed for cDNA synthesis and 
to eradicate any sequence error identified in the Turkey 2000 PPRV sequence 
determined previously. 
2. To establish the reverse genetics technique to rescue PPRV Nigeria75/1 
vaccine strain. 
3. To investigate both positive and negatively marked forms of the vaccine as 
potential DIVA vaccines. 
4. To attempt to increase vaccine valency through inclusion of a heterologous 
gene in the PPRV genome in either segmented or non-segmented forms. 
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Chapter 2 Materials and methods 
2.1 Cells and viruses 
2.1.1 Cells lines 
Vero.DogSLAMtag (VDS) cells were used in this study. The Vero cell lineage 
(ATCC CCL-81) is an epithelial cell that was isolated from the kidney of the African 
green monkey (Cercopithecus aethiops). VDS cells are the Vero cells constitutively 
expressing the canine morbillivirus receptor SLAM under the selection pressure of 
zeocin (Seki et al., 2003). 
 
2.1.2 Culturing and maintenance of the cell lines  
The cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 5% (v/v) foetal calf serum (FCS, Gibco), penicillin (100 U/ml, 
Sigma) and streptomycin sulphate (100 µg/ml, Sigma) at 37°C/ 5% CO2. Tissue 
culture flask (175 cm2) with confluent monolayer of cells were washed with 15 ml of 
calcium and magnesium (Ca/Mg) free phosphate buffered saline (PBS, Gibco) and 
overlaid with 5 ml of trypsin (0.25% solution, Gibco), incubated at 37°C for 5 
minutes. DMEM containing FCS (15 ml) was added to the detached cells to stop 
further trypsinisation and centrifuged at 290 g for 5 minutes. The cell pellet was re-
suspended in DMEM and the cells counted using a haemocytometer and passaged in 
a new tissue culture flask/ plate. 
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2.1.3 Virus stocks 
PPRV Nigeria 75/1 recombinant viruses were generated through reverse genetics in 
this study and its parental virus, Nigeria 75/1 vaccine strain, was obtained from the 
OIE-FAO Reference Laboratory for PPR at The Pirbright Institute, Pirbright, UK.  
PPRV was grown on VDS cells to prepare high titres of virus stock. VDS cells of ~ 
70% confluency were infected with virus at an multiplicity of infection (MOI) of 0.1 
and incubated at 37°C/ 5% CO2 for few days (usually 4-5 days) until the CPE and 
syncytia extended to 70-80% of total cell surface. Virus was harvested by one cycle 
of freezing and thawing followed by centrifugation at 290 g for 10 minutes to 
remove cell debris and the supernatant containing virus was stored at -80°C until 
further use. 
 
2.1.4 Virus isolation  
PPRV was isolated on VDS cells from the clinical samples. Cotton swabs were used 
to collect viral excretions in 1 ml of PBS. The liquid containing virus was used to 
infect the VDS cells in 25 cm2 tissue culture flasks and incubated at 37°C for one 
hour with intermittent shaking rocking. The cells were washed once with 2 ml of 
PBS followed by addition of 5 ml of media (containing 2.5% FCS) and incubated at 
37°C for a week. Cells were observed for the appearance of CPE and syncytia and 
were blindly passaged for at least two more times if no PPRV-specific CPE was 
observed. 
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2.1.5 Virus passage 
The stable maintenance of introduced mutations or inserted gene expression in the 
recombinant viruses was assessed by serial passage in VDS cells. VDS cells of 70% 
confluent in 25 cm2 tissue culture flask was infected with PPRV (at 1:200 dilution) 
and incubated at 37°C for few days until at least 80% CPE was observed. The virus 
was harvested by freeze-thawing once and clarified by centrifugation at 290 g for 10 
minutes. The supernatant containing the viruses was used for successive passage. 
 
2.1.6 Multi-step growth curves 
VDS cells were plated at 2.5x105 cells/ well in a six-well plate (BD falcon) and 
incubated overnight to reach ~70% confluency. Cell monolayers were washed once 
with DMEM and were infected (in duplicates) with 1 ml of virus inoculum diluted to 
0.01 MOI in DMEM and incubated at 37°C for an hour with intermittent shaking for 
even distribution of the inoculum. The excess of the virus inoculum was removed 
and the cells were washed twice with DMEM. For each well 2 ml of DMEM 
containing 5% FCS was added and incubated at 37°C. The plates were frozen at 0, 
12, 24, 36, 48, 60, 72, 84 and 96 hour post-infection (hpi). The virus was harvested 
by freeze-thawing and cell debris clarified by centrifuging at 290 g for 10 minutes. 
The supernatant containing the virus was stored at -80o C until use. 
 
2.1.7 Determination of virus titre  
Virus titre was determined by 50% tissue culture infectious dose (TCID50) in 96-well 
plates. Virus stock was serially diluted 10 fold outside the microtiter plate using 
serum free DMEM from neat, 10-1, 10-2, 10-3, 10-4, 10-5, 10-6, 10-7, 10-8, 10-9, 10-10 
and 10-11. Aliquots of 50 µl virus each was added into 8 wells in a 96 well plate, one 
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column for each dilution of virus, where the first column is for neat virus and last 
column is for cell control. VDS cell suspension of 5x104/ml was prepared in DMEM. 
VDS cell suspensions of 100 µl was added to all the wells and incubated for 5 days 
at 37°C/ 5% CO2. The CPE was observed under microscope and scored. The virus 
titre was calculated according to Read and Muench and expressed in log10 values 
(Reed and Muench, 1938). All assays using plaques have a lower limit of detection 
and the detection limit of this assay is more than 1 log10. 
 
2.1.8 Bacterial cells 
The JM109 strain of Escherichia coli was used for the transformation and cloning of 
plasmid DNA. The bacterial cells were plated on Luria Bertani (LB) agar and 
incubated overnight at 37°C. A single colony of bacteria was picked and grown 
overnight in LB broth and used for the preparation of competent cells for 
transformation. Glycerol stocks of the bacteria (15%) prepared and stored at -80°C 
for future use. 
 
2.2 RNA and DNA techniques 
2.2.1 RNA extraction 
Viral RNA was extracted either using robotic extraction methods (MagNA Pure LC 
Total Nucleic Acid Isolation Kit, Roche, UK) or Qiagen viral RNA mini kit. Robotic 
RNA extraction method was followed for a large number of animal experimental 
samples, to maintain uniformity by reducing bias in extraction method for the precise 
comparison of viral RNA amount between samples. Otherwise, in all other 
experiments Qiagen Viral RNA mini kit was routinely used following the 
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manufacturer’s protocol. Briefly, 140 µl of virus infected cell supernatant was mixed 
with 560 µl of kit supplied lysis buffer and left at room temperature for 10 minutes. 
To this mixture 560 µl of absolute ethanol was added and vortexed. This solution 
was passed through QIAamp mini spin column by centrifuge at 8000 g for 1 minute. 
The flow through was discarded and column filter was washed with 500 µl of wash 
buffer-1 (spun at 8000 g for 1 minute) and 500 µl wash buffer-2 (spun at 8000 g for 
3 minutes). The column was transferred to another clean and sterile tube and 50 µl of 
nuclease-free water was added and incubated for a minimum of one minute at room 
temperature. The column was centrifuged at 8000 g for 1 minute to elute RNA from 
the column and the RNA was stored at -80°C until further use. 
 
2.2.2 Quantification of nucleic acids 
The concentration and purity of DNA/ RNA was assessed by using 
spectrophotometer (NanoDrop 1000 Thermo Scientific) according to the 
manufacturer’s protocol. Briefly, RNA or DNA samples (1.5 µl) were loaded on 
pedestal of the spectrophotometer and absorbance reading taken at 260 and 280 ηm. 
The reading at 260 ηm gives the concentration of nucleic acid in the sample and the 
ratio between the readings at 260 and 280 ηm estimates the purity of the DNA (1.8) 
and RNA (2.0). 
 
2.2.3 Reverse-transcription polymerase chain reaction (RT-PCR) 
The SuperScript III One-Step RT-PCR System with Platinum Taq High Fidelity 
polymerase kit (Life technologies) was used for reverse transcription of viral RNA 
into cDNA and further amplification in a single step. The RT-PCR mixture 
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contained 25 µl of 2x Reaction mix, 1 µl (10 pmol/µl) of each forward and reverse 
primer, approximately 50-100 ηg of template RNA and 1 µl (1 U) of SuperScript III 
RT/ Platinum Taq High Fidelity Enzyme Mix. The final reaction volume of 50 µl 
was made up with nuclease-free water and subjected to the following amplification 
cycles. 
Step 1: Reverse transcription 50°C 30 minutes 
Step 2: Initial denaturation 94°C  2 minutes 
Step 3: Denaturation  94°C  15 seconds 
Step 4: Primer annealing 55°C 30 seconds 
Step 5: Elongation  72°C 1 minutes/Kb length of amplicon 
Step 6: Steps 3 – 5 repeated for 36 cycles 
Step 7: Final elongation 72°C  7 minutes 
Step 8: Holding  4°C  
PCR products were stored at -20°C until further use. 
 
2.2.4 Polymerase chain reaction 
The PCR mix was prepared using KOD High-Fidelity PCR polymerase (Novagen) 
kit following the manufacturer’s protocol. Briefly, reaction mix contain 5 µl of 10x 
buffer, 5 µl of dNTP mix (2 mM each), 3 µl of MgS04 (25 mM), 1.5 µl each of 
forward and reverse primers (10 pmol), 1 µl of KOD polymerase (1 U/µl), template 
DNA 50 to 100 ηg and final volume made up to 50 µl with water. The following 
amplification cycles was followed 
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Step 1: Initial denaturation 94°C  2 minutes 
Step 2: Denaturation  94°C  15 seconds 
Step 3: Primer annealing 55°C 30 seconds 
Step 4: Elongation  72°C 15 seconds /Kb length of amplicon 
Step 5: Steps 3 – 5 repeated for 36 cycles 
Step 7: Final elongation 72°C  7 minutes 
Step 8: Holding  4°C  
PCR products were stored at -20°C until further use. 
 
2.2.5 Random amplification of cDNA ends (RACE) 
The genome termini, leader and trailer sequence regions were amplified using 5’ and 
3’ rapid amplification of cDNA ends as described by Li et al, and Tillett et al (Li et 
al., 2005; Tillett et al., 2000) using PPR virus specific primers (VSP). The primers 
sets used in RACE are provided in Appendix III. The Schematic diagram of steps 
involved in 5’ and 3’ RACE is shown in Figure 2.1. The cDNA synthesis was carried 
out using ThermoScript RT-PCR Systems (Life technologies) and RNA ligation 
using T4 RNA Ligase 1 (NEB). For 5’ RACE, initially the cDNA was synthesised 
using virus specific primer P5-1 (Appendix III), template RNA digested by RNaseH 
treatment and the synthesised cDNA was ligated with adaptor (DT88). Adaptor 
constitutes modifications with ‘5'-phosphorylated, 3'-end inverted dA’ to ensures 
ligation occurs between 5’ end of adopter and 3’ end of target DNA/RNA. For 3’ 
RACE, first the adapter was ligated with viral RNA and followed by cDNA 
synthesis using DT89 primer that is unmodified and complementary to DT88 
adopter. The cDNA obtained from both 5’ and 3’ RACE were further amplified 
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through primary and hemi-nested PCRs using virus specific primers (Appendix III). 
For primary PCR, DT89 was used with either P5-2 in 5’ RACE or P3-1 in 3’ RACE. 
For hemi-nested PCR DT89 was used with either P5-3 in 5’ RACE or P3-2 in 3’ 
RACE.  
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Figure 2.1 Schematic diagram depicting methods to establish the genome 
termini for PPRV. The dotted lines represent the RNA genome in 3’ to 5’ direction, 
the solid lines represent cDNA, DT88 is an adapter, DT89 primer is complementary 
to DT88 and the virus specific primers (VSPs). Figure taken from Li et al., 2005. 
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2.2.6 Purification of DNA 
DNA in PCR or restriction enzyme reactions was column purified using illustra GFX 
PCR DNA and Gel Band Purification Kit following the manufacturer’s protocol and 
the final purified product was eluted in a final volume of 40 µl of DNase and RNase 
free water. 
 
2.2.7 Agarose gel electrophoresis 
Appropriate agarose gel (1 to 2 % based on DNA size) was prepared using 
electrophoresis grade agarose powder (Invitrogen) in Tris-acetate EDTA (TAE) 
buffer. GelRed (Biotium) was added to the molten agarose to obtain a final 
concentration of 1x and the gel was allowed to solidify for at least 30 minutes at 
room temperature. DNA samples were mixed with the sample loading dye 
(Invitrogen) before loading into the wells. 1Kb plus marker (Invitrogen) was used for 
the comparison of the DNA bands. Electrophoresis was performed using TAE buffer 
and at 100 V for an hour (5 V per centimetre). DNA bands were visualized on a gel 
documentation system (Biorad). 
 
2.2.8 Extraction of DNA from agarose gels 
The desired DNA fragment and non-specific or unwanted DNA present within a 
PCR or restriction enzyme digestion reaction was purified on agarose gel for use in 
the ligation or sequencing. Agarose gel (1%) was prepared using low melting point 
agarose powder (Invitrogen) and the electrophoresis was performed at ~ 20 V for 16 
-20 hours for better separation of DNA fragments. The expected specific DNA 
fragment was excised using sterile scalpel and purified using Illustra GFX PCR 
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DNA and Gel Band Purification Kit (GE healthcare). The purified DNA fragments 
were quantified using Nanodrop 1000 spectrophotometer (Thermo Scientific). 
 
2.2.9 Restriction enzyme digestion 
Approximately 100-200 ηg of plasmid DNA was digested with an appropriate 
restriction enzyme(s) and 1x buffer (NEB) in a reaction volume of 10 µl and 
incubated at the recommended temperature for 2 hours. The digested product was 
analysed by electrophoresis. However, for the preparation of DNA fragments for 
ligation experiments, about 5 µg of plasmid DNA was digested with 5 U of enzyme 
in a reaction volume of 50 µl and incubated at the recommended temperatures 
overnight. 
 
2.2.10 Phosphatase treatment 
Antarctic phosphatase enzyme was used for the removal of 5´ phosphate group from 
the linear vector DNA fragments and, thus prevents the self-ligation during ligation 
reaction. It also decreases the vector background during cloning steps. Five µl of 10x 
Antarctic phosphatase buffer (NEB) and 1 µl (1 U/µl) of Antarctic phosphatase 
enzyme (NEB) was added to the restriction enzyme-digested vector and the mixture 
was incubated for 30 minutes at 37°C. The enzyme was heat inactivated at 70°C for 
5 minutes followed by gel purification. 
 
2.2.11 Ligation reactions 
Ligation reactions in cloning was carried out using T4 DNA Ligase which catalyzes 
the joining of two strands of DNA between the 5´-phosphate and the 3´-hydroxyl 
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groups of adjacent nucleotides in either a cohesive-ended or blunt-ended 
configuration. In a reaction volume of 10 µl, vector (30-40 ηg) and insert DNA at a 
molar ratio of 1:3 and 1 µl of 10x T4 DNA ligase buffer (Promega) and 1U of T4 
DNA ligase enzyme (Promega) were added and incubated at 4°C overnight. 
 
2.2.12 Preparation of competent cells and transformation 
Competent E. coli JM109 cells were prepared fresh on the day of use by TSS-TCM 
method and transformed by ligation reaction or plasmid DNA as described below. 
An overnight culture of bacterial cells was diluted 1 in 200 in LB-broth medium and 
cultured at 37ºC until the OD600 reaches 0.25-0.35 (usually ~2 hours). The cells were 
centrifuged at 290 g for 10 minutes and re-suspended in 1/10th volume of TSS 
(Appendix I) and left on ice for an hour. At the same time, the ligation reaction or 
plasmid DNA was diluted to 200 µl in TCM (Appendix I) and left on ice for an hour. 
The TCM DNA mix was added to ~ 200 µl of competent cells and left on ice for an 
hour. Heat shock treatment was given to the mixture at 42°C for 5 minutes and 
immediately cooled on ice for 5 minutes. SOC media (Appendix I) of 600 µl was 
added to the sample and incubated at 37ºC in a shaker for an hour. The cells were 
plated onto LB-agar plates containing selective antibiotics (ampicillin or kanamycin) 
and/or IPTG/X-gal and incubated overnight at 37ºC. 
 
2.2.13 Plasmid mini and maxi preparations 
Bacterial culture of approximately 1 ml (miniprep) or 500 ml (maxiprep) was used in 
plasmid DNA preparations. The Qiagen Miniprep Kit for purification of small scale 
(up to 20 µg) molecular biology grade plasmid DNA or the Qiagen Plasmid Maxi Kit 
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for purification of large scale (up to 500 µg) transfection-grade plasmid DNA were 
used following manufacturer’s protocol. The kit procedure is based on alkaline lysis 
of bacterial cells followed by adsorption of DNA onto silica membrane in the 
presence of an appropriate salt concentration. The membrane columns are washed to 
remove impurities and the eluted DNA is concentrated and desalted by isopropanol 
precipitation. 
 
2.2.14 DNA sequencing 
BigDye Terminator v3.1 Cycle Sequencing Kits (Applied Biosystems) based on 
Sanger sequencing was used where each of the four dideoxy terminators (ddNTPs) 
were tagged with different florescent dye. The cycle sequenced products were then 
cleaned to remove excess dye terminators and analysed through ABI-3730 
automated sequencer. 
The sequencing reaction mix was prepared as follows: 
 Primer (10 pmol/µl)  1 µl 
 BigDye reaction buffer (2x) 2 µl 
 BigDye enzyme mix  0.25 µl 
 DNA template (50-100 ηg) 1 µl 
 Nuclease-free water  5.75 µl 
The cycle sequencing reaction was carried out using a thermal cycler under the 
following conditions with the initial denaturation of template DNA at 96°C for one 
minute. 
  
84 
 
Step 1. Denaturation at 96°C for 20 seconds 
Step 2. Annealing at 50°C for 10 seconds 
Step 3. Extension at 60°C for 4 minutes 
The above steps were repeated for 30 cycles. 
Removal of unincorporated dye terminators was carried out using EDTA/ethanol 
precipitation method. To the sequencing product 5 µl of 125 mM EDTA followed by 
60 µl of absolute ethanol was added and the precipitated DNA was pelleted by 
centrifugation at 600 g for 30 minutes. The pellet was washed once with 60 µl of 70 
% ethanol in water and vacuum dried. The pellet was re-suspended in 20 µl of Hi-Di 
Formamide (ABI) and loaded into a capillary and analysed through ABI-3730 
automated sequencer. 
 
2.2.15 Site-directed mutagenesis (SDM) 
SDM was carried out to introduce the desired nucleotide changes in the plasmid 
DNA. Two complementary primers incorporating the nucleotide sequence changes 
intended in the target nucleotide sequence in the middle of the primers were 
designed. The denatured and circular single-stranded plasmid DNA acts as template 
during the PCR and the annealed mutagenesis primer were extended by polymerase 
incorporating the desired mutations in both the strands of the plasmid DNA.  
The PCR mixture containing high fidelity enzyme KOD Hot Start DNA Polymerase 
(Novagen) was prepared as detailed below 
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10x KOD polymerase buffer (Novagen)  5 µl 
25 mM Magnesium sulphate    3 µl 
dNTPs (2 mM each)     5 µl 
Sense primer       15 pM 
Antisense primer     15 pM 
Template DNA     ~50 ηg 
KOD Hot start DNA polymerase   1 µl (0.02 U/µl) 
The thermal cycle reaction conditions were: 
Step 1:   95°C for 2 minutes  
Step 2:   95°C for 30 seconds  
Step 3:   55°C for 30 seconds  
Step 4:   70°C for 20 seconds per kbp of target amplification 
Steps 2 to 4 were repeated for 25 cycles.  
 
The resultant PCR product contained both the template plasmid DNA and the newly 
synthesized plasmid with introduced mutations. Since the template DNA was 
produced in JM109 strain of E. coli, it was DAM (DNA adenine methylase) 
methylated and therefore susceptible to DpnI digestion unlike the newly synthesized 
plasmid DNA. The parental DNA (methylated) was digested by treating the PCR 
product with 1 µl (10 U/µl) DpnI endonuclease (Promega) at 37 °C overnight. The 
DpnI enzyme digested product (5 µl) was transformed into bacterial cells for further 
amplification and checked for the desired mutations by sequencing. 
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2.3 Data analysis 
2.3.1 Nucleotide sequence analysis  
The sequences generated by different PPRV specific primers were assembled using 
the Seqman program in DNAstar (DNAstar, USA). The assembled sequences were 
aligned using ClustalW implemented in BioEdit software v7.2.0 (Hall, 1999). 
 
2.3.2 Statistical analysis 
Statistical analysis was performed either in Microscoft Excel 2010 or GraphPad 
Prism v6. 
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Chapter 3 PPRV complete genome sequencing and analysis 
3.1 Introduction 
Following the successful eradication of RPV, PPR has been targeted by the OIE and 
FAO as the next viral pathogen to be eradicated (FAO, 2014). Currently, the disease 
is controlled by vaccinating small ruminants against disease using live attenuated 
vaccines. However, the inability of laboratory tests to distinguish between vaccinated 
and naturally infected animals means that serological surveillance following a mass 
vaccination campaign would be very inefficient, as seen during the RPV eradication 
programme. In order to understand the epidemiology of PPRV, sequence data are 
required. Currently only partial gene sequences exist for the majority of 
characterised PPRV isolates. To enhance our understanding of the variation of PPRV 
at the genome level we set about generating full genome data for PPRV isolates in 
our repository. 
 
PPRV exists as a single serotype but at the genetic level four distinct lineages exist. 
This lineage differentiation is based on partial genome sequence of either N or F 
genes (Couacy-Hymann et al., 2002; Forsyth and Barrett, 1995). Full genome data 
for PPRV is scarce with no full genome sequence for lineage III isolates being 
available and only seven complete genome sequences available representing the 
other lineages. At the start of this project only one lineage I isolate full genome was 
available, two lineage II genome sequences and four lineage IV genome sequences. 
Current control methods across PPRV endemic areas have often relied on the 
application of vaccine strains generated from heterologous PPRV lineages. For 
example, across West Africa, where lineage I and II have predominated and across 
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North Africa and China where lineage IV is present vaccination using the lineage II 
Nigeria 75/1 vaccine strain has been used. Therefore it is expected that PPR 
outbreaks caused by lineage III would be readily controlled by using heterologous 
lineage II (Nigeria 75/1) or lineage IV (Sungri/96) vaccines. However from a genetic 
standpoint it is important to determine the full genome sequence from circulating 
isolates. More importantly, studying the genetic evolution of PPRV enables an 
understanding of the epidemiology of the virus, knowledge that may impact on the 
use of vaccines to control the disease. Finally, the requirement for a DIVA vaccine 
requires that a suitable reverse genetics system for PPRV is available and as such we 
aimed to establish sequences from different isolates and vaccines strains to ensure 
that the genome sequence was correct, a pre-requisite for the generation of a 
functional reverse genetics system. As discussed in chapter 1, previous attempts to 
establish a reverse genetics system for PPRV were unsuccessful (Bailey, 2006). 
Although essentially undefined, potential reasons for this failure were hypothesised 
to include problems surrounding the sequence of the constructed full length clone. 
To this end, the first step in this study was to ascertain a complete correct genome 
sequence for the Nigeria 75/1 vaccine strain and compare it with the existing 
available sequence before ordering/ assembling a full-length cDNA clone. As a 
backup study, it was planned to rescue another widely used vaccine strain 
(Sungri/96) whose whole genome sequence was available without the genomic 
promoter region. Therefore, the sequencing of the whole genome sequence of the 
Sungri/96 strain was also planned. In a further attempt to generate useful 
epidemiological data, full genome sequencing of a lineage III PPRV isolate was also 
performed. 
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The molecular evolution of PPRV and its role in disease epidemiology has not been 
explored in detail. The current molecular epidemiology of PPRV, which is based on 
sequence comparison of a small region of the F gene (322 nt) or the N gene (255 nt), 
has identified 4 distinct lineages (I–IV) of PPRV (Banyard et al., 2010). However, 
this analysis has not generated much information on the evolution and dispersal of 
each of the PPRV lineages. Many aspects of PPRV evolution, such as the origin of 
an ancestral virus, divergence and time of origin, and the historical and geographic 
patterns of spread, are poorly understood (Libeau et al., 2014). A better 
understanding of the evolution of PPRV would enable the prediction of how these 
viruses will lead to further outbreaks and epidemics and provide data for control 
strategies including application of vaccines. 
 
This Chapter describes the standardisation of PPRV complete genome sequencing 
techniques and the sequencing of both PPRV vaccine and field isolates. Further, a 
Bayesian analysis was carried out to study the evolutionary and epidemiological 
dynamics of PPRV using both complete and partial genome sequences of viruses 
from all the 4 lineages. 
 
3.2 Materials and methods 
3.2.1 PPR virus isolates 
For complete genome sequencing of PPRV, seven isolates Nigeria 75/1, Sungri 
1996, Uganda 2012, Ethiopia 2010, Morocco 2008, UAE 1986 and Oman 1983 were 
utilised in this study with the following passage history. PPRV Nigeria 75/1, UAE 
1986 and Oman 1983 isolates stock were obtained from the OIE-FAO Reference 
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Laboratory for PPR at The Pirbright Institute, UK. PPRV Nigeria 75/1 is a live 
attenuated vaccine strain widely used in disease control (Diallo et al., 1989). PPRV 
UAE 1986 virus was isolated from a Dorcas gazelle (Furley et al., 1987). PPRV 
Oman 1983 virus was isolated from the caecal tissue of a goat from Ibri, Oman 
(Taylor et al., 1990). PPRV Sungri 96, a commercially available vaccine strain 
generated by serial passage in cell culture (Sen et al., 2010) was provided by Intervet 
International B.V, Boxmeer, The Netherlands. The PPRV Uganda 2012 isolate was 
derived from an infected goat, received as swab sample from Uganda. The PPRV 
Ethiopia 2010 virus was isolated from the intestinal suspension of an infected goat at 
National Veterinary Institute, Addis Ababa, Ethiopia. This PPRV Ethiopia 2010 
isolate received as tissue suspension from Ethiopia. The PPRV Morocco 2008 isolate 
was derived from the mesenteric lymph node of an infected goat, following a single 
passage on VDS cells (Hammouchi et al., 2012). 
 
3.2.2 Complete genome sequencing of PPRV  
Viral RNA was extracted from PPRV Nigeria 75/1, Sungri 1996, Uganda 2012, 
Ethiopia 2010, Morocco 2008, UAE 1986 and Oman 1983 isolates. Oligonucleotide 
primer sets designed based on highly conserved regions of PPRV genome sequences 
previously available in the GenBank (accession number NC006383, X74443, 
EU267273 and AY560591). All primer sequences including 46 forward and 32 
reverse primers are provided in Appendix III. Seven to nine overlapping PCR 
fragments covering the entire PPRV genome were amplified using RT-PCR. The 
amplified PCR products were column purified and sequenced. 
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3.2.3 Sequence datasets 
Six complete genome sequences were available in GenBank with the Sungri/96 
sequence being complete with the exception of the GP. Seven complete genomes 
sequences of PPRV were generated in this study including re-sequencing of two 
vaccine strains (Nigeria 75/1 and Sungri 96) and an additional complete genome 
sequence (Ethiopia 1994 isolate) was obtained from the National Veterinary 
Institute, Sweden by Dr. M Munir (Table 3.1). However, of these 14 full genome 
sequences, Nigeria 1975/1 and Sungri 1996 represent vaccine strains generated after 
extensive serial passage of virus. Therefore, the evolutionary rate and time to most 
recent common ancestor (TMRCA) were compared with and without inclusion of the 
vaccine strains. The complete genome sequences of two clinical isolate each for 
RPV (GenBank accession nos. AB547189 and X98291) and MV (accession nos. 
AF266288 and JF791787) and 12 PPRV isolates, excluding vaccine strains, (Table 
3.1) were used for estimation of evolutionary rate and TMRCA. Furthermore, the 
coding and noncoding sequences of individual structural genes of PPRV (excluding 
vaccine strains) were used in this study. 
  
92 
 
Table 3.1 PPR isolates used for complete genome analysis 
Virus isolates GenBank accession 
no. 
Lineage Source (reference) 
Ivory Coast/1989 EU267273 I Goat (Chard et al., 
2008) 
Nigeria/1976 EU267274 II Sheep (Chard et al., 
2008) 
Nigeria/1975/1 X74443 II Goat (Diallo et al., 
1994), vaccine strain 
Uganda/2012* KJ867543 III Goat 
UAE/1986* KJ867545 III Dorcas gazelle 
(Furley et al., 1987) 
Oman/1983* KJ867544 III Goat (Taylor et al., 
1990) 
Ethiopia/1994 KJ867540 III Goat (Roeder et al., 
1994) 
Ethiopia/2010* KJ867541 IV Goat  
India/Sungri/1996* KJ867542  IV Goat (provided by 
Intervet International 
B.V, Boxmeer, the 
Netherlands) , 
vaccine strain  
Morocco/2008* KC594074 IV Goat (Muniraju et al., 
2013) 
China/Tibet 
Bharal/2008 
JX217850 IV Bharal, Pseudois 
nayaur (Bao et al., 
2012) 
China/Tibet33/2007 JF939201 IV Goat (Wang et al., 
2009) 
China/TibetGeg30/20
07 
FJ905304 IV Goat (Wang et al., 
2009) 
Turkey/2000 NC006383 IV Sheep (Bailey et al., 
2005) 
 
*Whole genome sequencing was conducted.  
 
Partial N gene sequences of PPRV isolates (nt positions 1253–1507) that have a 
detailed history of collection date and place were obtained from GenBank (available 
up to August 2013). These partial sequences were aligned by using the ClustalW 
algorithm in BioEdit software v7.2.0. (Hall, 1999) and edited to remove unreliable 
sequences and/ or regions. Furthermore, identical sequences originating from the 
same geographic location, host, and year were excluded to avoid redundancy in any 
subsequent analysis. The final dataset (partial N gene) contained 159 sequences 
sampled over a period of 45 years (1968–2012). 
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3.2.4 Selection analysis 
The nucleotide and amino acid sequence differences between the PPRV lineages for 
12 complete genome sequences were estimated by using BioEdit software v7.2.0. 
Analyses of selection pressures in individual PPRV genes was performed by 
obtaining mean ratios of nonsynonymous (dN) to synonymous (dS) substitutions per 
site. The dN/dS was calculated by using codon-based maximum likelihood 
approaches with the single-likelihood ancestor method implemented in hypothesis 
testing using the phylogenies package (Pond et al., 2005) 
(http://www.datamonkey.org). The proportion of dS substitutions per potential dS 
site and proportion of dN substitutions per potential dN site were calculated by using 
the method of Nei and Gojobori (Nei and Gojobori, 1986) and the suite of nucleotide 
analysis program (www.hiv.lanl.gov). 
 
3.2.5 Bayesian time-scaled phylogenetic analysis 
Molecular evolutionary rate and divergence times were co-estimated. A Bayesian 
maximum clade credibility (MCC) phylogenetic tree was constructed by using 
Bayesian Markov chain Monte Carlo (MCMC) analysis and Bayesian evolutionary 
analysis sampling trees (BEAST) software package v1.8.0 (Drummond et al., 2012), 
and BEAST runs were performed by using the CIPRES Science Gateway (Miller et 
al., 2010). For each sequence dataset, the best-fit nucleotide substitution model was 
determined on the basis of Akaike information criterion scores using JModel Test 
software v2.1.4 (Posada, 2008). An input file for BEAST analysis was obtained by 
using Bayesian evolutionary analysis utility software v1.8.0, in which sequences 
were tip dated according to the year of collection. Four molecular clock models 
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(strict, uncorrelated lognormal distribution [UCLD], uncorrelated exponential 
distribution [UCED], and random) were tested alongside different demographic 
models (nonparametric Bayesian skyline plot [BSP] and the parametric constant and 
exponential growth), and the best models were selected by means of a Bayes factor 
(BF) test (Kass and Raftery, 1995) using marginal likelihoods values (2lnBF>2) 
obtained from Tracer v1.5 software (http://beast.bio.ed.ac.uk/tracer). 
 
For each analysis, 2 independent MCMC chains were run to get a final output of 
10,000 trees (ESS >200 for all the parameters estimated) and were assessed for their 
proper mixing, convergence, and consistency by Tracer v1.5 with 10% burn in. The 
2 individual runs were combined by using LogCombiner v1.8.0 in the BEAST 
software package. The nucleotide substitution rate (substitutions/site/year) and the 
TMRCA (year) values were obtained from Tracer v1.5. The posterior tree 
distributions were summarized by using TreeAnnotator 
(http://beast.bio.ed.ac.uk/treeannotator) and exclusion of the first 10% of the trees as 
burn in. Phylogenetic MCC tree with median node heights were visualized in 
FigTree software v1.4.0 
(http://www.molecularevolution.org/software/phylogenetics/figtree). Furthermore, 
the demographic history of PPRV was studied by using the partial N gene dataset 
and less restrictive BSP models in which the changing profile of genetic diversity is 
plotted against time. 
 
3.2.6 Phylogeographic reconstruction 
Bayesian phylogeographic analysis was performed by using complete PPRV genome 
sequence and partial N gene sequence datasets, and isolates were annotated 
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according to their location (longitude and latitude). Partial N gene data were chosen 
instead of F gene data because of increased divergence reported for the N gene 
(Banyard et al., 2010). For complete genome datasets, sequences from 14 viruses 
were considered, including 2 vaccine strains (Nigeria 1975/1 and Sungri 1996) to 
represent all PPRV-endemic areas. Phylogeographic diffusion along the posterior 
sets of trees and relationships between these locations were identified by using the 
Bayesian stochastic search variable selection procedure in BEAST v1.8.0 (Lemey et 
al., 2009). Discrete phylogeographic analysis was performed by using the continuous 
time Markov chain model and the flexible Bayesian skyride tree. 
 
3.3 Results 
3.3.1 Sequence analysis  
All 7 PPRV complete genomes (Sungri 1996, Nigeria 75/1, Uganda 2012, Ethiopia 
2010, Morocco 2008, UAE 1986 and Oman 1983) were found to be 15,948 nt and so 
conformed to the rule of 6 as described for all other morbillivirus genomes (Radecke 
et al., 1995). Resequencing of the Nigeria 75/1 vaccine strain confirmed the 
sequence for this vaccine and was 100% identical to the previously published 
sequence (accession no. X7443). The Sungri/96 vaccine strain sequence was also 
confirmed and completed although 123 nucleotide differences were identified at 
different locations across the genome when compared to the previously available 
sequence (accession no. AY560591). The genome organization of all isolates was 
the same as that for other PPRV strains (as shown in Figure 1.3 and Table 1.2 
Chapter 1). The 3’ ends of the genomes start with a GP (1 - 107 nt), followed by six 
transcriptional units of the structural protein genes, N, P, M, F, H and L and end with 
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the 5’ AGP (nucleotide position 15840-15948). The ORF of the P gene also encodes 
the non-structural proteins C and V. The 5’ UTR of M gene and 3’UTR of F gene 
together was 1080 nt long and extremely GC rich (66-68%). The untranslated 
regions typically contain the gene end signal of the previous gene followed by an IG 
tri-nucleotide sequence (CTT) and the gene start signal of the subsequent gene. The 
sequences flanking the IG tri-nucleotide (10 nt) are conserved between the N/ P and 
P/ M junctions among all the PPRV isolates. 
 
Phylogenetic analysis of the complete genome sequences of PPRV clustered the 
sequences into 4 lineages. The complete genomes of PPRV isolates from Ethiopia 
1994, Oman 1983, UAE 1986, and Uganda 2012 sequenced in this study belonged to 
lineage III and the isolates Sungri 1996, Morocco 2008, and Ethiopia 2010 belong to 
lineage IV. Comparison of the 12 (excluding Nigeria 1975/1 and Sungri 1996 
vaccine strains) aligned complete genome sequences showed that nucleotide 
differences ranged from 0.1% to 11.9%, and amino acid differences ranged from 
0.1% to 7.2% (Table 3.2). 
 
Further, the selection analysis was performed on PPRV genes. The dN/dS for coding 
regions of the various genes of PPRV (n = 12) for all 4 lineages ranged from 0.06 to 
0.45 (Table 3.3). The dN/dS per site across the coding region of different genes of 
PPRV genome obtained by Nei and Gojobori method are shown in Figure 3.1. The 
highest dN/dS ratio was observed in the P gene, followed by the H, N, F, L, and M 
genes. The relative nucleotide substitution rates at all 3 codon positions of the 
structural genes of PPRV showed that substitutions were more frequent at the third 
codon position (Table 3.3) as expected.  
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Table 3.2 Nucleotide and amino acid sequence differences in complete genomes 
of PPRV lineages 
PPRV lineages I II III IV 
I  5.1 6.1-7.0 5.7-6.1 
II 9.0  5.7-6.3 4.0-4.2 
III 10.9-11-9 9.9-10.8 
             0.2-3.0 
0.2-6.2 
6.1-7.2 
IV 10.3-10.7 7.2-7.6 10.7-11.8 
             0.1-2.0 
0.1-3.2 
 
*Values are percentage nucleotide (bold) and amino acid sequences differences. 
 
Table 3.3 Nucleotide substitution rates at codon positions of PPRV genes by 
BEAST analysis and dN/dS by single-likelihood ancestor counting (SLAC) 
Gene 
Total amino 
acids 
Codon position 
Mean dN/dS 
CP1.mu CP2.mu CP3.mu 
N 526 0.44 0.33 2.23 0.13 
P 510 0.81 0.69 1.49 0.45 
M 336 0.48 0.15 2.36 0.06 
F 547 0.46 0.26 2.29 0.10 
H 610 0.57 0.37 2.06 0.19 
L 2184 0.42 0.18 2.40 0.08 
 
*BEAST, Bayesian evolutionary analysis sampling trees; dN/dS, nonsynonymous/ synonymous 
substitutions per site; CP, codon position.  
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Figure 3.1 Mean ratios of nonsynonymous (dN) to synonymous (dS) 
substitutions per site of concatenated coding regions of PPRV genome. Vertical 
dashed lines indicate gene junctions with sliding windows of size = 5 codons. dN/dS 
values ≥ 10 are shown as 10. Numbers along baseline indicate coding regions (base 
pairs) of individual genes. 
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3.3.2 Evolutionary rate estimates 
Complete genome sequences of 12 PPRV and partial N gene dataset (n = 159) were 
analyzed by using the coalescent-based Bayesian MCMC approach. The general 
time-reversible (GTR) nucleotide substitution model with a gamma distribution for 
rate variation was selected on the basis of Akaike information criterion scores. Bayes 
factor tests with marginal likelihood comparisons showed that the relaxed UCED 
clock model best fitted the PPRV complete genome and partial N gene datasets 
(Table 3.4). The 2lnBF value was >78 between UCED and strict clocks and 2–6 
between UCED/ UCLD and UCED/ random clocks, which provided strong evidence 
for the UCED clock model. There was no difference between different demographic 
models compared within the UCED clock model (2lnBF <2). However, the 
exponential demographic model was chosen because it provided a narrow margin of 
95% highest posterior density (HPD) estimates. 
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Table 3.4 Bayesian Markov chain Monte Carlo analysis for genomes of PPRV. 
Sequence 
dataset 
(no.) 
Models, Substitution/ 
clock/ demographic 
Mean nucleotide substitution rate, 
substitutions/site/y (95% HPD) 
TMRCA, y (95% 
HPD) 
Bayes 
factor, -log 
likelihood 
2lnBF 
PPRV 
Complete 
genome 
(12) 
GTR+G/ strict/ BSP 3.2 x 10-4 (2.02 x 10-4 - 4.31 x 10-4) 1763 (1653-1832) -46972.98 -93945.96 
GTR+G/ strict/ CS 3.21 x 10-4 (2.12 x 10-4 - 4.38 x 10-4) 1763 (1659-1834) -46973.06 -93946.12 
GTR+G/ strict/ EG 3.24 x 10-4 (2.12 x 10-4 - 4.33 x 10-4) 1765 (1668-1836) -46973.06 -93946.12 
GTR+G/ UCLD/ BSP 2.89 x 10-3 (3.21 x 10-8 - 6.92 x 10-4) 1691 (123BCE-
1944CE) 
-46935.66 -93871.32 
GTR+G/ UCLD/ CS 3.03 x 10-4 (8.99 x 10-9 - 7.07 x 10-4) 1705 (123-1961) -46935.86 -93871.72 
GTR+G/ UCLD/ EG 3.72 x 10-4 (3.01 x 10-5 - 7.93 x 10-4) 1767 (1222-1948) -46935.89 -93871.78 
GTR+G/ UCED/ BSP 7.91 x 10-4 (7.46 x 10-5 - 1.53 x 10-3) 1889 (1586-1968) -46933.82 -93867.64 
GTR+G/ UCED/ CS 7.98 x 10-4 (8.03 x 10-5 - 1.54 x 10-3) 1887 (1569-1968) -46933.98 -93867.96 
GTR+G/ UCED/ EG 9.09 x 10-4 (2.13 x 10-4 - 1.64 x 10-3) 1904 (1730-1966) -46933.96 -93867.92 
GTR+G/ random/ BSP 7.01 x 10-4 (5.55 x 10-4 - 8.50 x 10-4) 1888 (1862-1908) -46934.75 -93869.5 
GTR+G/ random/ CS 6.97 x 10-4 (5.38 x 10-4 - 8.41 x 10-4) 1887 (1860-1908) -46934.64 -93869.28 
GTR+G/ random/ EG 7.04 x 10-4 (5.57 x 10-4 - 8.57 x 10-4) 1888 (1861-1908) -46934.89 -93869.78 
N partial 
(159) 
GTR+G/ strict/ BSP 1.22 x 10-3 (9.39 x 10-4 - 1.51 x 10-3) 1890 (1857-1917) -2884.524 -5769.048 
GTR+G/ strict/ CS 1.23 x 10-3 (9.49 x 10-4 - 1.52 x 10-3) 1886 (1853-1913) -2887.723 -5775.446 
GTR+G/ strict/ EG 1.24 x 10-3 (9.71 x 10-4 - 1.56 x 10-3) 1893 (1863-1919) -2885.44 -5770.88 
GTR+G/ UCLD/ BSP 1.45 x 10-3 (1.06 x 10-3 - 1.87 x 10-3) 1896 (1815-1943) -2806.535 -5613.07 
GTR+G/ UCLD/ CS 1.41 x 10-3 (1.05 x 10-3 - 1.80 x 10-3) 1882 (1793-1935) -2805.535 -5611.07 
GTR+G/ UCLD/ EG 1.49 x 10-3 (1.10 x 10-3 - 1.89 x 10-3) 1904 (1838-1943) -2805.921 -5611.842 
GTR+G/ UCED/ BSP 1.52 x 10-3 (1.11 x 10-3 - 1.98 x 10-3) 1904 (1817-1949) -2799.572 -5599.144 
GTR+G/ UCED/ CS 1.46 x 10-3 (1.05 x 10-3 - 1.88 x 10-3) 1886 (1785-1940) -2799.512 -5599.024 
GTR+G/ UCED/ EG 1.56 x 10-3 (1.16 x 10-3 - 1.99 x 10-3) 1910 (1846-1947) -2799.444 -5598.888 
GTR+G/ random/ BSP 1.26 x 10-3 (9.44 x 10-4 - 1.58 x 10-3) 1881 (1837-1915) -2865.846 -5731.692 
GTR+G/ random/ CS 1.24 x 10-3 (9.38 x 10-4 - 1.57 x 10-3) 1875 (1831-1910) -2866.111 -5732.222 
GTR+G/ random/ EG 1.27 x 10-3 (9.62 x 10-4 - 1.60 x 10-3) 1880 (1841-1914) -2866.929 -5733.858 
NCDS (12) GTR+G/ UCED/ EG 1.01 x 10-3 (2.79 x 10-4 - 1.83 x 10-3) 1924 (1799-1970) NA NA 
N gene (12) GTR+G/ UCED/ EG 1.08 x 10-3 (3.19 x 10-4 - 1.93 x 10-3) 1923 (1804-1970) NA NA 
P CDS (12) GTR+I/ UCED/ EG 1.11 x 10-3 (3.46 x 10-4 - 1.29 x 10-3) 1931 (1833-1972) NA NA 
P gene (12) GTR+I/ UCED/ EG 1.19 x 10-3 (3.46 x 10-4 - 2.03 x 10-3) 1930 (1828-1971) NA NA 
M CDS (12) GTR+G/ UCED/ EG 6.52 x 10-4 (1.20 x 10-4 - 1.20 x 10-3) 1897 (1695-1964) NA NA 
M gene (12) GTR+I/ UCED/ EG 2.49 x 10-3 (9.96 x 10-4 - 4.14 x 10-3) 1944 (1879-1973) NA NA 
FCDS (12) GTR+I/ UCED/ EG 8.95 x 10-4 (2.43 x 10-4 - 1.58 x 10-3) 1914 (1766-1968) NA NA 
F gene (12) GTR+G/ UCED/ EG 1.33 x 10-3 (3.26 x 10-4 - 2.36 x 10-3) 1912 (1754-1967) NA NA 
H CDS (12) GTR+G/ UCED/ EG 1.21 x 10-3 (3.96 x 10-4 - 2.04 x 10-3) 1926 (1826-1969) NA NA 
H gene (12) GTR+G/ UCED/ EG 1.25 x 10-3 (4.34 x 10-4 - 2.14 x 10-3) 1925 (1821-1968) NA NA 
L CDS (12) GTR+I/ UCED/ EG 9.82 x 10-4 (3.76 x 10-4 - 1.67 x 10-3) 1929 (1834-1969) NA NA 
L gene (12) GTR+I/ UCED/ EG 9.69 x 10-4 (3.36 x 10-4 - 1.64 x 10-3) 1927 (1820-1969) NA NA 
PPRV/RPV/
MV (16) 
GTR+G+I/ UCED/ EG 1.89 x 10-3 (5.55 x 10-4 - 3.31 x 10-3) 1616 (1072-1859) NA NA 
 
Bold indicates best-fit models. HPD, highest posterior density; TMRCA, time to most recent common ancestor; 
GTR+G, general time-reversible with gamma distribution rates; BSP, Bayesian skyline plot; CS, constant size; EG, 
exponential growth; UCLD, uncorrelated lognormal distribution; UCED, uncorrelated exponential distribution; NA, not 
applicable; GTR + I, general time-reversible with invariant sites.  
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Accordingly, the UCED and exponential growth model have been directly used for 
the individual PPRV gene dataset and the PPRV/RPV/MV complete genome dataset 
to estimate the TMRCA and substitution rate per site per year. When we used the 
UCED and exponential growth models, we found that the mean evolutionary 
substitution rate of the PPRV complete genome was estimated to be 9.09 × 
10−4 (95% HPD 2.13 × 10−4–1.64 ×10−3). When 2 complete genome sequences of 
vaccine strains were added into this analysis, the same models (GTR nucleotide 
substitution model with a gamma distribution, UCED, and the exponential growth 
demographic models) were best fitted, and the mean substitution rate/site/year was 
reduced to 7.86 × 10−4 (95% HPD 2.17 × 10−4–1.4 × 10−3). Furthermore, the 
evolutionary nucleotide substitution rate for combined PPRV/RPV/MV complete 
genomes was 1.89 × 10−3 (95% HPD 5.55 × 10−4–3.31 × 10−3). Analysis of 
individual genes of the PPRV coding region dataset, coding and noncoding region 
datasets, and partial N gene dataset are shown in Table 3. 4. 
 
3.3.3 Temporal dynamics 
A Bayesian time-scaled MCC tree based on complete PPRV genomes was 
constructed (Figure 3.2) by using the UCED model with exponential growth 
demography. The estimated median TMRCA of PPRV for all 4 lineages and 
divergence of lineage III PPRV were found to be approximately 1904 (95% HPD 
1730–1966). Lineage I diverged in around 1939 (95% HPD 1843–1970). Lineages II 
and IV diverged from each other in around 1956 (95% HPD 1885–1973). The 
TMRCA for lineage III viruses (n = 4) used in this study was estimated to be 
around1956 (95% HPD 1887–1978). TMRCA for lineages I and II PPRV were not 
predicted because only 1 virus from each lineage was used. The TMRCA for lineage 
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IV viruses (n = 6) used in this study was estimated to be around 1987 (95% HPD 
1957–1998). When both Nigeria 1975/1 and Sungri 1996 vaccine strains were 
included in the study, the TMRCA for all lineages of PPRV shifted from 1904 (95% 
HPD 1730–1966) to 1891 (95% HPD 1705–1960). Analysis of the partial N gene 
dataset showed the TMRCA as 1910 (95% HPD 1846–1947) for all lineages of 
PPRV, 1960 (95% HPD 1941–1971) for lineage III, 1958 (95% HPD 1946–1971) 
for lineage I, 1961 (95% HPD 1941–1967) for lineage II, and 1987 (95% HPD 
1969–1988) for lineage IV. 
 
Results of TMRCA analysis using complete coding and coding and noncoding 
regions of individual PPRV genes are shown in Table 3.4. If one compares the 
difference in TMRCA between coding and noncoding sequences of individual genes 
in the analysis, the large change in TMRCA was found only for the M gene (i.e., 
1944, 95% HPD 1879–1973). The TMRCA of PPRV/RPV/MV was estimated to be 
around 1616 (95% HPD 1072–1859), and the TMRCA for PPRV was estimated to 
be 1931 (95% HPD 1858–1956) (Figure 3.3). 
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Figure 3.2 Time-scaled Bayesian maximum clade credibility phylogeny tree 
based on PPRV complete genome sequences. The tree was constructed by using 
the uncorrelated exponential distribution model and exponential tree prior. Branch 
tips correspond to the date of collection and branch lengths reflect elapsed time. Tree 
nodes were annotated with posterior probability values and estimated median dates 
of time to most recent common ancestor (TMRCA). Corresponding 95% highest 
posterior density (HPD) interval values of TMRCA are indicated as blue bars. 
Horizontal axis indicates time in years. UAE, United Arab Emirates. 
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Figure 3.3 Time-scaled Bayesian maximum clade credibility phylogeny tree 
based on PPRV, RPV and MV complete genome sequences. The tree was 
constructed by using the uncorrelated exponential distribution model and exponential 
tree prior. Branch tips correspond to the date of collection and branch lengths reflect 
elapsed time. Tree nodes were annotated with posterior probability values, estimated 
median dates of time to most recent common ancestor (TMRCA). Corresponding 
95% highest posterior density (HPD) values of TMRCA are indicated as blue bars. 
Horizontal axis indicates time in years. UAE, United Arab Emirates. 
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3.3.4 Population demography of PPRV 
The demographic history of PPRV was investigated by using the partial N gene 
sequence dataset according to the BSP method implemented in BEAST. The BSP 
with an assumed piecewise-constant model has facilitated estimation of effective 
population size through time. The BSP showed that the population did not show 
much genetic diversity (effective number of infections) until the mid-1990s when the 
diversity started to increase. Toward the first decade of the 21st century, the 
population size appeared to reach a peak and then showed a small decrease until the 
most recent sampling in 2012 (Figure 3.4). The HPD interval size for the plot is 
narrow (closer to median genetic diversity), which indicates strong support for this 
population trend. 
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Figure 3.4 Bayesian skyline plot showing demographic history of global PPRVs 
sampled during 1968–2012. Genetic diversity was estimated by using a partial 
nucleoprotein gene dataset (n = 159). The thick black line represents median genetic 
diversity and the blue shaded areas show 95% highest posterior density estimate. 
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3.3.5 Phylogeographic analysis 
To estimate the geographic origin of PPRV, the results of Bayesian phylogeographic 
analyses was summarised and visualised using annotated MCC tree (Figure 3.5). The 
complete genome sequence data used in this analysis incorporated all 14 isolates, 
including the vaccine strains, from 10 discrete locations so as not to leave out any 
reported virus-endemic area. The root state posterior probabilities for all the 
locations ranged between 9.02% and 12.69%; Nigeria and the Ivory Coast receiving 
marginally higher support, 12.69% and 10.53%, respectively, than the rest of the 
locations (Figure 3.5). 
 
Because the geographic origin of PPRV could not be localized to a single country by 
using 14 complete genome sequences, further phylogeographic analysis was 
performed by using 159 partial N gene sequences collected from 30 locations during 
1968–2012. The root state posterior probabilities of PPRV ranged from 0.11% to 
17.20%, and Nigeria (17.20%), Ghana (14.28%), and Sierra Leone (11.68%) showed 
the highest marginal support (Figure 3.6). The highest marginal support of root state 
posterior probabilities indicated that the geographic origin of lineage I PPRV was 
Senegal (27.44%), that of lineage II PPRV was Nigeria (27.00%), that of lineage III 
PPRV was Sudan (30.73%), and that of lineage IV PPRV was India (36.00%). 
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Figure 3.5 Maximum clade credibility tree constructed for the geospatial 
analysis of PPRVs by using complete genome data. Nodes are coloured according 
to the most probable location of their ascendant locations. Posterior probability 
values are shown along tree nodes. Posterior probability distribution (PPD) values of 
root location states of the ancestral node are shown along the x-axis at the top left. 
UAE, United Arab Emirates. 
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Figure 3.6 Probability of root locations of the most recent common ancestral 
PPRV. MCC trees were obtained by using the continuous time Markov chain and 
Bayesian stochastic search variable selection procedures. Root location probabilities 
of the most recent common ancestor using global PPRV isolates (panel A) are shown 
graphically alongside lineages I–IV (panels B–E) and were estimated by using a 
complete dataset of PPRV partial nucleoprotein gene data and individual lineages 
separately. Probabilities of root locations are shown as percentages along the x-axes. 
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3.4 Discussion 
The complete genomes of 3 lineage III (Uganda 2012, UAE 1986 and Oman 1983) 
and 3 lineage IV (Ethiopia 2010, Morocco 2008, and Sungri 1996) isolates and 1 
lineage II (Nigeria 1975/1) of PPRV were sequenced in this study. Partial genome 
sequence of PPRV Sungri 96 isolate was available at the time of study in GenBank 
(accession no AY560591), that lacked genome promoter sequence and with 
interspersed nucleotide deletions in M/F gene junction. PPRV genome termini 
determined by tailing of cDNA with cytosine residues using terminal deoxy-
nucleotidyl transferase (Bailey et al., 2005; Chard et al., 2008) was not found 
efficient to generate the sequences of 3’ and 5’ termini. An improved method was 
adopted here to determine PPRV genome 3’ and 5’ termini as described for closely 
related paramyxovirus genome (Li et al., 2005; Tillett et al., 2000) and this had been 
proved to be efficient as the seven PPRV genome termini were successfully 
determined. Recently, this novel method was also adapted by other researchers to 
determine PPRV genome termini (Dundon et al., 2014). Another difficult region to 
sequence in PPRV genome is the M/F gene junction, which is rich in GC content and 
not easily amplifiable and as such clean and acceptable chromatograph peaks are 
difficult to achieve using Sanger sequencing. During this study, it was found that the 
designing of primer sets at appropriate locations is the critical factor that determines 
the amplification followed by sequencing. 
 
Newly sequenced genomes and other available genomes in GenBank were utilised to 
assess the evolutionary substitution rate, TMRCA, and divergence of PPRV lineages 
and the geographic origin of PPRV. To the best of my knowledge, this is the first 
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study on the molecular evolutionary dynamics of PPRV using full genome sequences 
from all four lineages of PPRV. 
 
The measure of selective pressures acting across the PPRV genome showed only 
purifying (stabilizing) selection occurring across the genome and no evidence of 
positive selection. The conservation of amino acid residues was further confirmed by 
the fact that the relative substitution rates at the third codon position of all the genes 
were higher than those for the first and second codon positions. The observed upper 
limit of 11.9% nt divergence (7.2% aa divergence) among PPRVs is consistent with 
the low level of antigenic divergence observed because despite lineage 
differentiation, only a single serotype exists for PPRV. Homologous recombination 
events are generally rare or absent in negative-sense RNA viruses (Han and 
Worobey, 2011) and thus could not have been evaluated in this study. 
 
From a genetic perspective, substitution rates are critical parameters for 
understanding virus evolution, given that restrictions in genetic variation within a 
population of viruses can lead to lower adaptability and pathogenicity (Denison et 
al., 2011). Our analyses estimated a range of PPRV nucleotide substitution rates 
throughout the complete genome of 1.64 × 10−3–2.13 × 10−4 substitutions/site/year, 
which is similar to that predicted for other paramyxoviruses (10−3–
10−4 substitutions/site/year) (Furuse et al., 2010; Jenkins et al., 2002; Pomeroy et al., 
2008; Wertheim and Pond, 2011). Despite low levels of antigenic divergence, as 
shown by the existence of a single serotype, the genome plasticity of PPRV might 
explain its ability to emerge and adapt in new geographic regions and hosts, as 
reported extensively across vast areas in recent years. The TMRCA of PPRV 
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obtained from complete genome sequence was estimated to be during 1904 (95% 
HPD 1730–1966). Similarly, the estimated TMRCA obtained from individual gene 
sequence, partial N gene sequence of PPRV, and combined PPRV/RPV/MV 
complete genome sequences was during 1910–1944. 
 
That the predicted TMRCA for PPRV was during the early 20th century is 
reasonable because the first recorded description of PPRV was made in 1942 
(Gargadennec and Lalanne, 1942). The delay of a few decades before identification 
of PPRV as a distinct viral entity after its initial detection can likely be attributed to 
confusion in differentiation between PPRV and RPV, a virus for which extensive 
cross-neutralization is observed after vaccination and natural infection, and lack of 
differentiating diagnostic tools. Substitution rates were consistent across each gene 
for PPRV. However, greater substitution rates were observed in the GC rich regions 
of the F and M genes. Similarly, the substitution rate was greater, as predicted 
because of the variability seen at the nucleotide level, in the highly variable region of 
the N gene sequence (255 nt) for PPRV. The TMRCA estimation was not possible 
for lineage I and II viruses (the lineage II Nigeria 75/1 vaccine strain was omitted 
due to its passage attenuation) because only 1 complete genome sequence was 
available for each lineage. Therefore, more complete genome sequences are required 
to study evolutionary and phylogenetic relationships for these lineages. 
 
Biased estimates in substitution rate and TMRCA were observed by using datasets 
that included tissue culture–passaged, attenuated vaccine strain complete genome 
sequences, in which slower evolutionary substitution rates and earlier TMRCA were 
predicted. Similar observations were reported for PPRV/RPV/MV N gene sequence 
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analyses, in which a slower and biased nucleotide substitution rate was observed 
when vaccine strain sequences (Furuse et al., 2010) were included in the analysis 
and faster substitution rates and later TMRCA predictions were suggested when 
vaccine strain sequence data were excluded (Wertheim and Pond, 2011). 
 
Spatial and temporal dynamics of RNA viruses are often reflected by their 
phylogenetic structure (Biek et al., 2006). Potential divergence events for different 
PPRV lineages were inferred by using rooted, time-measured phylogenetic trees with 
higher confidence from the PPRV complete genome sequence dataset. The inferred 
phylogeny supports the initial divergence of lineage III isolates, followed by lineage 
I isolates; lineage II and IV isolates were predicted to have diverged from each other 
at a later time. The inference of divergence events presented facilitated a better 
understanding of historical divergence of PPRV and offered further opportunities to 
study viral demographic history and dispersal events. 
 
The demographic analysis of PPRV with the BSP indicated historically constant 
genetic variability of PPRV over time. This finding could be a reflection of the use 
of RPV vaccine in small ruminants to protect animals against PPRV through the 
1990s, which might have affected the evolution and spread of PPRV. In the early 
21st century, genetic diversity of PPRV has gradually increased, which reflects 
frequent outbreak reports. The increased genetic diversity may be a driver for 
selection pressures within individual lineages and might result in extinction events, 
as suggested by an absence of lineage I virus. In recent years, as efforts have 
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increased to actively control and eradicate PPRV, a decrease in genetic diversity has 
been observed. 
 
Phylogeographic reconstruction with spatial and temporal information of virus 
isolates has enabled an understanding of the historic emergence and dispersal 
patterns involved in virus evolution (Lemey et al., 2009). Although PPRV existed 
earlier than its first description in Ivory Coast in 1942 (Diallo, 1988), PPRV was 
later reported in Senegal, Chad, Togo, Benin, Ghana, Nigeria, Oman, Sudan, Saudi 
Arabia, India, Jordan, Israel, Ethiopia, Kenya, Uganda, and Pakistan (Sen et al., 
2010). Our phylogeographic analysis indicated that Nigeria was the geographic 
origin of the most recent common ancestor of PPRV because of the highest root 
location state probability. Furthermore, geographic origins of the most recent 
common ancestor of PPRV lineages I, II, and III were predicted to be across Africa; 
lineage IV likely emerged in India. In conclusion, these findings suggest that the 
origin of PPRV was in western Africa, which then spread to eastern Africa, the 
Middle East, and Asia. However, although these predictions are suggestive of a 
potential origin for PPRV, caution must be exercised in their interpretation because 
estimates of geographic origin rely on available datasets, and these datasets need 
enhancing to provide greater confidence for phylogenetic assessment. As more 
sequence data become available for PPRV and the other morbilliviruses, ancestral 
origins of each virus and intraspecies differentiation might become clearer. 
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Chapter 4 Establishment of reverse genetics system to rescue the Nigeria 75/1 
PPR vaccine strain for the development of marker vaccines  
4.1 Introduction 
Across the developing world, PPRV places a huge disease burden on agriculture, 
primarily affecting the production and sustainability of small ruminant farming. The 
disease is most effectively controlled by vaccinating sheep and goats with live 
attenuated vaccines that provide lifelong immunity. However, the current vaccines 
and serological tests are unable to enable DIVA. This factor precludes the 
meaningful assessment of vaccine coverage and epidemiological surveillance based 
on serology, in turn reducing the efficiency of control programs. The availability of a 
recombinant PPRV vaccine with a proven functionality is a prerequisite for the 
development of novel vaccines that may enable the development of DIVA tools for 
PPRV diagnostics. This Chapter describes the establishment of reverse genetics 
technique for PPRV that provides a means to manipulate RNA virus genomes 
through DNA copies (cDNA) of the RNA genome. Further, the rescue of the 
positively marked recombinant virus by insertion of eGFP and the negatively marked 
recombinant virus by mutation of C77 mAb binding epitope on H gene of PPRV. 
 
4.2 Materials and methods 
4.2.1 Design and synthesis of PPRV Nigeria 75/1 full-genome cDNA 
incorporating eGFP 
The full-length PPRV cDNA plasmids generated were based on the PPRV Nigeria 
75/1 vaccine strain (GenBank accession no X74443). The plasmid containing the 
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complete PPRV antigenome (positive sense strand) sequence (15948 nt) with the 
insertion of eGFP gene was designed and synthesised commercially (DNA2.0, USA) 
(Figure 4.1a and Appendix VII). The eGFP reporter gene (822 nt) was introduced to 
enable rapid evaluation of rescue events, as a separate transcriptional unit between 
the P and M gene with the authentic 5’ UTR of the M gene and the 3’ UTR of the P 
gene. Unique restriction enzyme sites were inserted by nucleotide substitution into 
the UTRs of each gene and as such did not affect the total genome length or viral 
protein sequences. The full length clone was under the expression control of the T7 
RNA polymerase promoter and the primary transcript was cleaved at the AGP by the 
hepatitis delta ribozyme (Figure 4.1a). The synthesised plasmid, pPPRV+GFP 
Nigeria 75/1 was sequenced in its entirety to ensure the sequence was 100% identical 
to the wild type vaccine strain. 
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Figure 4.1 Schematic representation of the PPRV recombinant plasmids. (a) the 
synthetic plasmid, pPPRV+GFP Nigeria 75/1, incorporating eGFP as a reporter gene 
between the P and M genes and restriction enzyme sequences. (b) plasmid pPPRV 
Nigeria 75/1 without the eGFP gene incorporating restriction enzyme sequences. GP 
represents genome promoter and AGP represents anti-genome promoter. 
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4.2.2 Construction of full-length PPRV Nigeria 75/1 cDNA plasmid with 
mutations at C77 monoclonal antibody binding site 
Initially, the eGFP gene in the plasmid pPPRV+GFP Nigeria 75/1 was removed 
using MluI to obtain pPPRV Nigeria 75/1 (Figure 4.1b). The C77 mAb binding site 
mapped previously through phage display peptide library screening (Buczkowski, 
2010) was altered in the plasmid pPPRV Nigeria 75/1 by SDM to obtain three 
mutated plasmids ( pPPRV-C77a, pPPRV-C77b and pPPRV-C77c). The C77 
epitope mapped on the H protein of PPRV by phage display peptide library 
screening is depicted in Figure 4.2. Further, the 3-dimensional (3D) structure of H 
protein of PPRV Nigeria 75/1 highlighting critical residues in the C77 mAb binding 
epitope are shown in Figure 4.3. The amino acid residues critical for C77 mAb 
binding were mutated (6 amino acids in the pPPRV-C77a Nigeria 75/1, 3 amino 
acids in the pPPRV-C77b Nigeria 75/1 and 3 amino acids in the pPPRV-C77c 
Nigeria 75/1) into alanine (A) residues on the H gene of the pPPRV Nigeria 75/1 
full-length cDNA plasmid through SDM using overlapping primer sets (Appendix 
III). An intermediate cloning vector pT7 Blue (Promega) containing the H gene from 
pPPRV Nigeria 75/1 was constructed and used to substitute either three or six amino 
acids as shown in the Figure 4.2. The H gene of the PPRV full-length plasmid was 
replaced with the mutated H genes using NotI and SwaI restriction enzyme sites. 
This resulted in the generation of 3 different full-length plasmids of PPRV Nigeria 
75/1: 
 
1. pPPRV-C77a Nigeria 75/1 Y540A I542A Y543A R547A S549A S550A 
2. pPPRV-C77b Nigeria 75/1 Y540A I542A Y543A 
3. pPPRV-C77c Nigeria 75/1 R547A S549A S550A 
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Figure 4.2 Schematic representation of predicted epitope for C77 mAb binding. 
The proposed epitope (upper strand) for the C77 mAb binding site on H protein of 
PPRV Nigeria 75/1 as determined by phage display, and the mutated H (lower 
strands). Residues critical for C77 mAb binding are indicated by the star symbols 
and the amino acids position on H protein are indicated by number. Amino acid 
residues mutated to alanine (A) in full-length plasmids are coloured red and 
underlined in lower strands. 
 
Figure 4.3 The 3D structure of H protein of PPRV Nigeria 75/1 highlighting the 
C77 mAb binding epitope. The 3D structure was obtained from SWISS-MODEL 
(homology-modelling server), accessible via the ExPASy web server. The H protein 
of PPRV Nigeria 75/1 as a homo-dimer structure was constructed utilising the 
template crystal structure of measles virus H protein (Hashiguchi et al., 2007), 
Protein Data Bank identification code is 2zb5.1.A. Critical amino acid residues for 
C77 mAb binding site Y540 I542 Y543 are coloured in red and R547 S549 S550 in 
blue on the 3D surface of the H protein of PPRV Nigeria 75/1.  
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4.2.3 Construction of helper plasmids of PPRV Nigeria 75/1 
The helper plasmids required for rescue of recombinant viruses, PPRV Nigeria 75/1 
N (pGEM-N), P (pGEM-P) and L (pGEM-L), were cloned under the control of the 
T7 RNA polymerase promoter in the pGEM3z vector (Promega). The N, P and L 
coding sequences of PPRV Nigeria 75/1 were amplified (Figure 4.4) using gene 
specific primer sets (Appendix III) and pPPRV+GFP Nigeria 75/1 as the template. 
The amplicons were gel purified and digested with unique restriction enzymes 
compatible with the multiple cloning site in the pGEM 3z vector. The amplified N 
fragment was digested with EcoRI and SalI enzymes, the P fragment was digested 
with SalI and PstI and the L fragment was digested with SalI. The digested products 
were gel purified and ligated with the pGEM 3z vector separately that was prepared 
by digesting the vector with the corresponding enzymes. JM109 cells were 
transformed with the ligated products and any resulting colonies were screened by 
miniprep and restriction enzyme digestion. The plasmids (Figure 4.4) were 
sequenced on both the strands to ensure no unwanted nucleotide changes were 
present. 
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Figure 4.4 Construction of helper plasmids containing the N, P and L coding 
sequences of PPRV Nigeria 75/1. (a) amplification of N, P and L coding sequence 
of PPRV Nigeria 75/1 with fragment size indicated in parenthesis, M indicates 1Kb 
plus DNA ladder (Appendix II). (b to d) plasmids pGEM-N, pGEM-P and pGEM-L 
containing the N, P and L coding sequences of PPRV Nigeria 75/1, respectively. The 
N, P and L genes were cloned under the control of the T7 promoter using unique 
restriction enzyme sites as indicated.  
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4.2.4 Transfection and recovery of recombinant PPRV from full length genome 
plasmids 
VDS cells were plated at 2.5x105 cells per well in 6-well cell culture plate (BD 
Falcon) and incubated at 37°C and 5% CO2 overnight. Cells (70% confluent) were 
washed with 1 ml of OPTI-MEM I reduced serum medium (Gibco) and infected with 
T7-polymerase expressing rFP virus at a MOI of 0.2 in 500 µl volume as described 
previously (Das et al., 2000). The plates were incubated at 37°C and 5% CO2 for an 
hour and rocked every 10 minutes for uniform distribution of the virus inoculum. 
During this period, the plasmid DNAs, TransFast Transfection Reagent (Promega) 
and OPTI-MEM I mix was prepared in order. Cells were washed and transfected 
with 1 µg of full-length PPRV cDNA plasmid and 1 µg pGEM-N, 1 µg pGEM-P and 
0.05 µg pGEM-L using TransFast transfection reagent (Promega) at a ratio of 6:1 
(wt/wt) in a total volume of 0.75 ml of OPTI-MEM I reduced serum medium/well 
(Gibco). Media was changed on cells at 24 hour post-transfection and observed for 
CPE for 3 days. Rescued viruses were harvested by freeze-thawing and further 
passaged in VDS cells. 
 
4.2.5 Immunofluorescence and confocal microscopy 
Immunofluorescences for the expression of N, H and or eGFP by the rescued viruses 
was carried out by labelling the N protein with an anti-PPRV-N C11 mAb and the H 
protein with anti-PPRV-H C77 mAb (BDSL, UK) and GFP autofluorescence 
(Mahapatra et al., 2006; Parida et al., 2007). Briefly, VDS cells were cultured on 
sterile glass coverslips in a 12-well plate to reach 60- 70% confluence and were 
infected with recombinant or wild PPRV Nigeria 75/1 viruses at an MOI of 0.01. 
Cells were fixed at 24 hours post-infection using 4% paraformaldehyde (PFA) 
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solution. The residual PFA was removed by washing the fixed cells twice with 
Ca/Mg free PBS. The cells were permeabilized using 0.1% Triton-X100 solution 
(Sigma) for 15 minutes and washed once with Ca/Mg free PBS. To block non-
specific binding of antibodies in the downstream steps, permeabilized cells were 
treated with 0.5% bovine serum albumin solution prepared in Ca/Mg free PBS 
(BSA-PBS, Sigma) for 30 minutes. The blocked cells were treated with primary 
mAbs anti-PPRV-N C11 (1 in 10) or anti-PPRV-H C77 (1 in 40) for an hour. The 
C11 mAb was raised in mice at Indian Immunologicals, Hyderabad, India and the 
C77 was generated from a hybridoma at the Pirbright Institute and is commercially 
available (BDSL, UK). The cells were washed thrice with Ca/Mg free PBS to 
remove any excess unbound primary antibodies. The conjugated secondary antibody 
IgG Alexa Fluor 568 (Molecular probes) (diluted 1 in 200) was incubated on cells 
for one hour. The cells were washed trice with Ca/Mg free PBS and treated with 4’,6 
diamidino-2-phenylindole (DAPI) for 10 minutes to stain the cell nuclear DNA. The 
coverslips were washed with deionised water and mounted on glass slides using 
aqueous mounting medium (Vectasheild H1000). Any excess of mounting media 
was removed and the edges of the coverslips were sealed using a transparent nail 
varnish. The slides were viewed under the Leica TCS SP2 Acousto-Optical Beam 
Splitter confocal scanning laser microscope at an appropriate excitation wavelength 
of 405 ηm (Blue) 488ηm (Green) or 568ηm (Red). Expression of GFP was 
visualised by autofluorescence. Images were captured and processed with the Leica 
Confocal Software (Leica Microsystems). 
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4.3 Results 
4.3.1 Rescue of recombinant PPRVs from cDNA clones 
Infectious recombinant viruses of PPRV Nigeria 75/1, with and without the eGFP 
(rPPRV+GFP Nigeria 75/1 and rPPRV Nigeria 75/1, respectively) and rPPRV-C77c 
Nigeria 75/1 were rescued from respective cDNAs. In contrast, despite several 
attempts at virus rescue of live virus from pPPRV-C77a Nigeria 75/1 and pPPRV-
C77b Nigeria 75/1 was unsuccessful. The CPE characteristic of PPRV infection was 
observed in the rescued viruses from three days post transfection with 100% 
efficiency. The CPE observed under light microscope for all the three recombinant 
viruses appeared to be identical to that of produced by the parental PPRV Nigeria 
75/1 vaccine strain. 
 
4.3.2 Confirmation of the identity of the rescued viruses 
Total RNA isolated from the recovered PPRV recombinants (rPPRV+GFP Nigeria 
75/1, rPPRV Nigeria 75/1 and rPPRV-C77c Nigeria 75/1) at passage 3 were 
subjected to RT-PCR using PPRV genome specific primers using a −RT as a control 
for carry over DNA. The expected amplicon sizes were observed on an agarose gel 
(Figure 4.5) and sequences were 100% identical to each respective plasmid (data not 
shown).  
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Figure 4.5 Confirmation of identity of rescued recombinant PPRVs. (a) RNA 
extracted from VDS cells infected with rPPRV+GFP Nigeria 75/1 or rPPRV Nigeria 
75/1 were subjected to RT-PCR using specific primers sets (PPR-F7 and PPR-R10) 
located on the P and M gene of PPRV. Lane 1; Marker 1Kb plus (Appendix II), lane 
2; PCR without RT enzyme with rPPRV+GFP Nigeria 75/1 RNA, lane 3; RT-PCR 
for rPPRV+GFP Nigeria 75/1 RNA, lane 4; PCR without RT enzyme with rPPRV 
Nigeria 75/1 RNA, lane 5; RT-PCR for rPPRV Nigeria 75/1 RNA and lane 6 (PCR) 
and 7 (RT-PCR) from VDS cell control RNA. (b) RNA extracted from VDS cells 
infected with rPPRV-C77c Nigeria 75/1 was subjected to RT-PCR using specific 
primers sets (PPR-F-15 and PPR-R-19) located on H and L gene of PPRV. 
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4.3.3 Immunofluorescence analysis for the assessment of eGFP expression and 
C77 mAb binding activity 
Immunofluorescence imaging demonstrated the expression of the N and H proteins 
of PPRV in infected cells following labelling with specific mAbs and their 
expression was comparable to that observed with the commercially available vaccine 
virus (Figure 4.6). The rPPRV-C77c Nigeria 75/1 could not be detected by the anti-
PPRV H mAb, but the viral N protein could be visualised using the anti-PPRV N 
mAb (Figure 4.6). The successful expression of eGFP from an additional 
transcriptional unit inserted within the PPRV genome was observed through its 
autofluorescence. 
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Figure 4.6 Characterisation of rescued PPR viruses using confocal microscopy. 
Expression of PPRV N, and H proteins and/or GFP with C77 mAb binding activity 
in the recombinants and parental PPR viruses in infected cells. VDS cells were 
infected with viruses at an MOI of 0.01 and fixed 24 hours post-infection using 4% 
PFA. Cells were stained separately with primary antibodies of mouse anti-PPRV H 
(C77) and mouse anti-PPRV N (C11) followed by a secondary Alexa Fluor 568 goat 
anti-mouse antibody. Cell nuclei were stained with DAPI. Confocal laser scanning 
overlay of recombinant or parental PPRV infected VDS cells using three different 
wavelengths – blue (405 ηm) for cell nucleus, red (568 ηm) for H or N protein of 
PPRV and green (488 ηm) for GFP are shown. The expression pattern of PPRV N 
and H proteins were comparable between the recombinant and parental viruses. 
Wild-type H protein in PPRV Nigeria 75/1, rPPRV+GFP Nigeria 75/1 and rPPRV 
Nigeria 75/1 were detected using the C77 mAb whilst H protein was not detected 
using this antibody in cells infected with rPPRV-C77c Nigeria 75/1. The 
autofluorescence of GFP was detected in the green channel for the rPPRV+GFP 
Nigeria 75/1 virus labelled with anti-PPRV H mAb. Fluorescence at 488 ηm was not 
visualised for the image showing the rPPRV+GFP Nigeria 75/1 virus labelled with 
anti-PPRV N mAb. 
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4.3.4 In vitro growth characterization of recombinant PPRVs 
The in vitro growth kinetics of the recombinant PPRVs and the parental virus was 
assessed in a multiple-step growth cycle as described (chapter 2). Multi-step growth 
curves were carried out to compare the growth of the recombinant viruses 
(rPPRV+GFP Nigeria 75/1, rPPRV Nigeria 75/1 and rPPRV-C77c Nigeria 75/1) 
with that of the parental vaccine strain (Nigeria 75/1) (Figure 4.7). The recombinant 
PPRVs grew to a similar titre and rate to that of the parental PPRV Nigeria 75/1 
virus. 
 
4.3.5 Assessing the stability of the heterologous protein and mutations to the 
C77 binding epitope 
To determine the stability of the inserted eGFP transcriptional unit and the mutations 
made to the proposed C77 mAb binding epitope in the recombinant virus genome, 
viruses were serially passaged in VDS cells for up to 9 passages and assessed for the 
expression of GFP and maintenance of the C77 binding site associated mutations 
using RT-PCR followed by sequencing and confocal microscopy. No changes were 
found in the passaged viruses compared to the originally rescued viruses. 
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Figure 4.7 The growth kinetics of recombinant and parental PPRVs in cell 
culture. A multi-step growth curve was obtained by infecting VDS cells with virus 
at an MOI of 0.01 and assessing viral growth at different time points by virus 
titration (TCID50).  
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4.4 Discussion 
Despite the availability of reverse genetics techniques for other morbilliviruses, a 
rescue system for PPRV was lacking until successful rescue was reported almost 
simultaneously by Hu et al and Muniraju et al (Hu et al., 2012a; Muniraju et al., 
2012; Muniraju et al., 2015). Initial attempts to rescue a field isolate of PPRV were 
unsuccessful and following extensive investigation, the high GC rich region of the 
genome (between M and F ORF) was believed to be a potential bottleneck for viable 
virus rescue (Bailey, 2006). To overcome potential sequence errors introduced by the 
techniques involved in stitching together a full-length DNA copy of the viral 
genome, a synthetic DNA approach was applied to generate error free plasmids for 
virus rescue. 
 
The insertion of unique restriction sites across the genome facilitates easy swapping 
of genes between PPRV isolates or from related viruses. The presence of unique 
restriction sites in RPV cDNA clone (Baron and Barrett, 1997) had facilitated 
swapping of M, F, H and N genes of PPRV efficiently (Das et al., 2000; Mahapatra 
et al., 2006; Parida et al., 2007). The presence of unique non-viral restriction sites in 
RPV has not affected the potency of the rinderpest vaccine as they are located in the 
non-conserved parts of the UTRs of genome and did not alter the protein coding 
sequence of the ORFs (Das et al., 2000; Mahapatra et al., 2006; Parida et al., 2007). 
The insertion of a novel transcription cassette within the genome facilitated ease of 
virus rescue and potential future evaluation of positive marker genes for DIVA 
activity. The new transcriptional unit was positioned between the P and the M genes 
of PPRV to ensure maintenance in the ratios of N and P protein required for efficient 
encapsidation, transcription and replication of the genomic RNA. In this study, the 
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insertion of eGFP within this transcription cassette is shown to be tolerated and 
facilitates potential future evaluation of positive marker genes for DIVA activity. 
Similar approaches had been investigated previously for RPV where in vitro 
development of positively and negatively marked vaccines has been assessed  
(Brown et al., 2005; Buczkowski et al., 2012; Das et al., 2000; Mahapatra et al., 
2006; Parida et al., 2007; Walsh et al., 2000a; Walsh et al., 2000b). Following the 
rescue and passage of the recombinant PPRV, CPE and growth characteristics 
observed with the recombinant virus was similar to that of the parental virus as seen 
by Hu et al (Hu et al., 2012a). The cellular distribution of N and H proteins in the 
recombinant virus was the same as in cells infected with the parental virus and was 
as expected for PPRV. 
 
Out of the three H mutated full-length c-DNAs (pPPRV-C77a, pPPRV-C77b and 
pPPRV-C77c), only the pPPRV-C77c was successfully rescued. The mutation of 
residues (R547 S549 S550) in pPPRV-C77c within H demonstrated the potential for 
a negative marker vaccine and H gene functionality and stability of the introduced 
mutations. A predicted 3D structure of the H protein of PPRV modelled using the 
crystal structure of measles virus H protein indicated that the amino acids Y540 I542 
Y543 were buried in the C77 mAb binding site and residues R547, S549, and S550 
of H protein are present on the outer surface. Live infectious virus could not be 
rescued from plasmids (pPPRV-C77a and pPPRV-C77b) containing substitutions at 
Y540 I542 Y543. Mutation of the pPPRV Nigeria 75/1 plasmid at residues R547 
S549 S550 allowed virus to be rescued suggesting that the Y540 I542 Y543 amino 
acids could be involved in important biological functions necessary for H protein 
function. These amino acids Y540 I542 Y543 region are highly conserved among all 
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the known PPRV isolates, but not the R547 S549 S550 region (Sungri 1996 vaccine 
strain has a leucine at position 547). However, it is possible that one or more amino 
acid in this region could be critical for the viability of the virus. Therefore, it would 
be interesting to find out whether single or combination of two amino acids 
substitution in this region (Y540 I542 Y543) would lead to a successful recovery of 
viable virus. 
 
The reverse genetics system developed in this study could be utilised for the 
investigation of the basic molecular biology of PPRV including protein-protein 
interactions, host-pathogen interactions or as a potential vaccine vector to express 
foreign immunogens to make a multivalent vaccine. The rPPRV-C77c Nigeria 75/1 
virus has been further assessed in vivo (Muniraju et al., 2015) (Chapter 5) for its 
vaccine potency, safety and DIVA strategy for use in the field that has the potential 
for serological differentiation between vaccinated and infected animals during a 
disease control programme. 
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Chapter 5 In vivo evaluation of the rPPRV-C77c Nigeria 75/1 rescued vaccine 
virus and its comparison with the parent PPRV Nigeria 75/1 vaccine strain 
5.1 Introduction 
In Chapter 4, the construction and rescue of various recombinant full-length PPRVs 
(rPPRV+GFP Nigeria 75/1, rPPRV Nigeria 75/1 and rPPRV-C77c Nigeria 75/1) and 
their in vitro characterisation was described. All the recombinant viruses were shown 
to be similar to their parental virus (PPRV Nigeria 75/1) in terms of CPE and 
syncytia formation and had comparable growth characteristics (rate and titre). The 
mutated H protein of rPPRV-C77c Nigeria 75/1 virus did not bind to the C77 mAb 
in VDS cells in an immunofluorescence study. Therefore, the next aim was to 
evaluate the rPPRV-C77c Nigeria 75/1 virus in vivo to determine its safety and 
potency and its fitness as a DIVA vaccine to differentiate between infected and 
vaccinated animals. As the mutation to the H protein had rendered the C77 mAb 
unable to bind to H protein in vitro we hypothesised that the serological response to 
the mutated H protein in vaccinated goats would be unable to bind to the H protein 
antigen present coated on the plates in the c-H ELISA (BDSL, UK). We also 
hypothesised that the serological response to the mutated H protein would enable 
differentiation between sera from vaccinated and naturally infected animals. 
 
5.2 Materials and methods 
5.2.1 Viruses 
The recombinant virus rPPRV-C77c Nigeria 75/1 and the parental PPRV Nigeria 
75/1 vaccine viruses were used for vaccination. The virulent PPRV Ivory Coast 89/1 
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was used as challenge virus. The rescued rPPRV-C77c Nigeria 75/1 (passage 3) and 
PPRV Nigeria 75/1 were grown in VDS cells to attain higher titres of TCID50 
(assessed in VDS cells). The PPRV Ivory Coast 89/1 strain, a virulent field strain, 
was passaged once in lamb kidney cells, before storage at -80 °C (Herbert et al., 
2014; Mahapatra et al., 2006). 
 
5.2.2 Animal experiment design 
Animal experimentation was conducted according to UK Home Office regulations 
(Project licence number: 70/6907) and following ethical approval from The Pirbright 
Institute, UK. European mixed breeds of 12 male goats, aged 6 to 9 months were 
randomly split into three groups (n= 4/ group) as shown in Table 5.1. Goats were 
kept under observation for a week for acclimatisation in the isolation unit at the 
Pirbright Institute. Animals in group one (G1, G2, G3 and G4) were immunised with 
104 TCID50 rPPRV-C77c Nigeria 75/1 virus whilst animals in group two (G7, G8, 
G9 and G10) received the PPRV Nigeria 75/1 conventional vaccine virus (104 
TCID50) via the sub-cutaneous route in a total volume of 1 ml (diluted in PBS). 
Groups one and two were housed in separate rooms along with two unvaccinated 
control animals per room (G5 and G6 with group one and G11 and G12 with group 
two). Animals were monitored daily for 28 days post vaccination (dpv). At 4 weeks 
post vaccination, all 4 control goats were segregated into a separate room and the 
animals from all 3 treatment groups were challenged with a pathogenic PPRV Ivory 
Coast 89/1 isolate (105 TCID50) by the intranasal route using a LMA® MAD 
Nasal™ Intranasal Mucosal Atomization Device (LMA, San Diego, USA). Animals 
which developed severe clinical signs were humanely terminated according to an 
established clinical score-card (Pope et al., 2013). Killing of animals was performed 
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by intravenous administration of a lethal dose of pentobarbitone (Vetoquinol, 
France). 
 
Table 5.1 Animal experiment design and treatments 
Animal group Animal number Vaccine treatment 
Group 1 
Goat 1 (G1) 
rPPRV-C77c Nigeria 75/1 
vaccine 
Goat 2 (G2) 
Goat 3 (G3) 
Goat 4 (G4) 
Group 2 
Goat 7 (G7) 
PPRV Nigeria 75/1 
vaccine 
Goat 8 (G8) 
Goat 9 (G9) 
Goat 10 (G10) 
Group 3 
Goat 5 (G5) 
Unvaccinated control 
Goat 6 (G6) 
Goat 11 (G11) 
Goat 12 (G12) 
 
5.2.3 Collection of clinical samples 
For all animals, rectal temperatures and clinical assessments were conducted twice 
daily. Ocular, nasal and saliva swabs (Table 5.2) were taken in 0.5 ml lysis buffer 
(MagNA Pure Roche, UK) on every alternate day for the first 2 weeks of both the 
vaccination and challenge period and then at weekly intervals to analyse the presence 
of PPRV nucleic acid by real-time RT-PCR using PPRV N gene specific primers 
(Batten et al., 2011). For virus isolation, samples were collected in 1 ml of PBS and 
used to infect VDS cells in a 25cm2 flask. Heparinised blood samples (Table 5.2) 
were collected for virus isolation from peripheral blood mononuclear cells (PBMCs) 
by co-cultivation with VDS cells. Clotted blood samples were collected for the 
evaluation of serum antibody responses specific to the PPRV H protein using a PPR 
Antibody ELISA kit (BDSL, UK) and the presence of PPRV neutralising antibodies 
were assessed using a virus neutralisation test (VNT). 
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Table 5.2 Clinical sample collection schedule 
Vaccination / challenge 
period 
Days post-vaccination 
(dpv)/ post-challenge 
(dpc) 
Sample name 
Vaccination 0 dpv Heparinised blood 
Clotted blood 
Ocular swab 
Nasal swab 
Saliva swab 
2 dpv 
4 dpv 
6 dpv 
8 dpv 
10 dpv 
12 dpv 
15 dpv 
22 dpv 
Challenge 28 dpv / 0 dpc Heparinised blood 
Clotted blood 
Ocular swab 
Nasal swab 
Saliva swab 
2 dpc 
4 dpc 
6 dpc 
8 dpc 
10 dpc 
12 dpc 
14 dpc 
 
5.2.4 White blood cells (WBCs) counts  
Heparinised blood was diluted 1:20 with 0.174 M acetic acid (10 µl blood + 190 µl 
glacial acetic acid) to lyse the red blood cells (RBC). Leucocytes were then counted 
using a modified Fuch's- Rosenthal haemocytometer and the cell count was 
expressed as the total number of leucocytes per mm3 of blood. 
 
5.2.5 Whole blood FACS analysis of lymphocytes 
The change in the proportion of live lymphocyte subsets (CD4+, CD8+, CD14+ and 
WC1/ γδ T cells) in peripheral blood samples collected from goats during both the 
vaccination and challenge period was analysed by antibody staining and flow 
cytometry as described by Herbert et al (Herbert et al., 2014). Monoclonal 
antibodies against cell surface markers used included CD4+ (647 clone 44.38, 
MCA2213A647 from Serotec), CD8+ (575 clone CC63, MCA837 from Serotec), 
CD14+ (405 clone CCG33 from Serotec) and WC1 (405 clone 197 from Serotec). 
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Appropriately diluted antibodies in a 25 µl volume along with 0.5 µl of live/dead 
aqua (495 life technologies) per sample was prepared and added in 200 µl of 
heparinised blood, vortexed and incubated for 20 minutes at room temperature. 
RBCs were lysed by adding 1 ml of RBC lysis buffer (Appendix I) and vortexed for 
1 minute. The mixture was diluted with 5 ml of PBS and centrifuged at 280 g for 5 
minutes. Cells were fixed in 200 µl of 4% PFA for 20 minutes. PFA was removed by 
diluting with 5 ml of PBS and centrifuged at 280 g for 5 minutes. Centrifuged cell 
pellets were re-suspended in 400 µl of PBS and read using the LSR Fortessa (BD 
Biosciences) with data acquired using the DIVA software (BD Biosciences) and 
analysed using FlowJo software (Tree Star Inc). Simultaneously, sample controls for 
live/ dead only and the single stain control with CD4+, CD8+, CD14+ and WC1 
containing live/dead aqua were prepared for compensation to correct the spectral 
overlap required in multicolour flow cytometry. 
 
5.2.6 Separation of goat peripheral blood mononuclear cells  
PBMCs were isolated from the heparinised peripheral blood samples using 
histopaque (Sigma 1083) density gradient centrifugation. 15 ml blood was diluted 
with an equal volume of PBS and 15 ml of histopaque (1.083 g/ml) was under-laid 
using a pipette. The samples were centrifuged for 45 minutes at 280 g at 20°C with 
the brake off. The buffy coat was carefully aspirated and residual RBCs were lysed 
using an ammonium chloride RBC lysis buffer (Appendix I). Cells were washed 
twice with 30 ml of ice-cold PBS and centrifuged for 10 minutes at 280 g at 4°C. 
The final cell pellet was re-suspended in 2 ml of complete media and cells were 
counted under the light microscope by staining the cells with a solution of trypan 
blue (0.4%, Gibco). 
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5.2.7 Virus isolation from the eye swabs and PBMCs 
Ocular swabs collected in PBS were squeezed on the wall of the tube and the 
released fluid was added to VDS cells (60-70% confluent) in 25 cm2 flask. The 
flasks were incubated at 37°C for an hour to allow virus adsorption with intermittent 
rocking of each flask every 15 minutes to ensure a uniform distribution of the 
inoculum. To the flasks, 4 ml of media (DMEM with 2.5% FCS and penicillin [100 
U/ml, Sigma]/ streptomycin sulphate [100 µg/ml, Sigma] and amphotericin B [2.5 
µg/ml, Sigma]) was added and incubated at 37°C for 5 days and observed under light 
microscope for assessment of CPE formation. Three blind passages were performed 
to ensure detection of low levels of virus. 
 
For virus isolation from PMBCs, fresh goat PBMCs (~1 x 106 cells in 1 ml total 
volume) were added to VDS cells (60-70% confluent) in a 25 cm2 flask containing 5 
ml of DMEM (2.5% FCS and penicillin / streptomycin sulphate and amphotericin) 
and incubated at 37°C overnight. The following day the PBMC were removed by 
washing the cell layer twice with PBS, the media was replaced and the cells were 
incubated at 37°C for another 4 days and observed under light microscope for 
assessment of CPE formation. As with attempts at virus isolation from ocular swabs, 
three blind passages were performed to maximise the potential for isolation. 
 
5.2.8 Virus neutralisation test 
The VNT was performed using VDS cells by following the method as described 
previously (OIE, 2012). Briefly, in 96-well microtitre cell culture plates, heat 
inactivated sera (at 56 °C for 30 minutes) was serially diluted two-fold in DMEM 
across the plate (100 µl per well and 8 replicates per dilution). An aliquot of PPRV 
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(100 µl containing 100 TCID50) was added to all wells including the virus control 
wells (no serum), with the exception of the cell control. The plates were incubated 
for an hour at 37 °C to allow serum virus reaction before being to 50 µl of VDS cells 
(1 x 105 cells per ml). The plates were incubated at 37 °C/ 5% CO2 for 7 days and 
read under light microscope to evaluate the presence/absence of CPE. In parallel, the 
virus used for the assay was titrated to re-confirm the anticipated titre (2000 to 2500 
TCID50 per ml). The virus titre was calculated according to the methods of Reed & 
Muench (1938) and the virus serum neutralisation titres were expressed as log10 with 
titres greater than 3 being considered positive. 
 
5.2.9 Competitive H protein ELISA 
The PPRV H protein-specific antibody response in the serum of vaccinated and 
challenged animals was assessed using the c-H ELISA (BDSL, UK). The assay 
works on the principle that antibodies to the PPRV H protein in test sera compete 
with the mAb (C77) in the test kit for binding to PPRV antigen. The binding of the 
C77 mAb is then detected using a secondary anti-mouse IgG conjugated to 
horseradish peroxidase and ortho-phenylene diamine (OPD) as substrate/chromogen. 
Briefly, the 96-well microtitre plate was coated with 50 µl of inactivated whole virus 
antigen appropriately diluted in PBS and incubated for an hour at 37°C on an orbital 
shaker. Following antigen adsorption, the plates were washed 3 times using PBS. 
Test sera were added at a dilution of 1/5 in a total volume of 50 µl blocking buffer 
(0.1% [v/v] Tween-20 and 0.3% [v/v] normal bovine serum) followed immediately 
by the addition of the C77 mAb at a dilution recommended by the manufacturer. 
Serum, antigen and mAb controls were included as recommended by the 
manufacturer. Following incubation for an hour at 37°C on an orbital shaker, plates 
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were washed thrice and incubated with secondary anti-mouse IgG conjugated to 
horseradish peroxidase for an hour at 37°C on an orbital shaker. Plates were washed 
thrice and the OPD substrate was added for 10 minutes and the plates were read 
using a VMax Kinetic ELISA microplate reader (Molecular devices) at an 
absorbance of 492 ηm. The optical density (OD) values were converted to percent 
inhibition (PI) values using the formula below: 
 
PI=100-([OD in test well/OD in mAb control well] x 100) 
 
Percentage inhibition values greater than 50% were considered positive as per the 
manufacturer’s instructions.  
 
5.2.10 RNA extraction and quantitative real-time polymerase chain reaction 
(qPCR) 
For viral RNA isolation swabs were collected in 0.5 ml of lysis buffer (MagNA Pure 
kit) and stored at -20° C until required for processing. RNA extraction was achieved 
using robotic extraction methods (MagNA Pure LC Total Nucleic Acid Isolation Kit, 
Roche, UK) following the manufacturer's protocols. 
 
The qPCR was performed following the method as described by Batten et al (Batten 
et al., 2011). Briefly, the RT-PCR reaction was performed using the Superscript 
III/Platinum Taq one-step RT-PCR kit (Invitrogen, Paisley, UK) using the 
Stratagene Mx3005p real-time PCR machine. Primers, probe and reaction condition 
were considered as described by Batten et al (Batten et al., 2011) with minor 
modifications. Briefly, 6 µl of test sample positive and negative control RNA were 
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loaded in duplicate onto 96-well optical reaction plates (Stratagene, UK). The PCR 
reaction mix of 19 µl was loaded into each well and contained 12.5µl Superscript III/ 
Platinum Taq One-step RT-PCR reaction mix, 0.5 µl Superscript III/ Platinum Taq 
One-step RT-PCR enzyme mix, 0.5 µl ROX reference dye, 0.5 µl probe (5 pmol/ µl), 
1 µl each of the forward and reverse primers (10 pmol/ µl) and 3µl nuclease free 
water. 
 
The thermal cycling conditions were as follows: 
Step 1: Reverse transcription (RT)   50°C 30 minutes 
Step 2: RT inactivation and DNA polymerase activation 95°C  10 minutes  
Step 3: Denaturation     95°C  15 seconds 
Step 4: annealing and elongation   60°C 1 minutes 
Step 5: Steps 3 and 4 repeated for 45 cycles 
 
Stratagene MxPro software (Stratagene, USA) was used for the data analysis. The 
threshold fluorescence was set using the software algorithm amplification-based 
threshold method. Samples with no detectable fluorescence above the threshold after 
40 cycles were considered negative (Batten et al., 2011). 
 
5.2.11 Sequencing of the C77 mAb binding epitope 
 The viruses isolated from the PBMCs of vaccinated animals were sequenced using a 
specific primer set PPR-F-P18 and PPR-R-P18 (Appendix III) based on the H gene 
of PPRV Nigeria 75/1. 
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5.3 Results 
5.3.1 Clinical protection of goats vaccinated with either the rPPRV-C77c or the 
conventional PPR vaccine following challenge with a virulent strain of PPRV 
Following vaccination, all animals remained healthy and did not show any 
vaccination-related adverse effects. Similarly, 28 dpv when the goats were 
challenged with virulent PPRV (Ivory Coast 89/1 strain), no clinical signs or high 
rectal temperatures (Figure 5.1) were observed in either the recombinant or 
conventional vaccinated groups. In contrast, the control unvaccinated animals 
developed severe clinical disease (pyrexia, mucopurulent nasal discharge, severe 
conjunctivitis, congested oro-nasal mucosa, lose motion and anorexic) and were 
humanely terminated at 8 days post challenge (dpc). The disease onset in control 
animals was observed from 3 dpc with an increase in rectal body temperatures to 
greater than 40°C. The increased temperatures remained high up to 8 dpc with the 
peak temperatures observed on 5 and 6 dpc. Animals in the vaccinated groups 
maintained their rectal body temperatures within the normal temperature range 
throughout the vaccination and challenge period of the experiment, displaying no 
clinical symptoms. 
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Figure 5.1 Rectal temperatures of vaccinated (rPPRV-C77c Nigeria 75/1 and 
PPRV Nigeria 75/1 parent vaccine virus) and unvaccinated goats upon 
challenge with virulent PPRV. Temperatures were measured twice per day, every 
alternate day during the vaccination period and every day during challenge period, 
and are presented as the mean values of the four animals in each group with the 
standard error. The threshold for pyrexic temperatures is indicated by the dashed 
line.  
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5.3.2 The immunosuppressive effect of PPRV on rPPRV-C77c Nigeria 75/1 and 
PPRV Nigeria 75/1 vaccinated animals upon challenge with virulent PPRV 
Suppression of the immune system during PPRV infection is due to the 
lymphotropic nature of PPRV and the diseased animal often develops a pronounced 
leukopenia, facilitating secondary infection. Vaccination with rPPRV-C77c Nigeria 
75/1 or the conventional live attenuated PPRV vaccine overcomes this 
immunosuppressive following natural infection with virulent PPRV and thus 
prevents exacerbation of opportunistic infection by secondary pathogens. No change 
in WBCs count was observed during the post-vaccination period in either of the 
vaccinated groups (Figure 5.2 and Appendix IV) except a transient reduction of 
WBC counts at 4 to 6 dpv. A significant (P<0.0001) reduction in live WBC counts 
was observed from 4 dpc to 8 dpc (the day of sacrifice of control goats on ethical 
grounds) in unvaccinated control animals in comparison to the WBC counts for both 
groups of vaccinated animals (Figure 5.2). No significant reduction (p<0.0001) in 
WBC counts was observed in either of the vaccinated groups during the challenge 
period. However, the leukocyte counts for both of the vaccinated groups went 
slightly down on 6 dpc and this transient reduction of leucocyte counts started 
increasing by 8 dpc. 
 
Further, analyses of whole blood samples using FACS staining of samples taken 
during the post-vaccination and post-challenge periods demonstrated, a specific and 
significant (2way ANOVA p<0.0001) decrease in CD4+ cells from day 4 post-
challenge in the non-vaccinated control animals (Figure 5.3a). The CD8+, CD14+ and 
WC1 cell counts in both vaccinated and unvaccinated animals were not altered 
significantly (P>0.05) in comparison with the normal cell counts (Figure 5.3b to d).  
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Figure 5.2 Leukocytes (WBC) counts for both vaccinated and unvaccinated 
goats following a virulent PPRV challenge. The total leukocytes were counted 
using a Neubauer haemocytometer and expressed as the total number of WBCs per 
ml of blood. The mean values of the four animals in each group ± the standard error 
of the mean are shown for both vaccination (a) and challenge periods (b).Significant 
differences in WBC counts between vaccinated and unvaccinated control groups 
(2way ANOVA p<0.0001) were observed from 4 days post-challenge. 
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Figure 5.3 CD4+, CD8+, WC1 T-cell and CD14+ monocyte/macrophage cell 
counts in vaccinated and control goats by whole blood FACS analysis. Blood 
was stained with anti-CD4+, anti-CD8+, anti-WC1 and anti-CD14+ monoclonal 
antibodies directly conjugated to flurochromes. Results were expressed as the mean 
percentage ± standard error of CD4+ lymphocytes (a), CD8+ lymphocytes (b), WC1 
lymphocytes (c) and CD14+ monocytes/macrophages (d) in peripheral blood. 
Significant differences in CD4+ cells between vaccinated and unvaccinated control 
groups (2way ANOVA p<0.0001) were observed from 4 days post-challenge. Whole 
blood FACS analysis for 6 day post-vaccination had not been conducted. 
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5.3.3 Vaccination prevents the replication of challenge virus in vaccinated goats 
Detection of virus specific RNA and live virus was observed in the eye swabs of 
control animals during the post-challenge period whereas no virus/ viral genome was 
detected from either of the vaccinated groups throughout the post-challenge period. 
To determine the level of virus replication and excretion in vaccinated and 
unvaccinated goats during the post-challenge period, clinical samples that had been 
collected from the eyes, nasal turbinates and saliva on each alternate day were 
subjected to extraction of RNA and qPCR. The actual Ct-values were subtracted 
from 40 (accepted maximum Ct value) and expressed as 40-Ct values. As shown in 
Figure 5.4, no Ct values were observed in vaccinated groups (rPPRV-C77c Nigeria 
75/1 and PPRV Nigeria 75/1) throughout the challenge period with few exceptions 
in both the vaccinated groups, specifically in nasal and saliva samples of animals at 6 
to 10 dpc (Appendix V). The unvaccinated control animals were positive by qPCR 
from 2 dpc in nasal and 4 dpc in ocular swabs and 6 dpc in all 3 samples (saliva, 
nasal and ocular). The Ct values in the unvaccinated control animals were high at 6 
dpc for all clinical samples and reached peak values at 8 dpc. Although the viral 
genome was detected late in saliva samples (6 dpc), the highest copy number was 
obtained in saliva samples from 6 to 8 dpc. 
 
Similarly, the ocular swab samples collected during the post-challenge period were 
used to isolate virus in VDS cells. It was not possible to recover virus from swabs 
taken from animals vaccinated with either rPPRV-C77c Nigeria 75/1 or PPRV 
Nigeria 75/1 following vaccination or challenge, even after three blind passages. 
However, it was possible to isolate PPRV successfully from the eye swabs of the 
unvaccinated control animals between 4 dpc and 8 dpc, the day of sacrifice (Table 
5.3).  
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Figure 5.4 Real time RT-PCR analyses for PPRV in lachrymal, nasal and 
salivary excretions during the post-challenge period. RNA extracted from clinical 
swab samples collected every alternative day post-challenge from each of the 
vaccinated and control goats were subjected to real-time PCR using specific N gene 
primers of PPRV. The mean 40-Ct value of each group was presented with ± 
standard error mean. The mean 40-Ct values ranging from 1 - 3 are considered as 
weak positive, 3 - 12 are positive and more than 12 are strong positive. 
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Table 5.3 PPRV isolation from clinical eye swab sample during post-challenge 
period. 
Treatment 
group 
Animal 
number 
Virus isolation* 
0dpc 2dpc 4dpc 6dpc 8dpc 10dpc 12dpc 14dpc 
 rPPRV-
C77c 
Nigeria 75/1 
vaccine 
G1 N N N N N N N N 
G2 N N N N N N N N 
G3 N N N N N N N N 
G4 N N N N N N N N 
PPRV 
Nig75/1 
vaccine 
G7 N N N N N N N N 
G8 N N N N N N N N 
G9 N N N N N N N N 
G10 N N N N N N N N 
Control un-
vaccinated  
G5 N N Y Y Y NA NA NA 
G6 N N Y Y Y NA NA NA 
G11 N N Y Y Y NA NA NA 
G12 N N Y Y Y NA NA NA 
 
* ‘N’ represents no virus isolation, ‘Y’ represents virus isolation, ‘NA’ represents not applicable, dpc 
represents day post-challenge. 
 
5.3.4 The mutations introduced to rPPRV-C77c Nigeria 75/1 were stably 
maintained in vaccinated animals 
The recombinant virus isolated from the PBMCs of with rPPRV-C77c Nigeria 75/1 
virus vaccinated goats at 4 dpv (Goat 1 and Goat 3) and 8 dpv (Goat 2 and Goat 4) 
confirmed that the mutated C77 mAb binding site on H protein of rPPRV-C77c had 
not been altered (Figure 5.5) or reverted back to its native sequence. 
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Figure 5.5 Sequence analysis of the rPPRV-C77c Nigeria 75/1 virus H protein 
following in vivo analysis. The mutations to the modified C77 mAb binding region 
were maintained following a passage of the mutated virus in goats. The RNA was 
extracted from virus isolated from PBMCs on 4 (from G1 and G3) and 8 (from G2 
and G4) days post-vaccination. An alignment of nucleotide sequences of the C77 
mAb binding region on the rPPRV-C77c Nigeria 75/1 virus with that of parental 
PPRV Nigeria 75/1 is shown. * indicates the residues mutated in at the proposed C77 
binding site in the rPPRV-C77c Nigeria 75/1 virus.  
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5.3.5 rPPRV-C77c Nigeria 75/1 virus induces a similar level of PPRV specific 
neutralizing antibodies to that induced by the parent Nigeria 75/1 vaccine strain  
Sera collected during both the vaccination and challenge periods were subjected to 
VNT using homologous PPRV vaccine strains. On the day of vaccination, animals 
were found to be negative for PPR specific antibodies whilst high titre virus 
neutralising antibodies were detected by second week of vaccination and reached at 
peak (4.76–5.31 log10) on 28 dpv, the day the animals were challenged, in both 
groups of vaccinated animals (Figure 5.6 and Appendix VI). All unvaccinated 
control animals remained negative during this vaccination period. Following 
challenge, titres of antibodies in both the vaccinated groups remained constant at two 
weeks post challenge. No statistically significant difference in neutralising antibody 
titre was seen between the recombinant and conventional vaccine groups. The 
unvaccinated animals developed PPRV specific neutralising antibodies by the 8 dpc, 
the day they were humanely terminated. Significant differences in the titer of 
neutralizing antibody was seen (2way ANOVA at p<0.0001) between the vaccinated 
groups (rPPRV-C77c Nigeria 75/1 and PPRV Nigeria 75/1) and the control groups at 
all days of sample analysis except on 0 dpv. However, no significant differences of 
neutralising titre were observed (P > 0.05) between both the vaccinated groups at all 
the sampling time points. 
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Figure 5.6 Detection of PPR specific neutralising antibodies in vaccinated and 
challenged goats. Mean virus neutralising titres (expressed as Log10) in vaccinated 
and challenged goats as assessed by virus neutralisation test. Serum samples were 
analysed at 0, 8, 15 and 28 days post-vaccination and 8 and 14 days post-challenge. * 
Represents a sample omission from the control unvaccinated animals due to their 
sacrifice on day 8 post-challenge. 
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5.3.6 rPPRV-C77c Nigeria 75/1 vaccination has precluded serological 
differentiation from the conventional vaccinated and challenged goats 
The PPRV H protein-specific antibody response in serum collected from vaccinated 
and challenged animals was assessed using the commercially available c-H ELISA 
kit (BDSL, UK). All animals were sero-negative for PPRV specific antibodies on the 
day of vaccination (Figure 5.7). Unexpectedly, both the recombinant and 
conventional vaccinated animals were positive for PPRV H protein-specific 
antibodies starting from 8 dpv and the antibody levels reached a peak by 2 weeks 
post-vaccination, after which the level was maintained. Two unvaccinated control 
goats (G 2 and G 3) became seropositive by 8 dpc with the remaining two goats 
being border-line for serological positivity on the day they were terminated with 
severe clinical disease. Significant differences in the PI values were seen (2way 
ANOVA at p<0.0001) among the vaccinated (rPPRV-C77c Nigeria 75/1 and PPRV 
Nigeria 75/1) and control groups from 8 dpv throughout all of the sampling points. 
However, no significant difference (P > 0.05) in the proportion of PI values was 
observed between the two vaccinated groups for any sampling day during the 
vaccination and challenge periods. 
  
156 
 
 
Figure 5.7 Detection of PPRV H specific antibodies in vaccinated and 
challenged goats. Mean percent inhibition values of PPRV H-specific antibody 
responses in animals vaccinated with the wild type vaccine, rPPRV-C77c Nigeria 
75/1 and unvaccinated animals as determined by c-H ELISA. Serum was collected 
on days 0, 6, 8, 10, 12, 15, 22 and 28 days post vaccination as well as on day 8 post-
challenge. The 50% inhibition value is considered as the cut-off titre and is indicated 
by a dotted line. The mean percent inhibition values with ± standard errors of mean 
are presented. 
  
157 
 
5.4 Discussion 
Recent studies reporting the rescue of PPRV expressing GFP or FMDV VP1 
proteins have been limited to in vitro data in their assessment of the protective 
efficacy of vaccines against challenge (Hu et al., 2012b; Yin et al., 2014). In the 
present study in vivo data has been generated to demonstrate that the rPPRV-C77c 
Nigeria 75/1 virus is able to generate adequate protection from virulent challenge in 
the natural host for PPRV, small ruminants. In vivo assessment is a necessary 
prerequisite to determine the utility of recombinant versions of vaccines prior to 
further development and licencing in the field. Both the parental (PPRV Nigeria 
75/1) and mutated (rPPRV-C77c Nigeria 75/1) vaccines provided complete 
protection against a lethal dose of PPRV challenge. None of the animals in either 
vaccinated group showed any evidence of PPR disease and survived the challenge 
with pathogenic PPRV without any systemic replication of the virus. Furthermore, 
there was no transmission of vaccine virus to in-contact unvaccinated control 
animals housed with the vaccinated animals during the 4 week period post-
vaccination demonstrating that both the parent and mutated (rPPRV-C77c Nigeria 
75/1) vaccines are highly unlikely to transmit between animals and potentially revert 
to virulence in the field. Indeed, none of the control animals seroconverted and all 
developed clinical disease following challenge. High titre PPRV specific serological 
responses were demonstrated at 28 dpv by both VNT and ELISA for all vaccinated 
animals and the antibody levels in vaccinated goats was not increased even after 
challenge. This maintained antibody level without any virus replication in the 
vaccinated animals after challenge suggests the provision of sterile immunity by both 
of the vaccines. Further analysis of whole blood samples in FACS staining and total 
leucocyte counts enabled the demonstration of leukopenia in the control animals 
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from 4 dpc and suggested that this response may be linked to the reduction in CD4+ 
cells as determined FACS analysis of samples from the post-challenge period. 
However the huge loss of leucocytes in the non-vaccinated, challenged control 
animals might be due to the death of granulocytes (neutrophils) alongside the death 
of the CD4+ cells. Total leucocyte counts demonstrated a transient leukopenia in 
both the vaccinated groups similar to Rajak et al (Rajak et al., 2005a).  
 
Although the rPPRV-C77c Nigeria 75/1 vaccine virus was indistinguishable from 
the parent vaccine strain in its ability to protect animals, DIVA potential was not 
fulfilled with the mutations applied to the residues within the H protein using the 
current c-H ELISA. Previous studies with other viral vaccines such as RPV 
(Buczkowski et al., 2012), NDV (Peeters et al., 2001) and classical swine fever virus 
(Wehrle et al., 2007) vaccines have postulated that epitope deletion may represent an 
efficient mechanism to generate DIVA vaccines. However, in the current study 
although the epitope mutation prevented binding of the C77 mAb in vitro it was not 
sufficient to enable DIVA in vivo. As mapped by phage display screening 
techniques, 6 critical residues were implicated for C77 binding. Mutation of 3 critical 
residues from wild type to alanine (R547, S549 and S550) prevented the binding of 
mAb to the H protein of the virus infected cells in immunofluorescence studies. 
These mutations were seen to be stable after several passages of rescued virus in cell 
culture. As it was not possible to rescue the virus after mutating the additional 3 
critical residues (Y540, I542 and Y543), the animal experiment was carried out by 
vaccinating goats with the rPPRV-C77c virus containing just 3 mutated residues 
(R547A, S549A and S550A) (Muniraju et al., 2015). It is likely that further 
mutations to the PPRV C77 mAb binding region are required to enable a serological 
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DIVA response to be generated following vaccination with a vaccine containing 
mutated H protein. Investigations to further explore mutation to the C77 binding 
region are planned. Another approach is currently underway to further develop a 
PPRV DIVA test using synthetic peptides specific to the C77 epitope region. The 
linear epitope present in the peptide may prevent the binding of the antibodies 
present in the serum.  
 
Additional approaches to generate a DIVA vaccine could focus on the generation of 
a recombinant vaccine strain containing a chimeric N protein gene whereby the 
variable C-terminus of N could be swapped with that of RP. In this, the RP specific 
variable part of N gene could be detected by a specific ELISA (Parida et al., 2007) 
whilst an ELISA specific for the PPRV C-terminus of the N protein (unpublished) 
would detect serological responses to naturally infected animals. If successful, the 
development of a DIVA test would be a great boon in the less developed regions of 
the world where PPRV represents a major obstacle to the development and 
maintenance of subsistence farming. 
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Chapter 6 Segmentation of PPRV to generate multivalent vaccines 
6.1 Introduction 
Several of the viral diseases that share common hosts (sheep and goat) with PPRV, 
including BTV, CPV, RVFV and pestiviruses, are under-reported (Kul et al., 2008; 
Mondal et al., 2009; Saravanan et al., 2007). In many cases, these diseases are 
endemic in areas where PPRV is also endemic and as such their epidemiological 
distribution overlap. Importantly, current vaccination strategies are lacking for 
several of these diseases and where vaccines exist they often require multiple 
administrations which is not cost effective in resource-limited settings. The 
development and application of multivalent vaccines in endemic regions would 
therefore greatly reduce the cost, and give more efficient use of resources leading to 
the successful control of multiple diseases including those with no effective vaccines 
currently available. BTV, an orbivirus with a ten-segmented genome, exists in 26 
serotypes and the inactivated vaccines employed in disease control programmes are 
expensive to produce (Calvo-Pinilla et al., 2014). RVFV with a three-segmented 
genome (bunyavirus) is a zoonotic disease and an expensive inactivated vaccine is 
used to control the disease with a safe live attenuated vaccine also available (Indran, 
2012). With the existence of effective live attenuated CPV vaccines, glycoproteins of 
PPRV have been added to CPV based recombinant thermostable bivalent vaccines, 
and protection against PPRV has been demonstrated (Berhe et al., 2003a; Chen et 
al., 2010; Diallo et al., 2002a). However, recombinant CPV vaccines expressing the 
F and H proteins of PPRV require multiple administrations and do not wholly protect 
against virulent PPRV challenge due to the presence of pre-existing immunity to 
CPV (Caufour et al., 2014). 
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Paramyxoviruses such as MV and NDV (NDV belonging to the genus Avulavirus) 
were developed as viral vectors expressing transgenes and have been proven to be 
safe and efficient (Brandler et al., 2013; Bukreyev et al., 2005; Nakaya et al., 2001; 
Singh et al., 1999). Further, a novel genome segmentation strategy (Figure 6.1) was 
adopted to overcome the genome length constraint for insertion of multiple and long 
transgenes, as demonstrated in pioneering work with MV (Takeda et al., 2006) and 
independently with NDV (Gao et al., 2008). 
 
This chapter describes the generation of two-segmented recombinant PPRV using 
reverse genetics techniques. The first segment incorporated eGFP as a heterologous 
protein whilst the second segment incorporated the VP2 outer capsid protein of BTV 
(serotype 1). The rescue of a segmented version of PPRV expressing heterologous 
proteins and their in vitro characterisation is described in this chapter. 
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Figure 6.1 Schematic representation of a two segment strategy to generate 
infectious morbilliviruses with a two-segment genome. The first segment consists 
of the N, P, M and F genes whilst the second segment consists of the H and L genes. 
Recombinant viruses were rescued by transfecting both segments of the genome and 
the N, P and L helper plasmids into susceptible cells. The new infectious virus 
particle recovered contains both the genome segments. The potential for generation 
of non-infectious defective particles containing only a single segment exists. 
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6.2 Materials and methods 
6.2.1 Construction of two-segmented PPRV cDNAs 
Two-segment PPRV genome plasmids were constructed from the full-length cDNA 
plasmids of the pPPRV+GFP Nigeria 75/1 vaccine strain that already contained the 
eGFP gene as a heterologous transcription unit (Chapter 4). A schematic diagram 
showing the segmentation strategy for the PPRV genome and the steps involved in 
generating the segmented plasmids are shown in Figures 6.2 and 6.3. The first 
segment consists of the N, P, GFP, M and F genes and the second segment consists 
of the BTV VP2 gene alongside the H and L genes of PPRV. At the termini of each 
segment the authentic 3’ GP and 5’ AGP sequences of PPRV were retained. The 
presence of unique restriction enzyme sites in the PPRV full-length clone 
(pPPRV+GFP Nigeria 75/1) were kept intact. The segmented gene constructs were 
under the transcriptional control of the T7 RNA polymerase promoter in a eukaryotic 
expression vector backbone (pJ711) as in the parental pPPRV+GFP Nigeria 75/1. 
The ‘rule of six’ was followed in each segment to achieve efficient genome 
replication. Newly constructed PPRV plasmid sequences were confirmed by 
sequencing the modified regions on both strands.  
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Figure 6.2 Schematic representation of the segmentation strategy and 
construction of a two-segmented (pPPRVseg1GFP and pPPRVseg2a) PPRV 
genomic plasmids. 
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6.2.1.1 Construction of the PPRV genome segment one plasmid, 
pPPRVseg1GFP 
The plasmid pPPRVseg1GFP consisted of the ‘GP-N-P-GFP-M-F-AGP’ sequence 
of pPPRV+GFP Nigeria 75/1 (Figure 6.2 and Appendix VII). The following steps 
were followed to construct pPPRVseg1GFP. 
 
1. pPPRV+GFP Nigeria 75/1 was digested with AcII and BsiWI to obtain a 7,873 
nucleotide long fragment containing ‘N-P-GFP-M-F’. 
2. Amplicons containing the ‘AGP-vector backbone-GP’ (3,971 nucleotides long) 
were amplified using primer set Seg1F BsiWI +3 and Seg1R AcII (Appendix III) and 
digested with the BsiWI and AcII enzymes. Additional nucleotides ‘TGA’ were 
inserted immediately after F gene stop codon through primer Seg1F BsiWI +3 to 
adjust the segmented genome length to make it multiple of six. 
3. Fragments obtained from steps 1 and 2 were gel purified, ligated and transformed 
into bacterial cells, to obtain pPPRVseg1GFP. The size of the pPPRVseg1GFP 
plasmid was 11,826 nucleotides (Figure 6.2). The pPPRVseg1GFP was sequenced to 
confirm the presence of the correct nucleotide sequences and organisation of the 
genes. 
 
6.2.1.2 Construction of PPRV genome segment two plasmid, pPPRVseg2a 
The plasmid, pPPRVseg2a consisting of the ‘GP-H-L-AGP’ sequence of PPRV 
(Figure 6.2 and Appendix VII) was constructed following the steps as described 
below. 
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1. pPPRV+GFP Nigeria 75/1 was digested with AcII and NotI to obtain a 10,590 
nucleotide long fragment containing the ‘L-AGP-vector backbone-GP’. 
2. Amplicons of the ‘H gene’ (1873 nucleotides) were obtained using the primer set 
Seg2F AcII and Seg2R NotI (Appendix III) and digested with both AcII and NotI 
enzymes. 
3. Fragments obtained from step 1 and 2 were gel purified, ligated and transformed 
into bacterial cells, to obtain pPPRVseg2a. The size of the pPPRVseg2a plasmid was 
12,456 nucleotides (Figure 6.2). The plasmid, pPPRVseg2a was sequenced to 
confirm the presence of correct nucleotide sequences and organisation of the genes. 
 
6.2.1.3 Insertion of the VP2 segment of BTV into pPPRVseg2a  
The pPPRVseg2a construct was used to insert and express the VP2 outer capsid 
protein sequence of BTV (serotype 1). The VP2 CDS (2,886 nucleotide) long with 5’ 
and 3’ UTR sequences of the N gene of PPRV was inserted as a separate 
transcriptional unit preceding the H gene to generate pPPRVseg2bVP2 (Figure 6.3 
and Appendix VII). Steps followed in the plasmid construction are described below. 
 
1. pPPRVseg2a was digested with AcII and NotI to obtain a 10,590 nucleotide long 
fragment containing the ‘L-AGP-vector backbone-GP ’. 
2. The amplicon containing the H gene (1,925 nucleotides) was amplified using the 
primer set Seg2F PacI and Seg2R NotI (Appendix III) and digested with PacI and 
NotI enzymes. The H gene was removed from pPPRVseg2a and re-introduced to 
include the compatible UTR sequence with the preceding BTV VP2 gene. The 5’ 
and 3’ UTR sequence of the N gene were introduced between the H and the VP2 
genes through PCR primers. 
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3. The amplicon of the ‘VP2’ CDS from BTV serotype 1 (2,886 nucleotides) was 
amplified using the primer set Seg2VP2F AcII and Seg2VP2R PacI and digested 
with AcII and PacI enzymes. 
4. The three fragments obtained from the above steps 1, 2 and 3 were gel purified, 
ligated and transformed into bacterial cells, to generate pPPRVseg2bVP2 with the a 
total plasmid size of 12,456 nucleotides (Figure 6.3). The recombinant plasmid 
construct was sequenced to confirm the presence of the exact nucleotide sequences, 
gene orientation and organisation. 
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Figure 6.3 Schematic representation for the construction of a 
(pPPRVseg2bVP2) segmented PPRV genome with the VP2 gene of BTV. 
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6.2.2 Transfection and recovery of recombinant PPRVs from two-segmented 
genome plasmids  
The two-segmented PPRV genome plasmids (pPPRVseg1GFP and pPPRVseg2a or 
pPPRVseg1GFP and pPPRVseg2bVP2) were transfected into VDS cells (pre-
infected with rFP-T7) using TransFast transfection reagent along with the helper 
plasmids to generate N, P and L as described in Chapter 4 (section 4.2.4). The total 
amount of genomic plasmid DNA (1µg/well) needed for the transfection procedure 
to rescue the non-segmented PPRV, was split into two equal proportions (i.e., 0.5 
µg/well) for each of the two segmented genome plasmids. 
 
6.2.3 RT-PCR and sequencing to confirm the identity of rescued segmented 
viruses  
RT-PCR was performed on total RNA extracted from passage 3 and passage 9 
segmented viruses using following primer sets. For identification of genome segment 
one, forward primer PPR-F-18 (Appendix III) located on the F gene and reverse 
primer PPR-R-32 (Appendix III) located on the AGP were utilised to amplify the F 
and AGP regions. The eGFP gene from genome segment one was also amplified 
using primer sets PPR-F-7 and PPR-R-12 (Appendix III) located on the P and F 
genes, respectively. For identification of PPRV genome segment PPRVseg2a, 
forward primer PPR-F-1 (Appendix III) located on the GP and reverse primer PPR-
R-18 (Appendix III) located on the H gene of PPRV were used to amplify GP and H 
regions. Amplification with primer sets PPR-F-1 and PPR-R-18 also encompassed 
the VP2 gene in genome segment PPRVseg2b. 
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6.2.4 Immunofluorescence investigations to confirm the identity of the rescued 
segmented viruses 
To identify the segmented viruses, an immunofluorescence investigation was carried 
out using the anti-PPRVH mAb (C77) and an anti-BTV polyclonal antibody. 
Expression of GFP was observed by autofluorescence using a confocal microscope 
as described in chapter 4 (section 4.2.5). 
 
6.2.5 Multi-step growth curve 
Rescued segmented PPRVs and the parental un-segmented wild-type PPRV Nigeria 
75/1 were grown in VDS cells to compare growth kinetics as described in chapter 2 
(section 2.1.6). 
 
6.3 Results 
6.3.1 Rescue of recombinant segmented PPRVs using two-segmented genome 
approach 
Infectious recombinant PPRV with a two-segmented genome, rPPRVsegGFP was 
rescued from the plasmids pPPRVseg1GFP and pPPRVseg2a using reverse genetics 
techniques. Further, infectious segmented PPRV containing the VP2 gene of BTV, 
rPPRVsegGFP+BTV was rescued from the plasmids, pPPRVseg1GFP and 
pPPRVseg2bVP2. The recombinant viruses showed CPE and syncytia formation 
from day three post-transfection in VDS cells and CPE was similar when compared 
to the positive control wells containing rescue of the non-segmented rPPRV Nigeria 
75/1 (Figure 6.4). The rescued viruses were freeze-thawed once, clarified to remove 
cell debris and serially passaged in VDS cells up to passage 9.  
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Figure 6.4 Cytopathic effect and syncytia formation of the rescued 
rPPRVsegGFP and rPPRVsegGFP+BTV viruses in VDS cells. Segmented or 
non-segmented PPRV genome plasmids were transfected into VDS cells and the 
rescued recombinant segmented viruses (a) rPPRVsegGFP and (b) 
rPPRVsegGFP+BTV showed similar syncytia formation compared with the positive 
control well of (c) rPPRV Nigeria 75/1. Uninfected VDS cells are shown in Figure 
6.4d. Images were captured using a Nikon D7000 camera observed under light 
microscope (10x objective). Syncytia are indicated by arrows.  
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6.3.2 Confirmation of the identity of the rescued viruses 
The identity of rescued viruses rPPRVsegGFP and rPPRVsegGFP+BTV at passage 
3 was confirmed by RT-PCR followed by sequencing of amplified products. The 
PPRV genome segment specific primer sets were used in the amplification of 
fragments. From the genome segment one of both recombinant viruses, the ‘partial 
F-AGP’ fragment was amplified using primer sets PPR-F-18 and PPR-R-32 and also 
the GFP gene was amplified using the primer set PPR-F-7 and PPR-R-12. 
Simultaneously, using common primer sets, PPR-F-1 and PPR-R-18, the smaller 
‘GP-H fragment’ was amplified from the rPPRVsegGFP and the larger ‘GP-VP2-H 
fragment’ was amplified from rPPRVsegGFP+BTV (Figure 6.5 and Figure 6.6). A 
single amplified fragment from each primer set was clearly identified with an 
expected fragment size as observed by agarose gel electrophoresis. The amplicons 
were sequenced on both the strands and no mutations were observed (Figure 6.7 and 
6.8). The expected nucleotide sequences in the rescued viruses were confirmed. 
Similarly, the presence of the eGFP gene in segment one of both recombinant viruses 
was also determined by RT-PCR and sequence analysis (data not shown). 
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Figure 6.5 Confirmation of the identity of rescued rPPRVsegGFP virus by RT-
PCR. RNA extracted from passage 3 rPPRVsegGFP was subjected to RT-PCR 
using genome segment specific primers. Parallel PCR without reverse transcriptase 
enzyme was performed to confirm that the fragments were not amplified from carry-
over of genomic plasmid DNAs. Lanes 1 and 8 show the 1Kb plus marker 
(Appendix II). Lane 2 is a minus RT enzyme control for amplicons in lane 3 that 
shows the amplification of ‘partial F and AGP’ fragment from genome segment one 
using primer sets PPR-F-18 and PPR-R-32. Lane 4 is a minus RT control for the lane 
5 amplification of the ‘partial P, GFP and partial M’ fragment from genome segment 
one using primer sets PPR-F-7 and PPR-R-12. Finally lane 6 is a minus RT control 
for the lane 7 amplification of the ‘GP and partial H’ fragment from genome segment 
two using primer sets PPR-F-1 and PPR-R-18. All primers are listed in the Appendix 
III. The sizes of the expected fragments are shown in parenthesis. 
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Figure 6.6 Confirmation of the identity of rescued rPPRVsegGFP+BTV virus 
by RT-PCR. RNA extracted from passage 3 rPPRVsegGFP+BTV was subjected to 
RT-PCR using genome segment specific primers. Amplifications are as detailed in 
Figure 6.5 with primers specific for the ‘partial F-AGP’ (Lane 3); ‘partial P, GFP 
and partial M’ (lane 5); and ‘GP, VP2 and partial H’ (lane 7). Lanes 1 and 8 
represent the 1Kb marker (Appendix II). Lanes 2, 4 and 6 are RT minus controls for 
each amplification. 
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Figure 6.7 Nucleotide sequence alignments to confirm the identity of the rescued rPPRVsegGFP virus. The RT-PCR product obtained 
using PPRV genome segment specific primers with passage 3 and 9 of rPPRVSegGFP were sequenced and aligned with the plasmid sequence 
used in the transfection experiments. The alignment in panel (a) represents the PPRV genome segment one ‘partial F -AGP’ sequence in the 
plasmid pPPRVseg1GFP and those found in passage 3 and 9 of rPPRVsegGFP. Similarly, the alignment in panel (b) represents the PPRV 
genome segment two ‘GP- partial H’ sequence in the plasmid pPPRVs175eg2a and those found in passage three and nine of rPPRVsegGFP.  
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Figure 6.8 Nucleotide sequence alignments to confirm the identity of the rescued rPPRVsegGFP+BTV virus. The RT-PCR product 
obtained using the PPRV genome segment specific primers with passage 3 and 9 of rPPRVSegGFP+BTV were sequenced and aligned with the 
plasmid sequences used in the transfection and rescue of recombinant virus. The alignment in panel (a) represents the PPRV genome segment 
one ‘partial F -AGP’ sequence in the plasmid pPPRVseg1GFP and those found in passage 3 and 9 of rPPRVsegGFP+BTV. Similarly, the 
alignment in panel (b) represents the PPRV genome segment two ‘GP- partial VP2’ sequence in the plasmid pPPRVseg2aVP2 and those found 
in passage 3 and 9 of rPPRVsegGFP+BTV. 
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6.3.3 Immunofluorescence investigation into the expression of both homologous 
and heterologous protein expression from segmented PPR viruses 
Immunofluorescence imaging demonstrated the expression of the H protein of PPRV 
and GFP in the VDS cells infected with the rPPRVsegGFP and rPPRVsegGFP+BTV 
viruses (Figure 6.9). The successful expression of eGFP from an additional 
transcriptional unit inserted into the genome segment one of rPPRVsegGFP and 
rPPRVsegGFP+BTV viruses was observed through its autofluorescence. Polyclonal 
serum raised against BTV (whole virus) was used in Western blotting and confocal 
microscopic studies but was unable to detect VP2 protein expression either in the 
recombinant segmented PPRV or wild-type serotype 1 of BTV due to nonspecific 
background staining in the negative control uninfected cells (data not shown). 
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Figure 6.9 Expression of the PPRV H protein and GFP in the recombinant PPR 
viruses with a two-segmented genome. VDS cells were infected with (a) 
rPPRVsegGFP, (b) rPPRVsegGFP+BTV and (c) rPPRV Nigeria 75/1 at an MOI of 
0.01 and fixed at 24 hours post-infection using 4% PFA. The uninfected cells (d) 
were used as a negative control. Cells were stained with mouse anti PPRV H (C77) 
primary mAb followed by Alexa Fluor 568 secondary antibody. Cell nuclei were 
stained with DAPI. Autofluorescence of GFP was visualised. Confocal laser 
scanning overlay of three different wavelengths – blue (405 nm) for the cell nucleus, 
red (568 nm) for the H protein of PPRV and green (488 nm) for GFP are shown. The 
H proteins of rPPRVsegGFP, rPPRVsegGFP+BTV and rPPRV Nigeria 75/1 viruses 
were detected using the C77 mAb. The autofluorescence of GFP was detected only 
for the rPPRVsegGFP and rPPRVsegGFP+BTV viruses. 
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6.3.4 In vitro growth characteristics of recombinant viruses  
The replication efficiency of the recombinant PPR viruses with two-segmented 
genomes, rPPRVsegGFP and rPPRVsegGFP+BTV, were assessed by multistep 
growth curve in VDS cells and compared with the non-segmented wild-type PPRV 
Nigeria 75/1 vaccine strain. The rPPRVsegGFP virus exhibited a similar growth rate 
compared to PPRV Nigeria 75/1 with peak titres achieved at 84 hpi (Figure 6.10). 
The rPPRVsegGFP+BTV virus showed similar initial growth rate although the peak 
titre attained was approximately one log10 less than that of the parent rPPRVsegGFP.  
 
6.3.5 Stability of the genome segments and maintenance of transgenes 
RNAs isolated from passage nine viruses (rPPRVsegGFP and rPPRVsegGFP+BTV) 
were subjected to RT-PCR followed by sequencing. The PPRV genome segment 
specific primer sets were used in the amplification of fragments as described earlier 
for the passage three recombinant virus identification (Section 6.3.2). A single 
amplified fragment from each primer set was clearly identified with an expected 
fragment size (data not shown). The sequences obtained from segment one and two 
amplicons were aligned with passage three virus sequences and plasmid sequences 
as shown in Figure 6.7 and 6.8. The RT-PCR and sequence analysis confirmed the 
presence of GFP in rPPRVsegGFP virus and GFP and VP2 of BTV in 
rPPRVsegGFP+BTV virus after nine passages. 
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Figure 6.10 Growth kinetics of the segmented and non-segmented PPRVs in cell 
culture. A multi-step growth curve was carried out by infecting VDS cells with 
segmented rPPRVsegGFP and rPPRVsegGFP+BTV viruses and non-segmented 
wild-type PPRV Nigeria 75/1 at an MOI of 0.01. Viruses were grown for different 
time periods and samples taken at timepoints were titrated to determine viral titre at 
each timepoint (TCID50). 
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6.4 Discussion 
Establishment of a reverse genetics system for PPRV facilitates the manipulation of 
the virus genome to make it either positively or negatively marked (as discussed in 
Chapter 4). Further, this study has investigated the use of this full-length cDNA 
clone as a viral vector to develop multivalent vaccines expressing foreign 
immunogens of other viruses of relevance to small ruminant agriculture in PPRV 
endemic regions. It is known from previous studies that altering the transcriptional 
gradient in negative strand viruses, including that for PPRV, through the insertion of 
multiple transgenes can lead to the further polar-attenuation of genes. Insertion of a 
transgene at the 3’ proximal end of paramyxovirus genomes provides a high level 
expression at the cost of virus propagation. In contrast, whilst gene insertion at 5’ 
end has less effect on viral fitness, it can result in inadequate expression of the 
heterologous gene (Walsh et al., 2000a; Zhao and Peeters, 2003). In addition, where 
expressing extra genes from a non-segmented genome, the overall genome length, 
following extension, can have a detrimental impact on ability of a virus to function, 
often through the increased likelihood of internal deletion (Rima et al., 1997). 
Therefore, a segmented genome approach was chosen for this study PPRV to 
develop a multivalent vaccine. 
 
As both PPRV and BTV circulate with a similar epidemiological distribution and a 
bivalent vaccine for both viruses would be of great use, a segmented PPRV 
expressing a BTV outer capsid protein (VP2) was generated and characterised in 
vitro. Following from the published MV and NDV genome segmentation 
approaches, a two-segmented PPRV rescued was attempted (pPPRVseg1GFP and 
pPPRVseg2bVP2) incorporating both eGFP and the VP2 protein of BTV. The 
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heterologous genes were expressed from different plasmids with pPPRVseg1GFP 
consisting of ‘GP-N-P-GFP-M-F-AGP’ and pPPRVseg2bVP2 consisting of ‘GP-
VP2-H-L-AGP’. In this way the genes, and subsequently translated proteins, 
required for viable virus production were present across the two segments meaning 
that both segments were required for true functionality. For MV whilst a two-
segmented version was efficiently rescued, a three-segment strategy (N-P, M-F and 
H-L) led to the production of unwanted satellite bodies (Takeda et al., 2006). For 
NDV, a two-segment strategy (N-P-L and P-M-F) that contrasts slightly with the 
approach taken in the present study led to a loss of virus yield following extensive 
passage (Gao et al., 2008). As indicated, in this study the essential viral proteins (N, 
P and L) required for the formation of the RNP complex and efficient viral growth 
are located on two different segments. Though each RNA genome segment will be 
replicated and transcribed independently, the proteins from each segments produced 
in a single infected cell should complete the virus life cycle and will produce 
infectious particles. However, for the production of infectious virus during limit 
dilution passage the virions should contain both genome segments to enable viable 
virus production. Where genetic material for only one segment becomes packaged 
the defective particles may be capable of infecting new cells following fusion due to 
the presence of both glycoproteins on the envelope of budded virion although the 
incoming genetic material will not be sufficient to establish viral replication. 
 
The rescued segmented viruses (rPPRVsegGFP and rPPRVsegGFP+BTV) were 
phenotypically similar to the non-segmented wild-type PPRV Nigeria 75/1 in vitro. 
The growth characteristics of rPPRVsegGFP were similar to the non-segmented 
PPRV Nigeria 75/1 and to that reported for the recombinant MV and NDV 
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segmented viruses (Gao et al., 2008; Takeda et al., 2006). However, the 
rPPRVsegGFP+BTV with an additional VP2 transgene of around 3Kbp had a 
slightly reduced final yield. The conservation of both the genome segments and 
inserted transgenes in the recombinant segmented PPRV over multiple passages 
reflects its stability and effectiveness for use as a viral vector. Although the presence 
of VP2 of BTV was confirmed in the rescued segmented virus and the expression of 
GFP was confirmed by autofluorescence, the expression of VP2 of BTV has not 
been confirmed in this study due to the lack of of VP2-specific antibodies for BTV 
serotype 1. A polyclonal serum raised against BTV (whole virus) was used in 
Western blotting and confocal microscopy but did not detect the expression of VP2 
protein either in the rescued segmented PPRV or in the wild-type serotype 1 BTV 
infected cells. After confirming the expression of VP2 protein of BTV, the 
segmented PPRV needs to be assessed further for in vivo safety, compatibility and 
vaccine potency, at least for BTV as recombinant non-segmented PPRV can 
provided full protection in goats. This approach could be further extended to express 
multiple transgenes from BTV, RVFV and CPV, to generate multivalent vaccines for 
the control diseases of small ruminants in PPRV endemic areas. 
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Chapter 7 General discussion and further perspectives 
PPR is a highly contagious disease, widely distributed in Africa, the Middle East and 
Asia where the small scale and marginal farmers are mainly dependent on goat and 
sheep rearing for their livelihoods. Outbreaks of PPRV can cause 100% mortality 
and morbidity, and as such can severely affect small ruminant production and 
sustainability. 
 
PPRV has caused several serious epidemics over the last 3 decades and since 1993, 
sub-Saharan Africa, the Middle East and major parts of the Indian subcontinent have 
been considered as endemic, reporting frequent disease outbreaks and huge 
economic losses (Dhar et al., 2002). The detection of PPRV or antibodies against 
PPRV has been reported from almost all African countries with the exception of vast 
territories across Southern Africa (Libeau et al., 2014). It is unclear what factors 
have favoured the emergence and spread of the disease, but millions of small 
ruminants in southern Africa, central Asia, Southeast Asia, China, the European part 
of Turkey and Southern Europe must now be considered at high risk from PPRV 
incursion (FAO, 2013). The molecular epidemiology of PPRV based on the partial F 
and N gene sequence has been routinely used for the detection of virus lineage. 
However, these studies are not enough for understanding PPRV evolution and 
spread. With the development of advanced sequencing technologies, molecular 
epidemiological studies of viruses have started to utilise whole gene, and even 
complete genome data. Historically, full sequence data was only available for three 
lineages of PPRV (lineage-I, II and IV). In this study, full genome data was 
generated for all four lineages and was utilised to investigate the evolutionary 
dynamics of PPRV through time and space (Muniraju et al., 2014). The increased 
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data has enabled a more precise evolutionary and phylogenetic assessment of the 
relationships between lineages by reducing the associated estimation errors resulting 
in increased confidence in estimates. A Bayesian phylogenetic analysis of all PPRV 
lineages mapped the time to most recent common ancestor and initial divergence of 
PPRV to a lineage III isolate at the beginning of 20th century. Substitution rates are 
critical parameters for understanding virus evolution because restrictions in genetic 
variation can lead to lower adaptability and pathogenicity. The nucleotide 
substitution rate throughout the complete genome for PPRV was found to be similar 
to that predicted for other paramyxoviruses (10-3 to 10-4 substitution/site/year) 
(Furuse et al., 2010; Jenkins et al., 2002; Pomeroy et al., 2008; Wertheim and Pond, 
2011). The demographic analysis of PPRV indicated an increased divergence during 
the post-rinderpest eradication era, however the recent decline observed in viral 
genetic diversity could be due to active efforts in the control and eradication of 
PPRV. A phylogeographic approach estimated the probability for the root location of 
an ancestral PPRV and individual lineages as being Nigeria for PPRV, Senegal for 
lineage I, Nigeria/Ghana for lineage II, Sudan for lineage III, and India for lineage 
IV. This suggests that the origin of PPRV was in western Africa with subsequent 
spread to eastern Africa, the Middle East, and Asia. However, the PPRV genome 
sequence data representing the entire geographic region needs to be enhanced further 
to provide greater confidence in such phylogenetic assessments. 
 
From the perspective of all lineages across endemic areas PPRV has been controlled 
using two existing commercially available live attenuated PPRV (Nigeria 75/1, 
Sungri 96) vaccine strains. Although these are safe and efficacious vaccines, due to 
generally inconsistent vaccination strategies in endemic countries PPR has continued 
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to emerge. No tools currently exist that allow serological differentiation between 
vaccinated and naturally infected animals. Marker vaccines are a potential solution to 
the DIVA concept that may help in PPR control programmes, especially if 
eradication efforts increase. Marker vaccines along with companion DIVA tests are 
especially required for sero-surveillance during the final stage of any eradication 
programme to enable declarations of freedom from disease to be made. Without a 
marker vaccine and DIVA test, the time taken and costs incurred in ensuring 
serological freedom from natural infection following the cessation of vaccination are 
increased significantly. This was exemplified by the rinderpest eradication 
programme where serological surveillance in the absence of vaccination was costly 
and took many years. The current commercially available PPRV diagnostic ELISAs 
target the N and H proteins and detect antibodies in vaccinated as well as naturally 
infected animals. However more recently, some DIVA strategies for PPRV have 
focussed on developing protein subunit vaccines expressing the PPRV F and or H 
gene in viral vectors like pox viruses (vaccinia, Capri pox and fowl pox) and 
adenoviruses (canine or human type) (Chandran et al., 2010; Chen et al., 2010; 
Diallo et al., 2002a; Herbert et al., 2014; Rojas et al., 2014). Here the absence of the 
PPRV N protein in the vaccine preparation facilitates positive serological 
identification of naturally infected animals. However, such subunit vaccines often 
require multiple doses and may have reduced efficacy due to: (i) potential pre-
existing immunity to the viral vector (Caufour et al., 2014); (ii) the potential for 
short lived antibody responses; (iii) potentially high costs of recombinant vaccine 
production. An alternative strategy is to use the existing live attenuated PPRV 
vaccine and manipulate a specific region or epitope of a viral protein to obtain 
positively and/or negatively marked vaccines. 
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Using reverse genetics techniques RNA virus genomes can be modified through 
cDNA copies of their genome. Using this technique, a RPV vector based chimeric 
marker vaccine was developed for PPRV by replacing the F and H or F, H and M 
genes of RPV with those from PPRV. Both chimeric vaccines elicited protective 
immune responses in goats challenged with virulent PPRV (Das et al., 2000; 
Mahapatra et al., 2006). Despite in vitro and in vivo characterisation, the abrogation 
of vaccination during the final stages of the RPV eradication campaign precluded the 
use of these chimeric vaccines. However, the establishment of reverse genetics for 
PPRV had been unsuccessful until recently (Hu et al., 2012a; Muniraju et al., 2012). 
Previously, only minigenome systems and the transient expression of different viral 
proteins had been reported (Bailey et al., 2007). Previous attempts to generate a 
reverse genetics system for PPRV had failed, most likely due to errors in the 
sequence of the cDNA clone (Bailey, 2006). Certainly, the availability of a correct 
complete genome sequence is critical for successful establishment of PPRV reverse 
genetics system and recent technological advances have enabled the generation of 
full genome sequence with relative ease, as described in chapter 4. Alongside this the 
advances in DNA synthesis have enabled the synthesis of full length genomes in a 
more efficient manner. Further, commercial genome synthesis has avoided the 
introduction of unintentional mutations during cloning and ligation procedures that 
may affect the rescue of virus. 
 
As a proof of principle, the full genome cDNA of PPRV of one of the most widely 
used vaccine strains (Nigeria 75/1) was synthesised and rescued using helper 
plasmids (Muniraju et al., 2015). Three recombinant viruses (rPPRV Nigeria 75/1, 
rPPRV+GFP Nigeria 75/1 and rPPRV-C77c Nigeria 75/1) were recovered from the 
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cDNA clones. Of these rPPRV+GFP Nigeria 75/1 has attributes that may enable its 
use as a positively marked vaccine. The recombinant PPRV Nigeria 75/1 vaccine 
strain expressing GFP rescued by Hu et al (Hu et al., 2012a) was reported as an aid 
to the detection of CPE through the expression of GFP in infected cells to optimise 
the OIE accredited VNT. The expression of a GFP maker will enable greater 
confidence in the evidence for virus infection without the need to test for neutralising 
antibodies in sera. Further, the creation of GFP tagged virulent PPRV was proposed 
as a research tool for the evaluation of host-pathogen interactions as described 
previously for measles virus (de Vries et al., 2010). 
 
It was hypothesised that the approach taken with rPPRV-C77c Nigeria 75/1 would 
enable the generation of a negatively marked vaccine that would allow 
differentiation between vaccinated and naturally infected animals through the 
response to the mutated H protein. As the C77 mAb binding site had been mutated, it 
was anticipated that only sera from naturally infected animals would compete with 
the C77 mAb to bind whole virus antigen whilst sera from animals vaccinated with 
the recombinant virus containing the mutated H protein would be less able to 
compete and bind. However, whilst this hypothesis worked in an in vitro 
immunofluorescence study, the in vivo study demonstrated that although the 
vaccinated animals were fully protected against virulent virus challenge, the 
antibodies raised against rPPRV- C77c Nigeria 75/1 virus in goats were able to bind 
to the antigen used in the c-H ELISA indicating incomplete abrogation of the 
binding site of the C77 antibody. Alternatively it is possible that the polyclonal 
antibodies elicited against alternative, potentially overlapping epitopes present in this 
region of the mature protein bound to the H protein present in the whole virus 
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antigen preparation used in the ELISA. This could still prevent the binding of the 
C77 mAb through steric hindrance. As only three residues were mutated to generate 
rPPRV- C77c Nigeria 75/1 it is plausible that further mutations in this area may 
enable the fulfilment of DIVA requisites with this approach. 
 
Should this strategy fail, other approaches may be possible to enable generation of a 
DIVA vaccine. Such strategies include generation of a virus containing a chimeric N 
gene such that the hyper-variable region at the C-terminus of the N protein is not 
recognised in an ELISA developed against the PPRV C-terminus of the N protein. 
By exchanging this region with that of RPV this could enable the use of an existing 
rinderpest recombinant N protein-based indirect ELISA (Parida et al., 2007) to 
detect PPRV vaccinated animals whilst the PPR recombinant N protein ELISA 
(unpublished data) would detect only naturally infected animals. Although PPRV 
and RPV are antigenically closely related, the two ELISAs based on the highly 
variable region of the C-terminal of the N proteins of PPRV and RPV have been 
shown to be specific and not cross-reactive. In the absence of DIVA, another 
approach would be to use large ruminant serosurveillance as an indicator for the 
circulation of wildtype virus in areas where small ruminants are regularly vaccinated. 
Large ruminants can be subclinically infected and develop antibodies against PPRV 
(Balamurugan et al., 2014; Balamurugan et al., 2012a; Khan et al., 2008; Sen et al., 
2014). Sen et al (2014) recently reported the transmission of PPRV from clinically 
infected goats to cattle with the recovery of PPRV from these sub-clinically infected 
cattle after 3 weeks of direct contact challenge. In developing countries, both large 
and small ruminants are generally farmed together within close contact, often sharing 
enclosed habitations as well as pasture and drinking areas. Such scenarios provide 
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ideal opportunities for the transmission of wild type virus between these animal 
populations. A recent study assessing cattle and buffalo populations in an endemic 
area of Pakistan (unpublished data) and Tanzania (Lembo et al., 2013) demonstrated 
serological detection of PPRV antibodies in cattle and buffalo that may help to 
identify PPR virus circulation in such localities in the absence of clinical disease 
indicators in small ruminant populations. 
 
A further aspect of this study sought to increase the valency of the current live 
attenuated PPRV vaccines by generating segmented versions of PPRV expressing 
heterologous proteins from other small ruminant pathogens of importance in PPRV 
endemic areas. This was used to evaluate the potential for the utilisation of a single 
dose live attenuated vaccine against more than one disease to reduce the cost and 
improve the efficiency of vaccination programmes. Paramyxoviruses such as MV 
and NDV have been proven to be safe and efficient vaccine vectors and have been 
used to develop multivalent vaccines expressing foreign antigen from a wide range 
of related viruses (Brandler et al., 2013; Bukreyev et al., 2005; Nakaya et al., 2001; 
Singh et al., 1999). In this study, a recombinant two-segmented PPRV was created, 
with one segment carrying the VP2 outer capsid protein of BTV and the other GFP. 
The recombinant rPPRVsegGFP+BTV was successfully recovered from the cDNA 
clone. This virus needs to be characterised further in vitro for assessment of 
transgene expression and in vivo for vaccine safety and potency for PPRV and BTV. 
Further, in two additional recombinant viruses the GFP gene on segment one was 
replaced with GcGn gene of RVFV and the P32 gene of CPV (Figure 7.1). 
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Figure 7.1 A schematic representation of approaches to develop PPRV vector based (a) bivalent or (b) trivalent vaccines expressing 
antigens of GcGn from RVFV, P32 from CPV and VP2 from BTV. 
 
192 
 
However transfection experiments to recover virus from the cDNA clones were not 
completed due to time constraints. Utilising a combination of PPRV segments 
harbouring either the RVFV or CPV antigen on segment one and the BTV antigen 
on segment two paves the way for potential bivalent or even trivalent vaccines to be 
developed (Figure 7.1). Alternatively, by mixing these rescued viruses a tetravalent 
vaccine could be produced for PPRV, BTV, CPV and RVFV and the multivalent 
vaccines could be used according to the circulation of viruses in a particular 
geographical location. Further work is planned to evaluate this area of study that 
could have important future ramifications on the small ruminant sector in PPRV 
endemic regions.  
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Appendix 
I. Solutions and reagents 
TAE (Tris-acetate EDTA) buffer (50X) 
242g  Tris 
18.61g  EDTA 
57ml  Glacial acetic acid 
Make up to 1L with water 
TSS solution 
12 ml  LB (2X) medium 
8ml  10% PEG + 60mM MgSO4 (3X) 
1.2ml  DMSO 
2.8ml  water 
10% PEG+60mM MgSO4 (3X) 
90g  PEG8000 
192ml  water 
18ml  1M MgSO4 
TCM solution 
0.25ml  1M CaCl2 
0.25ml  1M MgCl2 
0.25ml  1M Tris/Cl 
Make up to 25ml with water 
SOC media 
50µl  IM Glucose 
25 µl  IMMgCl2 
25 µl  lMMgS04  
24ml  LB (1X) medium 
Growth medium 
450ml  DMEM 
50ml  Fetal calf serum 
5ml  Penstrep (Sigma 100,000 IU/ml) 
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RBC lysis buffer (10x) 
8.02gm  NH4Cl (ammonium chloride) 
0.84gm  NaHCO3 (sodium bicarbonate) 
0.37gm  EDTA (disodium) 
Make up to 1L with water. 
 
II. DNA marker 1 kb plus (Invitrogen)  
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III. Primer sequences  
List of PPRV genome specific primers used for amplification and sequencing 
Name Sequence Name Sequence 
PPR-F-P1 accaaacaaagttgggtaagga PPR-R-P1 cgaacaaagataacatgctgatc 
PPR-F-P2 gaagagttcaatatgtt(g/a)ttag PPR-R-P2 agtatgagagataccatgaac 
PPR-F-P3 tcctctggagctatgc(g/c)at PPR-R-P3 gcgatttccgagactagtt 
PPR-F-P4 aagattctggagg(a/g)ccagg PPR-R-P4 ttgagagacttgatacattcc 
PPR-F-P5 aactctcaagtacagcgttac PPR-R-P5 ggagttaagaacttcttgaat 
PPR-F-P6 aggagtgcaaagacgatcc PPR-R-P6 ggagtcattctctttaggct 
PPR-F-P7 tccagctaaaacctgt(c/t)ga PPR-R-P7 ttagcatcttgtggaattcc 
PPR-F-P8 agtgattgaggataacgac PPR-R-P8 ttagcgctaaacacacttcc 
PPR-F-P9 tacacgtgggcaactttag PPR-R-P9 agatatcggttaagatcctc 
PPR-F-P10 gtcatcatcaacgatga(t/c)caa PPR-R-P10 cctaagttttgtttgatgatg 
PPR-F-P11 cgcagaaaggaag(g/c)ag(a/g)ca PPR-R-P11 ttgcgacccgtgtcatgatg 
PPR-F-P12 catcatgacacgg(g/a)tc(g/c)caa PPR-R-P12 tggtcttacattcttggttatc 
PPR-F-P13 ctatatcaacaatga(g/a)cttgtc PPR-R-P13 aatctcttgtgtccacatatgt 
PPR-F-P14 tgagcccattgct(t/c)cagga PPR-R-P14 actgccgacctgtattgtc 
PPR-F-P15 gggcttgtcacattaatatgct PPR-R-P15 atggtgattgacctttcgtc 
PPR-F-P16 tccagagtcggct(g/t)aatac PPR-R-P16 gagaaatgagctcttgttac 
PPR-F-P17 gggattattcggaagaacata PPR-R-P17 aaaatgaaggaggtcgagtc 
PPR-F-P18 cattttgcaatggcac(a/g)gga PPR-R-P18 tggaaacatcataagtggctg 
PPR-F-P19 tctctgaggatagagtgttt PPR-R-P19 ggtctggtcttcaag(a/g)acat 
PPR-F-P20 tatcaaagatagctgcatatct PPR-R-P20 aattatcacaacgaggtctc 
PPR-F-P21 tcttattgatgggttcttcc PPR-R-P21 ctgcatgccctttcatcata 
PPR-F-P22 ctgtgtatagacaa(c/t)tggaa PPR-R-P22 ttacctgacaggcccgca 
PPR-F-P23 aagataaccaccgaggtg PPR-R-P23 attagggacactgtccag(a/g)g 
PPR-F-P24 gaatcgcctcactagtgca PPR-R-P24 gatataaggatctgttggaaa 
PPR-F-P25 gggtctcaattatcttaacatg PPR-R-P25 tggtctaagatttcatgtgc 
PPR-F-P26 ttgacaaagaaaggg(c/a)agtgt PPR-R-P26 taggcccatgagtaaactg 
PPR-F-P27 agtctctacatccaccaac PPR-R-P27 tccaccaaatgtctcctgtg 
PPR-F-P28 gagaaagatcacatgaatgaa PPR-R-P28 acagagatgtttggcttgaat 
PPR-F-P29 ctcacacattacatcaagg PPR-R-P29 cagcattgaaccggaacc 
PPR-F-P30 caacagcggggt(a/g)acagc PPR-R-P30 ggcctttaatcctatcataataag 
PPR-F-P31 ccattaagcaaagcataat(c/t)aga PPR-R-P31 aagctgggaatagatacttatcc 
PPR-F-P32 ggagggaatggttgttcac PPR-R-32 accagacaaagctgggaata 
PPR-F-P12b agggacccgcccgagaacgt PPR-R-P21B gaatcccactcattcttcagtgca 
PPR-F-P20B caagacagagatgagatcaatga PPR-R-P11b catgatgtttacacatggatgtgccg 
PPR-F-P11b ccgaggccaggcgcc(g/a)ggca PPR-R-P10b ggaggtggtcctc(c/t)ctcggt 
PPR-F-P5B ggcacagacgggaactcagt PPR-R-P9B cttgggtcgggt(c/t)tgtgct 
PPR-F-11C tTgccctcgaccaccggga PPR-R-P20B tcgtgggtgat(a/g)aatacg 
PPR-F-15B tcaccatgtccgcacaaag PPR-F-25B attatgattatgaacaattc 
PPR-F-P21B acctacaattccatcactgaagga PPR-F-29B ctggctgcgta(c/t)aaggaagttc 
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List of RACE primers used to determine the 3’ and 5’ end of PPRV  
Name Sequence 
P5-1 (5'-RACE) caacagcaggcagcgtgaat 
P5-2 (5' nest 1) cggcactaatcagacaaacaat 
P5-3 (5' nest 2) atccaaagctgagaaactgctg 
P3-1 (3'-RACE) aacgggtaatgatggacgagtc 
P3-2 (3' nested) cgctttgtctttgttcctcttg 
DT88 (adaptor) 
gaagagaaggtggaaatggcgttttgg 
(5'-phosphorylated, 3'-end inverted dA) 
DT89 (anti-adaptor) ccaaaacgccatttccaccttctcttc 
 
List of primers used for helper plasmids (N, P and L) cloning 
Name Sequence 
N-ORF-For-Nig75 gaccatggctactctcc 
N-ORF-Rev-Nig75 gtcttatcagctgaggagatcc 
P-ORF-For-Nig75 accaccgatggcagaagaac 
P-ORF-Rev-Nig75 ggattgttacgctgcttgg 
L-ORF-SalI-For-Nig75 aggttgtagtcgacatggactcactatcagtc 
L-ORF-SalI-Rev-Nig75 agatgtatgtcgacttaacctctgacgagtgc 
 
List of primers used for C77 monoclonal antibody binding site directed 
mutagenesis 
Name Sequence 
i) PPRV Ng75/1 H Y540A I542A Y543A 
Forward primer gagcatgcaatcgtggcctatgccgctgacacgggt 
Reverse primer acccgtgtcagcggcataggccacgattgcatgctc 
ii) PPRV Ng75/1 H R547A S549A S550A 
Forward primer gacacgggtgcctcagcagcttacttctacccagtc 
Reverse primer gactgggtagaagtaagctgctgaggcacccgtgtc 
iii) PPRV Ng75/1 H Y540A I542A Y543A R547A S549A S550A 
Forward primer gagcatgcaatcgtggcctatgccgctgacacgggtgcctcagcagcttacttctacccagtc 
Reverse primer gagcatgcaatcgtggcctatgccgctgacacgggtgcctcagcagcttacttctacccagtc  
 
List of primers used for PPRV genome segmentation and insertion of VP2-BTV 
Name Sequence 
Seg1F BsiWI +3 gcgcgtacgtgagatcactgtagtaaatcgatatacatctgc 
Seg1R AcII Cataacgttagatcttgctcctcct 
Seg2F AcII Acgaacgttatgtccgcacaaaggga 
Seg2R NotI  accatcgctcgaggcggccgccgagccat 
Seg2VP2F AcII gagcaagatctaacgttatggatgaactaggcatcc 
Seg2VP2R PacI atgtttaattaatgatttggacggagggtgcgtctgcgctcatacgttgagaagttttgt 
Seg2F PacI tcattaattaaacatcgcccgccagtattataaaaaacttaggacgaaaggtcaatcacc 
Seg2R NotI gatggctcggcggccgcctcgagcgat 
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IV. White blood cells count (per mm3 blood) in goats during post vaccination 
and post challenge period 
Period 
rPPRV-C77 Nigeria 75/1 rPPRV Nigeria 75/1 Unvaccinated control 
Goat 1 Goat 2 Goat 3 Goat 4 Goat 7 Goat 8 Goat 9 Goat 10 Goat 5 Goat 6 Goat 11 Goat 12 
0dpv 13600 11800 14800 10340 15400 12040 15800 9240 14640 14900 11400 11880 
2dpv 12900 11885 12000 10200 13180 11100 16260 9220 12900 14000 11550 12000 
4dpv 11780 10040 11680 8160 10080 9510 10940 8160 13000 14200 13960 10080 
6dpv 10560 9260 11680 7480 8080 8520 11880 7880 13740 15380 10680 10800 
8dpv 12250 12960 10860 9240 12560 9620 12820 7720 14080 14420 12040 12140 
10dpv 13600 12820 10520 9400 12060 10380 16500 8680 14780 16460 11860 11060 
12dpv 12260 11440 11940 10180 14640 8800 16020 9780 15360 14980 12440 12420 
15dpv 13040 12340 12100 10580 14540 9940 16100 9400 14140 14340 13420 12200 
22dpv 14060 12760 13460 10080 14380 11000 15540 8700 13600 14540 12460 12200 
28dpv/ 
odpc 14880 13240 11400 10420 14440 11680 17500 8200 13900 14660 11860 11980 
0dpc 
12880 13240 11400 10420 14440 11680 17500 8200 13900 14660 11860 11980 
2dpc 
10540 12380 12920 10320 14820 12280 13160 8280 13500 14620 12520 11780 
4dpc 
12900 11580 12180 11020 14220 11240 17000 9780 5900 6820 5600 6060 
6dpc 
9360 8980 8640 8100 9040 7580 12820 5780 4020 4340 3080 3380 
8dpc 
10780 10480 9200 8560 12340 8900 11720 7680 2640 4640 3920 3900 
10dpc 
10560 9900 10060 9100 11800 8400 11080 5940 
NA NA NA NA 
12dpc 
11280 10480 10260 9360 11300 8520 11860 6920 
NA NA NA NA 
* dpv, days post vaccination; dpc, days post challenge; NA, not applicable.  
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V. Ct-values from reverse-transcription real-time PCR in the clinical samples of vaccine-challenge experimental animals during 
challenge 
Treatment 
group 
Animal 
no 
Ct-values* 
0dpc 2dpc 4dpc 6dpc 8dpc 10dpc 12dpc 14dpc 
E N S E N S E N S E N S E N S E N S E N S E N S 
rPPRV-
C77 virus 
G1 - - - - - - - - - - - - - - - - - - - - - - - - 
G2 - - - - - - - - - - - - - - - - - - - - - - - - 
G3 - - - - - - - - - - - - - - - - - - - - - - - - 
G4 - - - - - - - - - - 37.7 - - -  - - - - - - - - - 
PPRV 
Nig75/1 
vaccine 
G7 - - - - - - - - - - - - - - 32.7 - - - - - - - - - 
G8 - - - - - - - - - - - - - 38.9 - - 39.7 - - - - - - - 
G9 - - - - - - - - - - - 33.2 - - - - - - - - - - - - 
G10 - - - - - - - - - - - - - - - - - - - - - - - - 
Control un-
vaccinated 
G5 - - - - - - 37.5 - - 29.2 30.0 25.2 24.2 21.9 19.2 NA NA NA NA NA NA NA NA NA 
G6 - - - - - - 35.8 - - 26.9 29.5 23.3 25.1 21.5 19.4 NA NA NA NA NA NA NA NA NA 
G11 - - - - - - - 40.5 - 30.4 31.8 28.1 25.5 27.0 23.5 NA NA NA NA NA NA NA NA NA 
G12 - - - - 37.2 - 38.6 37.3 - 28.5 28.8 26.5 27.6 25.1 20.6 NA NA NA NA NA NA NA NA NA 
 *Ct-value more than 40 are not considered and represented as '-'; Eye sample (E); Nasal Sample (N); Saliva sample (S); Days post-challenge (dpc); Not applicable (NA). 
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VI. PPRV specific neutralising antibody titres detected in serum of individual 
vaccinated and unvaccinated challenged goats. 
Treatment 
group 
Animal 
no 
Neutralisation titre (log10) 
0dpv 8dpv 15dpv 28dpv 8dpc 14dpc 
 rPPRV-
C77c 
Nigeria 75/1 
G1 0 2.8 4.16 5.31 5.31 5.31 
G2 0 2.83 4.36 4.76 4.36 5.31 
G3 0 2.91 5.61 5.01 5.01 5.01 
G4 0 2.66 4.36 5.31 5.01 5.36 
PPRV 
Nigeria 75/1  
G7 0 2.83 4.16 5.06 5.27 5.27 
G8 0 2.66 4.16 5.31 5.01 5.31 
G9 0 2.91 4.36 4.76 5.36 5.01 
G10 0 2.51 4.31 5.16 5.31 5.31 
Control 
G5 0 0 0 0 3.31 NA 
G6 0 0 0 0 3.06 NA 
G11 0 0 0 0 3.11 NA 
G12 0 0 0 0 3.06 NA 
Days post-vaccination (dpc); Days post-challenge (dpc); Not applicable (NA). 
 
VII. Plasmid sequences of un-segmented and segmented PPRV genome 
pPPV+GFP Nigeria75/1 
aataagatgatcttcttgagatcgttttggtctgcgcgtaatctcttgctctgaaaacgaaaaaaccgccttgcagggcggtttt
tcgaaggttctctgagctaccaactctttgaaccgaggtaactggcttggaggagcgcagtcaccaaaacttgtcctttcagttt
agccttaaccggcgcatgacttcaagactaactcctctaaatcaattaccagtggctgctgccagtggtgcttttgcatgtcttt
ccgggttggactcaagacgatagttaccggataaggcgcagcggtcggactgaacggggggttcgtgcatacagtccagcttgga
gcgaactgcctacccggaactgagtgtcaggcgtggaatgagacaaacgcggccataacagcggaatgacaccggtaaaccgaaa
ggcaggaacaggagagcgcacgagggagccgccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccaccactga
tttgagcgtcagatttcgtgatgcttgtcaggggggcggagcctatggaaaaacggctttgccgcggccctctcacttccctgtt
aagtatcttcctggcatcttccaggaaatctccgccccgttcgtaagccatttccgctcgccgcagtcgaacgaccgagcgtagc
gagtcagtgagcgaggaagcggaatatatcctgtatcacatattctgctgacgcaccggtgcagccttttttctcctgccacatg
aagcacttcactgacaccctcatcagtgccaacatagtaagccagtatacactccgctagcgctgaggtcccgcagccgaacgac
cgagcgcagcggcgagagtagggaactgccaggcatcctgggcggttctgataacgagtaatcgttaatccgcaaataacgtaaa
aacccgcttcggcgggtttttttatggggggagtttagggaaagagcatttgtcagaatatttaagggcgcctgtcactttgctt
gatatatgagaattatttaaccttataaatgagaaaaaagcaacgcactttaaataagatacgttgctttttcgattgatgaaca
cctataattaaactattcatctattatttatgattttttgtatatacaatatttctagtttgttaaagagaattaagaaaataaa
tctcgaaaataataaagggaaaatcagtttttgatatcaaaattatacatgtcaacgataatacaaaatataatacaaactataa
gatgttatcagtatttattatgcatttagaataccttttgtgtcgcccttattcgactccctatagaagttcctattctctagcc
taccgttgctccggtgatcctgcaccgcgccaattctaatctaggccgaggatcttcagcgtacgccggagtacacgcgcaaagg
ccggacatcagcttaacgcgccaattgcgcgtcgcctatgcatggggccgcctagccatgtaaacgtggtcctgtctaactggtc
cggccctagtggggtaattccttcgagccgggttcgagcaatttgatattctgtgtaaaactccgcctaaggtgctggttcgcca
atttgtggagcgctttgaacgtccgtcgggcgagaagattgcgagctgtgcggctgagttgacgtatctgtgctggatgattact
cataacggcaccgctatcaaacgtgccacgttcatgtcctacaatttttaatacgactcactataaccagacaaagctgggtaag
gatagttcttataatgactatagactggcaaacttaggagtaaagatcctactgtcggggagaggaggaggagcaagatctaacg
ttatggctactctccttaaaagcttggcattgttcaagaggaacaaagacaaagcgcctactgcgtcgggttcaggaggggccat
ccgggggattaagaatgttatcatagtccccattcccggggactcatccatcattacccgttcaagactgctcgacaggcttgtc
agattggccggagatcctgacatcaacgggtcaaagctgaccggcgtgatgatcagcatgttatctttgttcgtggagtcacccg
ggcaattgatacagcggatcacagatgatccagatgttagcatccgccttgttgaggtagttcaaagtactaggtcccagtccgg
gttgacctttgcatcacgtggtgctgatttggacaatgaggcagatatgtatttttcaactgaaggaccctcgagtggaagtaag
aaaaggatcaactggtttgagaacagagaaataatagacatagaggtgcaagatgcagaagagttcaatatgttgttagcctcca
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tcttagcacaagtttggatcctcctggccaaggcggttacggcaccggatacggcagctgactcagaactgagaaggtgggttaa
atacacacaacaaaggagagtgattggggaatttcgccttgacaaagggtggctggacgcagtccgcaacaggattgcagaagat
ctatcacttcggcggttcatggtatctctcatacttgacatcaaaaggacccccggcaacaagccaaggattgcagaaatgatct
gcgacattgacaactatattgtagaagccggactcgccagtttcattcttactatcaaatttggtattgaaaccatgtatcctgc
attaggccttcacgagttcgccggggaattgtccactattgaatccttgatgaacttgtatcaacagctaggagaggttgcaccc
tacatggtgattctagagaactcaattcagaacaagtttagtgcaggagcctatcctctcctctggagctatgcgatgggtgtcg
gagtcgagttggagaactcaatggggggcctgaactttggcaggtcatattttgacccggcctatttccgtctcggacaggagat
ggtcagaagatctgcaggaaaggtcagctctgtaatcgcggctgagcttggtatcacagcagaggaagccaaactagtctcggaa
atcgcctcacagactggggatgaacgaaccgtcagagggactgggcctcgacaggcgcaggtctccttcctccagcataaaacag
atgagggagagtcgcctacaccagcgaccagagaagaagtcaaagctgcgatcccaaatgggtccgaaggaagggacacaaagcg
aacacgctcaggaaagcccagaggagaaactcccggccaactgcttccggagatcatgcaagaggatgaactctcgcgagagtct
agtcaaaaccctcgtgaggctcaaagatcggctgaggcactcttcaggctgcaggccatggccaagattctggaggaccaggagg
agggagaagacaacagtcagatctacaacgacaaggatctcctcagctgagcagacgcaccctccgtccaaatcattaattaaac
atcgcccgccagtattataaaaaacttaggacccaggtccaagcaaccacacatcgacaccccagccaatcgagtagagaccacc
gatggcagaagaacaagcataccatgtcaacaagggactggaatgtatcaagtctctcaaagcctctcccccggatctatccacc
atcaaagatgcccttgagagctggagagaggggcttagcccctcaggccgtgcaacaccgaaccctgatacgtccgagggagacc
atcagaatatcaaccaatcatgctcaccagcaatcggatcagacaaagtcgacatgtctcctgaagataatctcggatttagaga
gatcacttgtaatgacagtgaggctgggctcggaggagttctggataaaggatccaactctcaagtacagcgttactatgtttat
agccacgggggtgaagagattgaaggactcgaggatgctgactctctcgtggttcaagcaaatcctccagttactgacaccttca
atggaggagaggatggatctgacgacagcgatgtggactctggcccagatgatcccggcagagatcctctatatgaccggggatc
tgctgccggcaatgatgtctctaggtcaacagatgtcgaaaaattagaaggtgatgacattcaagaagttcttaactcccagaag
agtaaaggaggaagattccaaggcgggaaaatcttgcgggtcccggaaatacccgatgtcaagaactctagaccatcagcccaat
caattaaaaagggcacagacgggaactcagtcttatctggaacggtgacagagtgttcatcgataagtggtgcaacccaagctgt
gccagagtccagatgggagtcatcagagcgaaatgcgtctgtggggagtgtccccaaatctgcgaggagtgcaaagacgatccag
gggttgacacaagaatctggtaccatagcatcactgactcagcctaaagagaatgactccgagtttgagtatgaggatgatctat
tcacagagatgcaggagattcgtgcaagcattgctaagatccatgatgacaacaaaactatcctctcaaaacttgattctctact
gttattgaaaggagaaatcgatactatcaagaaacaaatcagcaaacaaaatataagtatatctaccattgagggccatctatcc
agtataatgatagccatcccgggctttgggaaggacatcaaggacccaacatctgaggttgagttgaacccggatttgagaccta
taatcagccgtgattctggcagggctcttgcggaggtcctcaagaaacccgctgttgataggtctcagaaaagcggaatcaaagt
caactccggttcaaagggtcagctccttaaggatctccagctaaaacctgtcgacaaacaggcaagctctgcaatcgagtttgtt
ccatctgaccatgaatcatccaggagtgtcatccgctccataatcaagtcgagcaagcttaacattgatcacaaggactatcttc
tagatttactgaatgatgtgaaaggctccaaggatcttaaggaattccacaagatgctaacagccattcttgccaagcagccgta
acacatcctataatcaacatctcatactcggttgaaaacatcctctacgcgtggctattacaaaaaacttaggagcaagggcaac
tgagcttcacagacaagatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgt
aaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccacc
ggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatga
agcagcacgacttcttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaa
gacccgcgccgaggtgaagttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaac
atcctggggcacaagctggagtacaactacaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtga
acttcaagatccgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccc
cgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgcgatcacatggtcctg
ctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaagtgatgacatcctataatcaacatctcatact
cggttgaaaacatcctctacgcgtggctattacaaaaaacttaggagcaagggcaactgagcttcacagacaagatgaccgagat
ctacgattttgataaatcagcatgggatgtcaaagggtcaattgctcgcatagaacccaccacctatcacgacggccgactgata
ccccatgtgagagtcatcgatcctggtctgggagacaggaaagatgagtgcttcatgtacctgtttcttctaggagtgattgagg
ataacgaccccctgtctcccccagtcggtagaaccttcgggtctttacctctaggggttggtagatcaaccgccaggccagaaga
actactaagggaggccacagaactagacatagtggtgaggcgcacggcaggactaaatgagaaactggtattttacaacaacact
ccgctgtctttgttaacaccttggaggaaagtcttgacaaccggaagtgtgtttagcgctaaccaggtttgcaatgcagtcaacc
tagtcccacttgatactccccagagattcagggttgtgtacatgagtataactagattgtcagataatggttattatagtgtccc
cagaagaatgttggagttccgctcagccaatgcagtcgccttcaatatcttggttacactgagaattgaaaatggcacaaaccct
agcagatacatagtcggctcatgggagaatccagaggtcacatttatggtacacgtgggcaactttagaagaaagaagaacaagg
tatactctgctgattattgcaaaatgaagattgaaaagatgggtctagtttttgccttgggaggaataggtggaacaagtctcca
tattcgaagcacagggaaaatgagcaagaccctccatgcacagctggggttcaagaaaatcctatgctaccccctaatggatatt
aatgaggatcttaaccgatatctctggcgggcagagtgccgaatagtcaaaatccaggccgtcttacagccatcagtaccccaag
aattccgtgtctacgacgacgtcatcatcaacgacgatcaaggcctgttcaagatcctgtaattggccggccgggccacggaccc
acccccagggagaggccttcctccctcccgtccaaaacacacaccccaaggttccccgaaacagcgccgacacagccacccctct
ggcggaacgaggccgaaccccccaacaaactcgctccaggggggggccccccccacgacccgccgggcgccgaccgcgcgagccg
gcgagacacccccaagaggccccgacgaagaccgggcaaccctcccccagaaaacggcccaccaacacacccgaggccaggcgcc
gggcacccccagccccgccaccggcgggacaggaggacaagacggggtccccccaaccaaagggaccaccagggaagggtccgcc
gacccagcacagacccggcccaaacaaagcagacccccaagacgaaatcgcccggccggccccattcatcatcaaacaaaactta
ggggtcaagtccagacgacagcgcgcggtccgccaggcagcaagccgcagaaaggaaggagacaagaccggcccggaaggaggac
acccaaccacagaaacccccaacaccaggggaggagccccccctccacacggcggaggaacgggcgagggacaccgaggagaacc
cgatcgggagccaggagccggagacgccagcggtaaacaggccgggcacacatccgacaccaccggaggaccagagaagggcccg
accccgcgtggacccgacggcaggggatctaaccccgccacaaagagaggcgagaaccctcccccccgcacacaaccggcagaca
gaccgagggaggaccacctcccaaccagacaggcggctctcccgcagccgagccgcaggtcccaagaagaggacacccccgaaac
ctcccagaacccctccgctcccggccgccgggacaggagctccgccgccaaaaaccagagtcaccgagagccaaccaggggtccc
ccccaatccctcccggcgccctcccacagaggctccagcaaagtccctcggcccgacgacccctgcaggcgcgccaagagaaacc
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caccaaaggacgtccagtacatccatgtataaacatcatgacacgggtcgcaaccttagtatttctgtttcttttcccaaacact
gtcacgtgccagattcactggggcaatctatccaagatcgggattgtaggaacggggagtgccagctacaaggtgatgactaggc
caagccaccaaactctagttataaagttgatgccaaatataacagccatcgacaattgtacgaaatcagagatttcagagtacaa
aagattgctgatcacagtgttaaagcctgtagaggatgccctgtcagtgataaccaagaatgtaagaccaattcaaactctaaca
cctgggcgcaggacccgccgttttgtcggagctgttctggccggagtagcacttggagtcgcgacagccgctcaaataactgccg
gagtcgcactccatcagtcattgatgaattcccaagcaattgaaagtttaaaaaccagtcttgagaagtcgaatcaggcaataga
agaaatcagacttgcaaataaggagaccatactggcggtacagggcgtccaagactatatcaacaatgagcttgtcccctctgtt
catagaatgtcatgtgagcttgtaggtcacaaactcagtctcaagctccttaggtattataccgagatcctgtctatattcgggc
ctagccttcgagacccgatagctgctgaaatatcaatccaggcactcagctatgcattaggcggagacatcaataaaattctgga
caagcttgggtatagcggcggggatttccttgctatcctagaaagcaaggggataaaggcccgggtcacatatgtggacacaaga
gattactttataattcttagcatagcctacccaaccttatctgagatcaagggggtgatagttcataagatagaagctatatcct
acaatattggggcacaggaatggtatactactatccctagatatgtagccactcagggatatctgatatcgaatttcgatgagac
gtcatgcgtcttcactccagaggggacagtctgcagccagaatgcgttgtatccaatgagcccattgcttcaggaatgcttcagg
gggtcgacaaaatcgtgcgccagaaccctagtttcagggaccacaagtaatagatttatcctatcaaaagggaacttgattgcaa
attgtgcgtcagttttgtgcaagtgttacacaacggagacagttatcaaccaagatcctgataaactactaactgttatagcctc
cgataagtgtcccgtagtcgaggtggatggagtgacaatacaggtcggcagtcgagagtacccagattctgtatacctacatgaa
atagacttaggcccagccatctccctggagaaactggatgtaggcaccaatttaggcaatgcagtcacaagactggagaatgcaa
aggagctactagatgcatcagaccagatactgaagactgttaaaggggtacctttcagtggcaatatatacatagcactggcagc
ttgcattggggtatccctagggcttgtcacattaatatgctgctgtaaggggagatgtaggaacaaggagattcctgcctccaaa
atcaacccagggctcaaacccgacctaaccgggacttcaaagtcgtacgtgagatcactgtagttagaataacccgaatcatcca
gcatcacacatttaaatgtgcgacacaagcagtcagaggacgcagaagattcaacttccgatcaccgaccagaccccactctacg
ccctattacacattggtcatcaaacaaaacttaggacgaaaggtcaatcaccatgtccgcacaaagggaaaggatcaatgccttc
tacaaagacaatcttcataataagacccatagggtaatcctggatagggaacgcttaactattgaaagaccctacatcttacttg
gagtcctactggtaatgtttctgagtctaatcgggctgctggccattgcagggatcaggcttcaccgagccaccgttgggactgc
ggagatccagagtcggctgaataccaacattgagttgaccgaatccattgatcatcaaactaaggatgtcttaactcccctgttt
aaaatcattggtgatgaagtcggcatcagaattccacagaagttcagtgatcttgtcaagttcatctccgataagattaagttcc
tcaaccctgacagagaatatgattttagggatctccggtggtgtatgaatccccctgagagagtcaaaattaactttgaccagtt
ttgtgaatacaaagccgcagtcaagtcagttgaacatatatttgagtcatcactcaacaggtcagaaaggttgcgattattgact
cttgggcccggaacaggctgtctcggcaggacagtaacaagagctcagttctcagagcttacgctgaccctgatggacctggatc
tcgagataaagcacaacgtgtcctcagtgtttaccgtagtcgaagagggattattcggaagaacatatactgtctggagatccga
caccggaaaaccgagcaccagtccaggtattggccattttttaagagtcttcgagatcgggctggtgagagatctcgagctgggt
gcccctattttccatatgaccaactacctcacagtaaacatgagtgatgactatcggagctgtcttttagcagtaggggagttga
agctgacagccctatgcaccccatctgagactgtgactctgagtgagagtggagttccaaagagagagcctcttgtggttgtgat
actcaacctagctgggcctactctagggggcgaactatacagtgtattgcctaccactgaccccacggtggagaaactctattta
tcctcacatagggggattatcaaagataacgaggccaattgggtagtaccgtcgaccgatgttcgtgatcttcaaaacaaaggag
aatgtctggtggaagcatgcaagactcgacctccttcattttgcaatggcacaggaataggcccatggtcagaggggagaatccc
tgcctacggggtgatcagggtcagtcttgacttagctagtgacccgggtgtagttatcacttcagtgtttggcccattgatacct
cacctatccggtatggatctttacaacaatccgttttcaagagctgcatggttggctgtaccaccttatgagcagtcatttctag
gaatgataaatacaattggcttcccggacagagcagaggttatgccgcacattttgaccacagagatcagagggcctcgaggtcg
ttgtcatgttcctatagagttgtccagcaggattgatgatgatatcaagatcgggtccaacatggttgtattgccgacgaaggac
ctgaggtacataacagccacttatgatgtttccaggagcgagcatgcaatcgtgtactatatctatgacacgggtcgctcatcat
cttacttctacccagtccgattgaatttcaggggcaatcctctctctctgaggatagagtgttttccctggtatcataaggtgtg
gtgctaccatgattgtcttatatacaacaccataacaaacgaagaagtccacacgagagggctgaccggtatagaggtaacatgt
aatccagtctgagtagagctgcaaccatcgctcgaggcggccgccgagccatcccctagtccaagcagcataccctgggacactc
agcagcacaacccagccaacaatgttataaaaaacttaggagccaaggttgtaggagccatggactcactatcagtcaatcaggt
cttgtaccctgaggtccatctagatagccctattgtcacaaacaaactagttgccatccttgaatactcggggatcgaccacaac
tatgttcttgaagaccagacccttatcaagaatattagatatagactggggtgcggtttttcaaatcaaatgatcatcaataata
ggggggtaggtgaaacagtcaattccaaacttaaaagttacccccgtaattgtcatatcatatacccagactgcaataaggattt
gttttgtatcaaagatagctgcatatctaggaagctctcggagctattcaagaagggtaattccttgtactctaagataagtcac
aaggtactggattgtcttaagagagtcaacgggaaattaggcctgggcacagatcttactcacggcctgaaggagggtatcctcg
acttggggttgcacatgcatagctctcaatggttcgagacctttctgttctggttcactatcaagacagagatgagatcaatgat
caaagaacagtcccatatatgccacaagaggaggtataacccaatttttgtgtcgggggatgcattcgaggtgctcgtatcacga
gacctcgttgtgataattgataagaacacccagtatgtcttctacctgacatttgagttggtccttatgtattgtgatgtcatag
agggcagacttatgacggagacagccatggctatagaccagagatattcagagctcctaaaccgggtcagatacttgtgggatct
tattgatgggttcttcccaacactgggtaacaccacataccaagttgttgctctgcttgaaccactgtcgttggcttatcttcaa
cttcaggatgtcactctagagttaagaggtgcttttttggaccactgcttcaaagaactttatgagatactggagcattgtggca
ttgacacggaaggtacctacaattccatcactgaaggattggattacgtatttatcacccacgatatacacttaactggggagat
tttttcattttttcggagtttcggacacccccgcctcgaagcggtcaccgctgcagagaatgtcagaaaacatatgaaccaaccg
aaggtaatcagttatgagactatgatgaaagggcatgcagtattttgcgggataatcataaatggttttagggaccggcacggcg
gcagctggccccctgttgcattgccagaacatgcttctgctgcgatccggaatgcgcaggcatccggtgaaggactgacccatga
cctgtgtatagacaactggaagtcctttgttggattcagatttggctgcttcatgccgctcagcctagatagtgatttgaccatg
tacctcaaagacaaagcactggctgcactgaagaatgagtgggattcagtttacccgaaagaatacctccgttataatccaccta
gagggacagagtcaaggcgactggtagaggtgttcctgaatgactccagctttgatccttataacatgataatgtacgtggtgaa
tggctcctaccttaaagaccctgagtttaatctctcatacagcctaaaggagaaagagataaaagagacagggcgattgtttgcc
aaaatgacctacaagatgcgggcctgtcaggtaattgctgaaaatctgatatcaaatggtgttgggaagtatttccgagacaatg
ggatggcaaaagacgagcatgacctaacaaaagcccttcacactctagcagtctcaggtgttcctaagaataacaaagataacca
ccgaggtgggcctcccagaaggaccacaagccgagagatgagatcaagccaagacatcaacacacaaaatagagacaagatccaa
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gggggccctatgtacaactacttgcgatgccaaccgaccggccctgatcagggtgagtcatacgagactgttagtgcattcatca
ctgctgaccttaagaagtattgcctaaattggagatacgagacaatcagcatatttgcacagagactgaatgaaatatatgggtt
gccatccttctttcaatggttacacagggtattggaaaaatccgtgctctacgtcagtgatccgcattgccctcccgacttagat
gatcatatccctctggacagtgtccctaatgcccaaatattcatcaagtacccaatgggcggagtagaaggttattgtcaaaaac
tatggacaatcagtactataccttacttgtatctggcagcctatgagagcggagtaagaatcgcctcactagtgcaaggtgacaa
tcagacaattgcagtgacaaaaagagttccaagttcttggccttattcactaaaaaagagggaggcatccaaagcagctcaaaat
tacttcgtggtcctaaggcaaaggttgcacgatgtaggtcatcacttaaaggctaatgagaccatagtatcttctcacttttttg
tatactctaaagggatttattatgacggcctgttagtctcacaatcactaaagagcatcgccagatgtgtcttctggtccgagac
tattgtggatgaaaccagagcggcctgcagcaatattgcaacaactatcgccaagagtatagagaggggttatgataggtacctc
gcatactctttgaatatcctcaaaattttccaacagatccttatatctcttgacttcacgattaacacaacaatgactcaagatg
tcgtggcaccgatcatcgagaacggtgatttactaataaggatggcactcttgccagcacccattgggggtctcaattatcttaa
catgagcaggttatttgtgagaaatatcggtgacccggtcacttcctccatagccgacctgaagaggatgatagccgctgggcta
atgcctgaagaaacattgcatcaagtgatgacccagaccccgggagaatcatcctacctcgattgggcaagtgacccttattctg
ccaacctaacctgcgtacagagtataactcgccttctcaagaacatcactgcacggtatattttaatcagcagcccaaatccgat
gctgaaaggattgtttcatgaggggagtagagatgaagacgaagagcttgcgagtttcttgatggatcggcatataattgttccg
agagctgcacatgaaatcttagaccatagcataaccggagcaagagaagctatagccgggatgttggacaccaccaagggtctga
ttagaacaagtatgaagcggggtggcctcacccctcgagtattagcccgcctttccaattatgattatgaacaattcagatccgg
aataacattattgacaaagaaagggcagtgttatctcattgacaaggactcgtgctcggtgcagctcgctatagccctgagggac
cacatgtgggccaggttagctcgcgggagacctatctatgggttggaggtgcctgatatactggaatcgatgaacggctacctta
tcaaacgccatgagtcctgtgccatctgtgaaacgggctcaagtcactacgggtggtttttcgtccctgcagggtgccagcttga
cgatgtctcaagagagacttcggctcttcgtgtaccttatgtcggatcaaccactgaggaaaggacagatatgaaacttgctttc
gttagatctccaagccgagccctcaaatcagcagtcagaattgccacagtttactcatgggcctacggggatgatgagaaatcat
ggagtgaagcttggatgctagctaggcagagagctgatatcaccttagatgaattgagaatgatcactccagtctctacatccac
caacctagcccatcggttgagggatcggagcacccaggtgaaatattcggggacatcccttgtgagggttgcaagatacacaacc
atctccaatgacaatttgtcatttgtgatatctgagaaaaaagtagataccaacttcatttaccagcaagggatgctgctcggtc
ttgggatccttgagaatctcttcagattagaggccaccacaggggtatccaacacagtgctacacctacacgtggaaacagaatg
ttgtgttgtacccatggttgatcacccaaggataccgagtctccgtaatattaaagttacgaatgagctatgcacaaaccctctg
atctacgacaggtcccccatcatagaacacgatgcaactcgattatactcacaaagccacaggagacatttggtggagtttgtta
cctggtcaacaagccagctttatcatatactggccaaatctacagcaatgtccatgattgagttgatcacaagatttgagaaaga
tcacatgaatgaaatagccgccctgattggcgatgacgacatcaacagtttcatcacagaatttttgctagtagagcccagattg
tttatagtttaccttggccagtgtgctgccatcaattgggcttttgatatacattatcatcggccctcggggaagtaccagatgg
gggaactcctctactccttactctctcggatgagcaaaggagtatataagatcttcactaatgctctgagtcaccctaaagttta
caagaaattttggcgaagtggtgtaattgagccgattcatggcccatccctagatacacagaatttacatgtcactgtctgtgac
atgatatacggatcatacgtcacctatctggatcttttgctgaatgatgagctagatgattacccgtatttgctctgcgagagtg
atgaggacgtggtcacagacaggttcgacaacattcaagccaaacatctctgtgtactggccgatgtctactgcagctccaagag
atgtccctcgatcatcgggatgtctcctatagaaaaatgcaccatcctcacacattacatcaagggagaatcggtacaatccccg
tccgggatctcatggaacactgatccccttgtagtagatcattactcatgctctctgacctaccttcgccgcggttccatcaaac
aaatcaggttgagagtggatcctgggtttgtattcgaggcgttgacagacatcgacttcaaacagcctcgcaaggctaagttgga
tgtatcggttgtggggttgactgatttttctcccccttgggataacgtcggtgattttctagggactatcaacacattgaggcac
aatctgcccgtcaccggaaccggggtctcgaactatgaagtccacgcttatcgtagaatcggcctgaattcatcagcatgttata
aagctgtagagatctccacgttaatcaagtcatctttagaagtcggagagaatgggttgttcttaggagaaggttccggttctat
gctggctgcgtacaaggaagttcttaaattggcaaactgttattacaacagcggggtaacagcggagggcagagccggacagagg
gaaatctctccctatccctcagagatgagcctagtagagaatcagatggggatagagaggagtgttaaagtgctgttcaatggca
aacctgaagtaacctgggtagggaccaccgattgctacaagtatataatcagtaacattcagacctctagtctgggtttcataca
ctcggatattgagacactcccaaccaaggatgccgttgagaagttagaagaatttgcctctatcctatccctatccctaattttg
ggaaaaatcggctctattacagttgtcaaaattatgcccattagcggagattttacccaaggcttcatagcctatgccattcaat
attttagagagagcctgcttgcctacccgagatatagtaacttcatctcgactgagtgttaccttattatgataggattaaaggc
caatcggttgataaacccagaagccattaagcaaagcataatcagagtggggactaggactgcaccaggacttgtgagccacata
ttatcagagaaacagaaaggttgtattcaatcttttctgggtgatccttatatccaaggagacttcaataagcaccttaaagctc
taacccctattgagaaaatcctagtaaattgtggtctctcgatcaatggcacaaaaatctgtagggatctaatccaccatgatat
cgcctccggtccagacggtctgatgagctccacaattattttgtatagggaactggcccatttcaaagacaatataagaagtcag
cacggtatgttccacccctatccagtattggccagtagcaggcaacgtgaattaatccttcgaatagccaagaaattctgggggt
atgtcttgctatattcagatgacccggcactaatcaaacaaacgatcaagaacttgaagcggaatcacctaacctttgacttaca
cagtaatccgtttattaagggcttatccaaagctgagaaactgctagtgcggacaagttcactcagaagggaatggttgttcact
ctcaatacgaaagaagtgaaagagtggttcaaattggtgggttacagtgcactcgtcagaggttaaatcgatatacatctgcccc
cttctcctccgccatgagactctactggcaatctaaaagattaaagaaaactacatattggataagtatctattcccagctttgt
ctggtggccggcatggtcccagcctcctcgctggcgccggctgggcaacattccgaggggaccgtcccctcggtaatggcgaatg
ggacgatgcagcccaagctgatccggctgctaacaaagcccgaaaggaagctgagttggctgctgccaccgctgagcaataacta
gcataaccccttggggcctctaaacgggtcttgaggggttttttgctgaaaggaggaactatatccggatcgaattgatccggct
gctaacaaagcccgaaaggaagctgagttggctgctgccaccgctgagcaataactagcataaccccttggggcctctaaacggg
tcttgaggggttttttgcccccactgtcattagcaactccttgtccttcgatctcgtcaacaacagcttgcagttcaaatacaag
acccagaaggcgactattctggaagcgagcttgaagaaattgattccggcctggcaattcaccatcatcccatacaatggccaga
agcatcagtctgacatcaccgacattgtttcgtatagcgtgcaattagaattggatcgcttatccgggcgcgcggccgatggcgc
aagctccatgacgcggctagacatgcacgaccagggctacaatgaactcgaaacgaccggggcgcgctcggcctagagatccgta
ctgtactttgttgttcaattggcgcatagcggccgtttgggtcttacggtccccactagaggcccggcctagagaataggaactt
ccctatagagtcgaataagggcgacaccccctaattagcccgggcgaaaggcccagtctttcgactgagcctttcgttttatttg
atgcctggcagttccctactctcgcatggggagtccccacactaccatcggcgctacggcgtttcacttctgagttcggcatggg
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gtcaggtgggaccaccgcgctactgccgccaggcaaacaaggggtgttatgagccatattcaggtataaatgggctcgcgataat
gttcagaattggttaattggttgtaacactgacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgaga
caataaccctgataaatgcttcaataatattgaaaaaggaagaatatgagccatattcaacgggaaacgtcgaggccgcgattaa
attccaacatggatgctgatttatatgggtataaatgggctcgcgataatgtcgggcaatcaggtgcgacaatctatcgcttgta
tgggaagcccgatgcgccagagttgtttctgaaacatggcaaaggtagcgttgccaatgatgttacagatgagatggtcagacta
aactggctgacggaatttatgccacttccgaccatcaagcattttatccgtactcctgatgatgcatggttactcaccactgcga
tccccggaaaaacagcgttccaggtattagaagaatatcctgattcaggtgaaaatattgttgatgcgctggcagtgttcctgcg
ccggttgcactcgattcctgtttgtaattgtccttttaacagcgatcgcgtatttcgcctcgctcaggcgcaatcacgaatgaat
aacggtttggttgatgcgagtgattttgatgacgagcgtaatggctggcctgttgaacaagtctggaaagaaatgcataaacttt
tgccattctcaccggattcagtcgtcactcatggtgatttctcacttgataaccttatttttgacgaggggaaattaataggttg
tattgatgttggacgagtcggaatcgcagaccgataccaggatcttgccatcctatggaactgcctcggtgagttttctccttca
ttacagaaacggctttttcaaaaatatggtattgataatcctgatatgaataaattgcagtttcatttgatgctcgatgagtttt
tctaaaagctt 
 
pPPRVseg1GFP 
aataagatgatcttcttgagatcgttttggtctgcgcgtaatctcttgctctgaaaacgaaaaaaccgccttgcagggcggtttt
tcgaaggttctctgagctaccaactctttgaaccgaggtaactggcttggaggagcgcagtcaccaaaacttgtcctttcagttt
agccttaaccggcgcatgacttcaagactaactcctctaaatcaattaccagtggctgctgccagtggtgcttttgcatgtcttt
ccgggttggactcaagacgatagttaccggataaggcgcagcggtcggactgaacggggggttcgtgcatacagtccagcttgga
gcgaactgcctacccggaactgagtgtcaggcgtggaatgagacaaacgcggccataacagcggaatgacaccggtaaaccgaaa
ggcaggaacaggagagcgcacgagggagccgccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccaccactga
tttgagcgtcagatttcgtgatgcttgtcaggggggcggagcctatggaaaaacggctttgccgcggccctctcacttccctgtt
aagtatcttcctggcatcttccaggaaatctccgccccgttcgtaagccatttccgctcgccgcagtcgaacgaccgagcgtagc
gagtcagtgagcgaggaagcggaatatatcctgtatcacatattctgctgacgcaccggtgcagccttttttctcctgccacatg
aagcacttcactgacaccctcatcagtgccaacatagtaagccagtatacactccgctagcgctgaggtcccgcagccgaacgac
cgagcgcagcggcgagagtagggaactgccaggcatcctgggcggttctgataacgagtaatcgttaatccgcaaataacgtaaa
aacccgcttcggcgggtttttttatggggggagtttagggaaagagcatttgtcagaatatttaagggcgcctgtcactttgctt
gatatatgagaattatttaaccttataaatgagaaaaaagcaacgcactttaaataagatacgttgctttttcgattgatgaaca
cctataattaaactattcatctattatttatgattttttgtatatacaatatttctagtttgttaaagagaattaagaaaataaa
tctcgaaaataataaagggaaaatcagtttttgatatcaaaattatacatgtcaacgataatacaaaatataatacaaactataa
gatgttatcagtatttattatgcatttagaataccttttgtgtcgcccttattcgactccctatagaagttcctattctctagcc
taccgttgctccggtgatcctgcaccgcgccaattctaatctaggccgaggatcttcagcgtacgccggagtacacgcgcaaagg
ccggacatcagcttaacgcgccaattgcgcgtcgcctatgcatggggccgcctagccatgtaaacgtggtcctgtctaactggtc
cggccctagtggggtaattccttcgagccgggttcgagcaatttgatattctgtgtaaaactccgcctaaggtgctggttcgcca
atttgtggagcgctttgaacgtccgtcgggcgagaagattgcgagctgtgcggctgagttgacgtatctgtgctggatgattact
cataacggcaccgctatcaaacgtgccacgttcatgtcctacaatttttaatacgactcactataaccagacaaagctgggtaag
gatagttcttataatgactatagactggcaaacttaggagtaaagatcctactgtcggggagaggaggaggagcaagatctaacg
ttatggctactctccttaaaagcttggcattgttcaagaggaacaaagacaaagcgcctactgcgtcgggttcaggaggggccat
ccgggggattaagaatgttatcatagtccccattcccggggactcatccatcattacccgttcaagactgctcgacaggcttgtc
agattggccggagatcctgacatcaacgggtcaaagctgaccggcgtgatgatcagcatgttatctttgttcgtggagtcacccg
ggcaattgatacagcggatcacagatgatccagatgttagcatccgccttgttgaggtagttcaaagtactaggtcccagtccgg
gttgacctttgcatcacgtggtgctgatttggacaatgaggcagatatgtatttttcaactgaaggaccctcgagtggaagtaag
aaaaggatcaactggtttgagaacagagaaataatagacatagaggtgcaagatgcagaagagttcaatatgttgttagcctcca
tcttagcacaagtttggatcctcctggccaaggcggttacggcaccggatacggcagctgactcagaactgagaaggtgggttaa
atacacacaacaaaggagagtgattggggaatttcgccttgacaaagggtggctggacgcagtccgcaacaggattgcagaagat
ctatcacttcggcggttcatggtatctctcatacttgacatcaaaaggacccccggcaacaagccaaggattgcagaaatgatct
gcgacattgacaactatattgtagaagccggactcgccagtttcattcttactatcaaatttggtattgaaaccatgtatcctgc
attaggccttcacgagttcgccggggaattgtccactattgaatccttgatgaacttgtatcaacagctaggagaggttgcaccc
tacatggtgattctagagaactcaattcagaacaagtttagtgcaggagcctatcctctcctctggagctatgcgatgggtgtcg
gagtcgagttggagaactcaatggggggcctgaactttggcaggtcatattttgacccggcctatttccgtctcggacaggagat
ggtcagaagatctgcaggaaaggtcagctctgtaatcgcggctgagcttggtatcacagcagaggaagccaaactagtctcggaa
atcgcctcacagactggggatgaacgaaccgtcagagggactgggcctcgacaggcgcaggtctccttcctccagcataaaacag
atgagggagagtcgcctacaccagcgaccagagaagaagtcaaagctgcgatcccaaatgggtccgaaggaagggacacaaagcg
aacacgctcaggaaagcccagaggagaaactcccggccaactgcttccggagatcatgcaagaggatgaactctcgcgagagtct
agtcaaaaccctcgtgaggctcaaagatcggctgaggcactcttcaggctgcaggccatggccaagattctggaggaccaggagg
agggagaagacaacagtcagatctacaacgacaaggatctcctcagctgagcagacgcaccctccgtccaaatcattaattaaac
atcgcccgccagtattataaaaaacttaggacccaggtccaagcaaccacacatcgacaccccagccaatcgagtagagaccacc
gatggcagaagaacaagcataccatgtcaacaagggactggaatgtatcaagtctctcaaagcctctcccccggatctatccacc
atcaaagatgcccttgagagctggagagaggggcttagcccctcaggccgtgcaacaccgaaccctgatacgtccgagggagacc
atcagaatatcaaccaatcatgctcaccagcaatcggatcagacaaagtcgacatgtctcctgaagataatctcggatttagaga
gatcacttgtaatgacagtgaggctgggctcggaggagttctggataaaggatccaactctcaagtacagcgttactatgtttat
agccacgggggtgaagagattgaaggactcgaggatgctgactctctcgtggttcaagcaaatcctccagttactgacaccttca
atggaggagaggatggatctgacgacagcgatgtggactctggcccagatgatcccggcagagatcctctatatgaccggggatc
227 
 
tgctgccggcaatgatgtctctaggtcaacagatgtcgaaaaattagaaggtgatgacattcaagaagttcttaactcccagaag
agtaaaggaggaagattccaaggcgggaaaatcttgcgggtcccggaaatacccgatgtcaagaactctagaccatcagcccaat
caattaaaaagggcacagacgggaactcagtcttatctggaacggtgacagagtgttcatcgataagtggtgcaacccaagctgt
gccagagtccagatgggagtcatcagagcgaaatgcgtctgtggggagtgtccccaaatctgcgaggagtgcaaagacgatccag
gggttgacacaagaatctggtaccatagcatcactgactcagcctaaagagaatgactccgagtttgagtatgaggatgatctat
tcacagagatgcaggagattcgtgcaagcattgctaagatccatgatgacaacaaaactatcctctcaaaacttgattctctact
gttattgaaaggagaaatcgatactatcaagaaacaaatcagcaaacaaaatataagtatatctaccattgagggccatctatcc
agtataatgatagccatcccgggctttgggaaggacatcaaggacccaacatctgaggttgagttgaacccggatttgagaccta
taatcagccgtgattctggcagggctcttgcggaggtcctcaagaaacccgctgttgataggtctcagaaaagcggaatcaaagt
caactccggttcaaagggtcagctccttaaggatctccagctaaaacctgtcgacaaacaggcaagctctgcaatcgagtttgtt
ccatctgaccatgaatcatccaggagtgtcatccgctccataatcaagtcgagcaagcttaacattgatcacaaggactatcttc
tagatttactgaatgatgtgaaaggctccaaggatcttaaggaattccacaagatgctaacagccattcttgccaagcagccgta
acacatcctataatcaacatctcatactcggttgaaaacatcctctacgcgtggctattacaaaaaacttaggagcaagggcaac
tgagcttcacagacaagatggtgagcaagggcgaggagctgttcaccggggtggtgcccatcctggtcgagctggacggcgacgt
aaacggccacaagttcagcgtgtccggcgagggcgagggcgatgccacctacggcaagctgaccctgaagttcatctgcaccacc
ggcaagctgcccgtgccctggcccaccctcgtgaccaccctgacctacggcgtgcagtgcttcagccgctaccccgaccacatga
agcagcacgacttcttcaagtccgccatgcccgaaggctacgtccaggagcgcaccatcttcttcaaggacgacggcaactacaa
gacccgcgccgaggtgaagttcgagggcgacaccctggtgaaccgcatcgagctgaagggcatcgacttcaaggaggacggcaac
atcctggggcacaagctggagtacaactacaacagccacaacgtctatatcatggccgacaagcagaagaacggcatcaaggtga
acttcaagatccgccacaacatcgaggacggcagcgtgcagctcgccgaccactaccagcagaacacccccatcggcgacggccc
cgtgctgctgcccgacaaccactacctgagcacccagtccgccctgagcaaagaccccaacgagaagcgcgatcacatggtcctg
ctggagttcgtgaccgccgccgggatcactctcggcatggacgagctgtacaagtgatgacatcctataatcaacatctcatact
cggttgaaaacatcctctacgcgtggctattacaaaaaacttaggagcaagggcaactgagcttcacagacaagatgaccgagat
ctacgattttgataaatcagcatgggatgtcaaagggtcaattgctcgcatagaacccaccacctatcacgacggccgactgata
ccccatgtgagagtcatcgatcctggtctgggagacaggaaagatgagtgcttcatgtacctgtttcttctaggagtgattgagg
ataacgaccccctgtctcccccagtcggtagaaccttcgggtctttacctctaggggttggtagatcaaccgccaggccagaaga
actactaagggaggccacagaactagacatagtggtgaggcgcacggcaggactaaatgagaaactggtattttacaacaacact
ccgctgtctttgttaacaccttggaggaaagtcttgacaaccggaagtgtgtttagcgctaaccaggtttgcaatgcagtcaacc
tagtcccacttgatactccccagagattcagggttgtgtacatgagtataactagattgtcagataatggttattatagtgtccc
cagaagaatgttggagttccgctcagccaatgcagtcgccttcaatatcttggttacactgagaattgaaaatggcacaaaccct
agcagatacatagtcggctcatgggagaatccagaggtcacatttatggtacacgtgggcaactttagaagaaagaagaacaagg
tatactctgctgattattgcaaaatgaagattgaaaagatgggtctagtttttgccttgggaggaataggtggaacaagtctcca
tattcgaagcacagggaaaatgagcaagaccctccatgcacagctggggttcaagaaaatcctatgctaccccctaatggatatt
aatgaggatcttaaccgatatctctggcgggcagagtgccgaatagtcaaaatccaggccgtcttacagccatcagtaccccaag
aattccgtgtctacgacgacgtcatcatcaacgacgatcaaggcctgttcaagatcctgtaattggccggccgggccacggaccc
acccccagggagaggccttcctccctcccgtccaaaacacacaccccaaggttccccgaaacagcgccgacacagccacccctct
ggcggaacgaggccgaaccccccaacaaactcgctccaggggggggccccccccacgacccgccgggcgccgaccgcgcgagccg
gcgagacacccccaagaggccccgacgaagaccgggcaaccctcccccagaaaacggcccaccaacacacccgaggccaggcgcc
gggcacccccagccccgccaccggcgggacaggaggacaagacggggtccccccaaccaaagggaccaccagggaagggtccgcc
gacccagcacagacccggcccaaacaaagcagacccccaagacgaaatcgcccggccggccccattcatcatcaaacaaaactta
ggggtcaagtccagacgacagcgcgcggtccgccaggcagcaagccgcagaaaggaaggagacaagaccggcccggaaggaggac
acccaaccacagaaacccccaacaccaggggaggagccccccctccacacggcggaggaacgggcgagggacaccgaggagaacc
cgatcgggagccaggagccggagacgccagcggtaaacaggccgggcacacatccgacaccaccggaggaccagagaagggcccg
accccgcgtggacccgacggcaggggatctaaccccgccacaaagagaggcgagaaccctcccccccgcacacaaccggcagaca
gaccgagggaggaccacctcccaaccagacaggcggctctcccgcagccgagccgcaggtcccaagaagaggacacccccgaaac
ctcccagaacccctccgctcccggccgccgggacaggagctccgccgccaaaaaccagagtcaccgagagccaaccaggggtccc
ccccaatccctcccggcgccctcccacagaggctccagcaaagtccctcggcccgacgacccctgcaggcgcgccaagagaaacc
caccaaaggacgtccagtacatccatgtataaacatcatgacacgggtcgcaaccttagtatttctgtttcttttcccaaacact
gtcacgtgccagattcactggggcaatctatccaagatcgggattgtaggaacggggagtgccagctacaaggtgatgactaggc
caagccaccaaactctagttataaagttgatgccaaatataacagccatcgacaattgtacgaaatcagagatttcagagtacaa
aagattgctgatcacagtgttaaagcctgtagaggatgccctgtcagtgataaccaagaatgtaagaccaattcaaactctaaca
cctgggcgcaggacccgccgttttgtcggagctgttctggccggagtagcacttggagtcgcgacagccgctcaaataactgccg
gagtcgcactccatcagtcattgatgaattcccaagcaattgaaagtttaaaaaccagtcttgagaagtcgaatcaggcaataga
agaaatcagacttgcaaataaggagaccatactggcggtacagggcgtccaagactatatcaacaatgagcttgtcccctctgtt
catagaatgtcatgtgagcttgtaggtcacaaactcagtctcaagctccttaggtattataccgagatcctgtctatattcgggc
ctagccttcgagacccgatagctgctgaaatatcaatccaggcactcagctatgcattaggcggagacatcaataaaattctgga
caagcttgggtatagcggcggggatttccttgctatcctagaaagcaaggggataaaggcccgggtcacatatgtggacacaaga
gattactttataattcttagcatagcctacccaaccttatctgagatcaagggggtgatagttcataagatagaagctatatcct
acaatattggggcacaggaatggtatactactatccctagatatgtagccactcagggatatctgatatcgaatttcgatgagac
gtcatgcgtcttcactccagaggggacagtctgcagccagaatgcgttgtatccaatgagcccattgcttcaggaatgcttcagg
gggtcgacaaaatcgtgcgccagaaccctagtttcagggaccacaagtaatagatttatcctatcaaaagggaacttgattgcaa
attgtgcgtcagttttgtgcaagtgttacacaacggagacagttatcaaccaagatcctgataaactactaactgttatagcctc
cgataagtgtcccgtagtcgaggtggatggagtgacaatacaggtcggcagtcgagagtacccagattctgtatacctacatgaa
atagacttaggcccagccatctccctggagaaactggatgtaggcaccaatttaggcaatgcagtcacaagactggagaatgcaa
aggagctactagatgcatcagaccagatactgaagactgttaaaggggtacctttcagtggcaatatatacatagcactggcagc
ttgcattggggtatccctagggcttgtcacattaatatgctgctgtaaggggagatgtaggaacaaggagattcctgcctccaaa
atcaacccagggctcaaacccgacctaaccgggacttcaaagtcgtacgtgagatcactgtagtaaatcgatatacatctgcccc
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cttctcctccgccatgagactctactggcaatctaaaagattaaagaaaactacatattggataagtatctattcccagctttgt
ctggtggccggcatggtcccagcctcctcgctggcgccggctgggcaacattccgaggggaccgtcccctcggtaatggcgaatg
ggacgatgcagcccaagctgatccggctgctaacaaagcccgaaaggaagctgagttggctgctgccaccgctgagcaataacta
gcataaccccttggggcctctaaacgggtcttgaggggttttttgctgaaaggaggaactatatccggatcgaattgatccggct
gctaacaaagcccgaaaggaagctgagttggctgctgccaccgctgagcaataactagcataaccccttggggcctctaaacggg
tcttgaggggttttttgcccccactgtcattagcaactccttgtccttcgatctcgtcaacaacagcttgcagttcaaatacaag
acccagaaggcgactattctggaagcgagcttgaagaaattgattccggcctggcaattcaccatcatcccatacaatggccaga
agcatcagtctgacatcaccgacattgtttcgtatagcgtgcaattagaattggatcgcttatccgggcgcgcggccgatggcgc
aagctccatgacgcggctagacatgcacgaccagggctacaatgaactcgaaacgaccggggcgcgctcggcctagagatccgta
ctgtactttgttgttcaattggcgcatagcggccgtttgggtcttacggtccccactagaggcccggcctagagaataggaactt
ccctatagagtcgaataagggcgacaccccctaattagcccgggcgaaaggcccagtctttcgactgagcctttcgttttatttg
atgcctggcagttccctactctcgcatggggagtccccacactaccatcggcgctacggcgtttcacttctgagttcggcatggg
gtcaggtgggaccaccgcgctactgccgccaggcaaacaaggggtgttatgagccatattcaggtataaatgggctcgcgataat
gttcagaattggttaattggttgtaacactgacccctatttgtttatttttctaaatacattcaaatatgtatccgctcatgaga
caataaccctgataaatgcttcaataatattgaaaaaggaagaatatgagccatattcaacgggaaacgtcgaggccgcgattaa
attccaacatggatgctgatttatatgggtataaatgggctcgcgataatgtcgggcaatcaggtgcgacaatctatcgcttgta
tgggaagcccgatgcgccagagttgtttctgaaacatggcaaaggtagcgttgccaatgatgttacagatgagatggtcagacta
aactggctgacggaatttatgccacttccgaccatcaagcattttatccgtactcctgatgatgcatggttactcaccactgcga
tccccggaaaaacagcgttccaggtattagaagaatatcctgattcaggtgaaaatattgttgatgcgctggcagtgttcctgcg
ccggttgcactcgattcctgtttgtaattgtccttttaacagcgatcgcgtatttcgcctcgctcaggcgcaatcacgaatgaat
aacggtttggttgatgcgagtgattttgatgacgagcgtaatggctggcctgttgaacaagtctggaaagaaatgcataaacttt
tgccattctcaccggattcagtcgtcactcatggtgatttctcacttgataaccttatttttgacgaggggaaattaataggttg
tattgatgttggacgagtcggaatcgcagaccgataccaggatcttgccatcctatggaactgcctcggtgagttttctccttca
ttacagaaacggctttttcaaaaatatggtattgataatcctgatatgaataaattgcagtttcatttgatgctcgatgagtttt
tctaaaagctt 
 
pPPRVseg2a 
aataagatgatcttcttgagatcgttttggtctgcgcgtaatctcttgctctgaaaacgaaaaaaccgccttgcagggcggtttt
tcgaaggttctctgagctaccaactctttgaaccgaggtaactggcttggaggagcgcagtcaccaaaacttgtcctttcagttt
agccttaaccggcgcatgacttcaagactaactcctctaaatcaattaccagtggctgctgccagtggtgcttttgcatgtcttt
ccgggttggactcaagacgatagttaccggataaggcgcagcggtcggactgaacggggggttcgtgcatacagtccagcttgga
gcgaactgcctacccggaactgagtgtcaggcgtggaatgagacaaacgcggccataacagcggaatgacaccggtaaaccgaaa
ggcaggaacaggagagcgcacgagggagccgccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccaccactga
tttgagcgtcagatttcgtgatgcttgtcaggggggcggagcctatggaaaaacggctttgccgcggccctctcacttccctgtt
aagtatcttcctggcatcttccaggaaatctccgccccgttcgtaagccatttccgctcgccgcagtcgaacgaccgagcgtagc
gagtcagtgagcgaggaagcggaatatatcctgtatcacatattctgctgacgcaccggtgcagccttttttctcctgccacatg
aagcacttcactgacaccctcatcagtgccaacatagtaagccagtatacactccgctagcgctgaggtcccgcagccgaacgac
cgagcgcagcggcgagagtagggaactgccaggcatcctgggcggttctgataacgagtaatcgttaatccgcaaataacgtaaa
aacccgcttcggcgggtttttttatggggggagtttagggaaagagcatttgtcagaatatttaagggcgcctgtcactttgctt
gatatatgagaattatttaaccttataaatgagaaaaaagcaacgcactttaaataagatacgttgctttttcgattgatgaaca
cctataattaaactattcatctattatttatgattttttgtatatacaatatttctagtttgttaaagagaattaagaaaataaa
tctcgaaaataataaagggaaaatcagtttttgatatcaaaattatacatgtcaacgataatacaaaatataatacaaactataa
gatgttatcagtatttattatgcatttagaataccttttgtgtcgcccttattcgactccctatagaagttcctattctctagcc
taccgttgctccggtgatcctgcaccgcgccaattctaatctaggccgaggatcttcagcgtacgccggagtacacgcgcaaagg
ccggacatcagcttaacgcgccaattgcgcgtcgcctatgcatggggccgcctagccatgtaaacgtggtcctgtctaactggtc
cggccctagtggggtaattccttcgagccgggttcgagcaatttgatattctgtgtaaaactccgcctaaggtgctggttcgcca
atttgtggagcgctttgaacgtccgtcgggcgagaagattgcgagctgtgcggctgagttgacgtatctgtgctggatgattact
cataacggcaccgctatcaaacgtgccacgttcatgtcctacaatttttaatacgactcactataaccagacaaagctgggtaag
gatagttcttataatgactatagactggcaaacttaggagtaaagatcctactgtcggggagaggaggaggagcaagatctaacg
ttatgtccgcacaaagggaaaggatcaatgccttctacaaagacaatcttcataataagacccatagggtaatcctggataggga
acgcttaactattgaaagaccctacatcttacttggagtcctactggtaatgtttctgagtctaatcgggctgctggccattgca
gggatcaggcttcaccgagccaccgttgggactgcggagatccagagtcggctgaataccaacattgagttgaccgaatccattg
atcatcaaactaaggatgtcttaactcccctgtttaaaatcattggtgatgaagtcggcatcagaattccacagaagttcagtga
tcttgtcaagttcatctccgataagattaagttcctcaaccctgacagagaatatgattttagggatctccggtggtgtatgaat
ccccctgagagagtcaaaattaactttgaccagttttgtgaatacaaagccgcagtcaagtcagttgaacatatatttgagtcat
cactcaacaggtcagaaaggttgcgattattgactcttgggcccggaacaggctgtctcggcaggacagtaacaagagctcagtt
ctcagagcttacgctgaccctgatggacctggatctcgagataaagcacaacgtgtcctcagtgtttaccgtagtcgaagaggga
ttattcggaagaacatatactgtctggagatccgacaccggaaaaccgagcaccagtccaggtattggccattttttaagagtct
tcgagatcgggctggtgagagatctcgagctgggtgcccctattttccatatgaccaactacctcacagtaaacatgagtgatga
ctatcggagctgtcttttagcagtaggggagttgaagctgacagccctatgcaccccatctgagactgtgactctgagtgagagt
ggagttccaaagagagagcctcttgtggttgtgatactcaacctagctgggcctactctagggggcgaactatacagtgtattgc
ctaccactgaccccacggtggagaaactctatttatcctcacatagggggattatcaaagataacgaggccaattgggtagtacc
gtcgaccgatgttcgtgatcttcaaaacaaaggagaatgtctggtggaagcatgcaagactcgacctccttcattttgcaatggc
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acaggaataggcccatggtcagaggggagaatccctgcctacggggtgatcagggtcagtcttgacttagctagtgacccgggtg
tagttatcacttcagtgtttggcccattgatacctcacctatccggtatggatctttacaacaatccgttttcaagagctgcatg
gttggctgtaccaccttatgagcagtcatttctaggaatgataaatacaattggcttcccggacagagcagaggttatgccgcac
attttgaccacagagatcagagggcctcgaggtcgttgtcatgttcctatagagttgtccagcaggattgatgatgatatcaaga
tcgggtccaacatggttgtattgccgacgaaggacctgaggtacataacagccacttatgatgtttccaggagcgagcatgcaat
cgtgtactatatctatgacacgggtcgctcatcatcttacttctacccagtccgattgaatttcaggggcaatcctctctctctg
aggatagagtgttttccctggtatcataaggtgtggtgctaccatgattgtcttatatacaacaccataacaaacgaagaagtcc
acacgagagggctgaccggtatagaggtaacatgtaatccagtctgagtagagctgcaaccatcgctcgaggcggccgccgagcc
atcccctagtccaagcagcataccctgggacactcagcagcacaacccagccaacaatgttataaaaaacttaggagccaaggtt
gtaggagccatggactcactatcagtcaatcaggtcttgtaccctgaggtccatctagatagccctattgtcacaaacaaactag
ttgccatccttgaatactcggggatcgaccacaactatgttcttgaagaccagacccttatcaagaatattagatatagactggg
gtgcggtttttcaaatcaaatgatcatcaataataggggggtaggtgaaacagtcaattccaaacttaaaagttacccccgtaat
tgtcatatcatatacccagactgcaataaggatttgttttgtatcaaagatagctgcatatctaggaagctctcggagctattca
agaagggtaattccttgtactctaagataagtcacaaggtactggattgtcttaagagagtcaacgggaaattaggcctgggcac
agatcttactcacggcctgaaggagggtatcctcgacttggggttgcacatgcatagctctcaatggttcgagacctttctgttc
tggttcactatcaagacagagatgagatcaatgatcaaagaacagtcccatatatgccacaagaggaggtataacccaatttttg
tgtcgggggatgcattcgaggtgctcgtatcacgagacctcgttgtgataattgataagaacacccagtatgtcttctacctgac
atttgagttggtccttatgtattgtgatgtcatagagggcagacttatgacggagacagccatggctatagaccagagatattca
gagctcctaaaccgggtcagatacttgtgggatcttattgatgggttcttcccaacactgggtaacaccacataccaagttgttg
ctctgcttgaaccactgtcgttggcttatcttcaacttcaggatgtcactctagagttaagaggtgcttttttggaccactgctt
caaagaactttatgagatactggagcattgtggcattgacacggaaggtacctacaattccatcactgaaggattggattacgta
tttatcacccacgatatacacttaactggggagattttttcattttttcggagtttcggacacccccgcctcgaagcggtcaccg
ctgcagagaatgtcagaaaacatatgaaccaaccgaaggtaatcagttatgagactatgatgaaagggcatgcagtattttgcgg
gataatcataaatggttttagggaccggcacggcggcagctggccccctgttgcattgccagaacatgcttctgctgcgatccgg
aatgcgcaggcatccggtgaaggactgacccatgacctgtgtatagacaactggaagtcctttgttggattcagatttggctgct
tcatgccgctcagcctagatagtgatttgaccatgtacctcaaagacaaagcactggctgcactgaagaatgagtgggattcagt
ttacccgaaagaatacctccgttataatccacctagagggacagagtcaaggcgactggtagaggtgttcctgaatgactccagc
tttgatccttataacatgataatgtacgtggtgaatggctcctaccttaaagaccctgagtttaatctctcatacagcctaaagg
agaaagagataaaagagacagggcgattgtttgccaaaatgacctacaagatgcgggcctgtcaggtaattgctgaaaatctgat
atcaaatggtgttgggaagtatttccgagacaatgggatggcaaaagacgagcatgacctaacaaaagcccttcacactctagca
gtctcaggtgttcctaagaataacaaagataaccaccgaggtgggcctcccagaaggaccacaagccgagagatgagatcaagcc
aagacatcaacacacaaaatagagacaagatccaagggggccctatgtacaactacttgcgatgccaaccgaccggccctgatca
gggtgagtcatacgagactgttagtgcattcatcactgctgaccttaagaagtattgcctaaattggagatacgagacaatcagc
atatttgcacagagactgaatgaaatatatgggttgccatccttctttcaatggttacacagggtattggaaaaatccgtgctct
acgtcagtgatccgcattgccctcccgacttagatgatcatatccctctggacagtgtccctaatgcccaaatattcatcaagta
cccaatgggcggagtagaaggttattgtcaaaaactatggacaatcagtactataccttacttgtatctggcagcctatgagagc
ggagtaagaatcgcctcactagtgcaaggtgacaatcagacaattgcagtgacaaaaagagttccaagttcttggccttattcac
taaaaaagagggaggcatccaaagcagctcaaaattacttcgtggtcctaaggcaaaggttgcacgatgtaggtcatcacttaaa
ggctaatgagaccatagtatcttctcacttttttgtatactctaaagggatttattatgacggcctgttagtctcacaatcacta
aagagcatcgccagatgtgtcttctggtccgagactattgtggatgaaaccagagcggcctgcagcaatattgcaacaactatcg
ccaagagtatagagaggggttatgataggtacctcgcatactctttgaatatcctcaaaattttccaacagatccttatatctct
tgacttcacgattaacacaacaatgactcaagatgtcgtggcaccgatcatcgagaacggtgatttactaataaggatggcactc
ttgccagcacccattgggggtctcaattatcttaacatgagcaggttatttgtgagaaatatcggtgacccggtcacttcctcca
tagccgacctgaagaggatgatagccgctgggctaatgcctgaagaaacattgcatcaagtgatgacccagaccccgggagaatc
atcctacctcgattgggcaagtgacccttattctgccaacctaacctgcgtacagagtataactcgccttctcaagaacatcact
gcacggtatattttaatcagcagcccaaatccgatgctgaaaggattgtttcatgaggggagtagagatgaagacgaagagcttg
cgagtttcttgatggatcggcatataattgttccgagagctgcacatgaaatcttagaccatagcataaccggagcaagagaagc
tatagccgggatgttggacaccaccaagggtctgattagaacaagtatgaagcggggtggcctcacccctcgagtattagcccgc
ctttccaattatgattatgaacaattcagatccggaataacattattgacaaagaaagggcagtgttatctcattgacaaggact
cgtgctcggtgcagctcgctatagccctgagggaccacatgtgggccaggttagctcgcgggagacctatctatgggttggaggt
gcctgatatactggaatcgatgaacggctaccttatcaaacgccatgagtcctgtgccatctgtgaaacgggctcaagtcactac
gggtggtttttcgtccctgcagggtgccagcttgacgatgtctcaagagagacttcggctcttcgtgtaccttatgtcggatcaa
ccactgaggaaaggacagatatgaaacttgctttcgttagatctccaagccgagccctcaaatcagcagtcagaattgccacagt
ttactcatgggcctacggggatgatgagaaatcatggagtgaagcttggatgctagctaggcagagagctgatatcaccttagat
gaattgagaatgatcactccagtctctacatccaccaacctagcccatcggttgagggatcggagcacccaggtgaaatattcgg
ggacatcccttgtgagggttgcaagatacacaaccatctccaatgacaatttgtcatttgtgatatctgagaaaaaagtagatac
caacttcatttaccagcaagggatgctgctcggtcttgggatccttgagaatctcttcagattagaggccaccacaggggtatcc
aacacagtgctacacctacacgtggaaacagaatgttgtgttgtacccatggttgatcacccaaggataccgagtctccgtaata
ttaaagttacgaatgagctatgcacaaaccctctgatctacgacaggtcccccatcatagaacacgatgcaactcgattatactc
acaaagccacaggagacatttggtggagtttgttacctggtcaacaagccagctttatcatatactggccaaatctacagcaatg
tccatgattgagttgatcacaagatttgagaaagatcacatgaatgaaatagccgccctgattggcgatgacgacatcaacagtt
tcatcacagaatttttgctagtagagcccagattgtttatagtttaccttggccagtgtgctgccatcaattgggcttttgatat
acattatcatcggccctcggggaagtaccagatgggggaactcctctactccttactctctcggatgagcaaaggagtatataag
atcttcactaatgctctgagtcaccctaaagtttacaagaaattttggcgaagtggtgtaattgagccgattcatggcccatccc
tagatacacagaatttacatgtcactgtctgtgacatgatatacggatcatacgtcacctatctggatcttttgctgaatgatga
gctagatgattacccgtatttgctctgcgagagtgatgaggacgtggtcacagacaggttcgacaacattcaagccaaacatctc
tgtgtactggccgatgtctactgcagctccaagagatgtccctcgatcatcgggatgtctcctatagaaaaatgcaccatcctca
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cacattacatcaagggagaatcggtacaatccccgtccgggatctcatggaacactgatccccttgtagtagatcattactcatg
ctctctgacctaccttcgccgcggttccatcaaacaaatcaggttgagagtggatcctgggtttgtattcgaggcgttgacagac
atcgacttcaaacagcctcgcaaggctaagttggatgtatcggttgtggggttgactgatttttctcccccttgggataacgtcg
gtgattttctagggactatcaacacattgaggcacaatctgcccgtcaccggaaccggggtctcgaactatgaagtccacgctta
tcgtagaatcggcctgaattcatcagcatgttataaagctgtagagatctccacgttaatcaagtcatctttagaagtcggagag
aatgggttgttcttaggagaaggttccggttctatgctggctgcgtacaaggaagttcttaaattggcaaactgttattacaaca
gcggggtaacagcggagggcagagccggacagagggaaatctctccctatccctcagagatgagcctagtagagaatcagatggg
gatagagaggagtgttaaagtgctgttcaatggcaaacctgaagtaacctgggtagggaccaccgattgctacaagtatataatc
agtaacattcagacctctagtctgggtttcatacactcggatattgagacactcccaaccaaggatgccgttgagaagttagaag
aatttgcctctatcctatccctatccctaattttgggaaaaatcggctctattacagttgtcaaaattatgcccattagcggaga
ttttacccaaggcttcatagcctatgccattcaatattttagagagagcctgcttgcctacccgagatatagtaacttcatctcg
actgagtgttaccttattatgataggattaaaggccaatcggttgataaacccagaagccattaagcaaagcataatcagagtgg
ggactaggactgcaccaggacttgtgagccacatattatcagagaaacagaaaggttgtattcaatcttttctgggtgatcctta
tatccaaggagacttcaataagcaccttaaagctctaacccctattgagaaaatcctagtaaattgtggtctctcgatcaatggc
acaaaaatctgtagggatctaatccaccatgatatcgcctccggtccagacggtctgatgagctccacaattattttgtataggg
aactggcccatttcaaagacaatataagaagtcagcacggtatgttccacccctatccagtattggccagtagcaggcaacgtga
attaatccttcgaatagccaagaaattctgggggtatgtcttgctatattcagatgacccggcactaatcaaacaaacgatcaag
aacttgaagcggaatcacctaacctttgacttacacagtaatccgtttattaagggcttatccaaagctgagaaactgctagtgc
ggacaagttcactcagaagggaatggttgttcactctcaatacgaaagaagtgaaagagtggttcaaattggtgggttacagtgc
actcgtcagaggttaaatcgatatacatctgcccccttctcctccgccatgagactctactggcaatctaaaagattaaagaaaa
ctacatattggataagtatctattcccagctttgtctggtggccggcatggtcccagcctcctcgctggcgccggctgggcaaca
ttccgaggggaccgtcccctcggtaatggcgaatgggacgatgcagcccaagctgatccggctgctaacaaagcccgaaaggaag
ctgagttggctgctgccaccgctgagcaataactagcataaccccttggggcctctaaacgggtcttgaggggttttttgctgaa
aggaggaactatatccggatcgaattgatccggctgctaacaaagcccgaaaggaagctgagttggctgctgccaccgctgagca
ataactagcataaccccttggggcctctaaacgggtcttgaggggttttttgcccccactgtcattagcaactccttgtccttcg
atctcgtcaacaacagcttgcagttcaaatacaagacccagaaggcgactattctggaagcgagcttgaagaaattgattccggc
ctggcaattcaccatcatcccatacaatggccagaagcatcagtctgacatcaccgacattgtttcgtatagcgtgcaattagaa
ttggatcgcttatccgggcgcgcggccgatggcgcaagctccatgacgcggctagacatgcacgaccagggctacaatgaactcg
aaacgaccggggcgcgctcggcctagagatccgtactgtactttgttgttcaattggcgcatagcggccgtttgggtcttacggt
ccccactagaggcccggcctagagaataggaacttccctatagagtcgaataagggcgacaccccctaattagcccgggcgaaag
gcccagtctttcgactgagcctttcgttttatttgatgcctggcagttccctactctcgcatggggagtccccacactaccatcg
gcgctacggcgtttcacttctgagttcggcatggggtcaggtgggaccaccgcgctactgccgccaggcaaacaaggggtgttat
gagccatattcaggtataaatgggctcgcgataatgttcagaattggttaattggttgtaacactgacccctatttgtttatttt
tctaaatacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagaatatgag
ccatattcaacgggaaacgtcgaggccgcgattaaattccaacatggatgctgatttatatgggtataaatgggctcgcgataat
gtcgggcaatcaggtgcgacaatctatcgcttgtatgggaagcccgatgcgccagagttgtttctgaaacatggcaaaggtagcg
ttgccaatgatgttacagatgagatggtcagactaaactggctgacggaatttatgccacttccgaccatcaagcattttatccg
tactcctgatgatgcatggttactcaccactgcgatccccggaaaaacagcgttccaggtattagaagaatatcctgattcaggt
gaaaatattgttgatgcgctggcagtgttcctgcgccggttgcactcgattcctgtttgtaattgtccttttaacagcgatcgcg
tatttcgcctcgctcaggcgcaatcacgaatgaataacggtttggttgatgcgagtgattttgatgacgagcgtaatggctggcc
tgttgaacaagtctggaaagaaatgcataaacttttgccattctcaccggattcagtcgtcactcatggtgatttctcacttgat
aaccttatttttgacgaggggaaattaataggttgtattgatgttggacgagtcggaatcgcagaccgataccaggatcttgcca
tcctatggaactgcctcggtgagttttctccttcattacagaaacggctttttcaaaaatatggtattgataatcctgatatgaa
taaattgcagtttcatttgatgctcgatgagtttttctaaaagctt 
 
pPPRVseg2bVP2 
aataagatgatcttcttgagatcgttttggtctgcgcgtaatctcttgctctgaaaacgaaaaaaccgccttgcagggcggtttt
tcgaaggttctctgagctaccaactctttgaaccgaggtaactggcttggaggagcgcagtcaccaaaacttgtcctttcagttt
agccttaaccggcgcatgacttcaagactaactcctctaaatcaattaccagtggctgctgccagtggtgcttttgcatgtcttt
ccgggttggactcaagacgatagttaccggataaggcgcagcggtcggactgaacggggggttcgtgcatacagtccagcttgga
gcgaactgcctacccggaactgagtgtcaggcgtggaatgagacaaacgcggccataacagcggaatgacaccggtaaaccgaaa
ggcaggaacaggagagcgcacgagggagccgccagggggaaacgcctggtatctttatagtcctgtcgggtttcgccaccactga
tttgagcgtcagatttcgtgatgcttgtcaggggggcggagcctatggaaaaacggctttgccgcggccctctcacttccctgtt
aagtatcttcctggcatcttccaggaaatctccgccccgttcgtaagccatttccgctcgccgcagtcgaacgaccgagcgtagc
gagtcagtgagcgaggaagcggaatatatcctgtatcacatattctgctgacgcaccggtgcagccttttttctcctgccacatg
aagcacttcactgacaccctcatcagtgccaacatagtaagccagtatacactccgctagcgctgaggtcccgcagccgaacgac
cgagcgcagcggcgagagtagggaactgccaggcatcctgggcggttctgataacgagtaatcgttaatccgcaaataacgtaaa
aacccgcttcggcgggtttttttatggggggagtttagggaaagagcatttgtcagaatatttaagggcgcctgtcactttgctt
gatatatgagaattatttaaccttataaatgagaaaaaagcaacgcactttaaataagatacgttgctttttcgattgatgaaca
cctataattaaactattcatctattatttatgattttttgtatatacaatatttctagtttgttaaagagaattaagaaaataaa
tctcgaaaataataaagggaaaatcagtttttgatatcaaaattatacatgtcaacgataatacaaaatataatacaaactataa
gatgttatcagtatttattatgcatttagaataccttttgtgtcgcccttattcgactccctatagaagttcctattctctagcc
taccgttgctccggtgatcctgcaccgcgccaattctaatctaggccgaggatcttcagcgtacgccggagtacacgcgcaaagg
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ccggacatcagcttaacgcgccaattgcgcgtcgcctatgcatggggccgcctagccatgtaaacgtggtcctgtctaactggtc
cggccctagtggggtaattccttcgagccgggttcgagcaatttgatattctgtgtaaaactccgcctaaggtgctggttcgcca
atttgtggagcgctttgaacgtccgtcgggcgagaagattgcgagctgtgcggctgagttgacgtatctgtgctggatgattact
cataacggcaccgctatcaaacgtgccacgttcatgtcctacaatttttaatacgactcactataaccagacaaagctgggtaag
gatagttcttataatgactatagactggcaaacttaggagtaaagatcctactgtcggggagaggaggaggagcaagatctaacg
ttatggatgaactaggcatcccagtttataagagaggatttcccgaacacctgcttcgtggttacgagttcataatagatgttgg
aaccaagatagaaagtgttggaggacgtcatgatgtaacgaaaataccagaaatgaatgcatatgacatcaagcaggagagcatc
cgaaccgcattatggtataatccgataagaaatgatggttttgtattgccgcgagtgctggatatcacattgaggggttacgatg
aaagacgggcggttgttgaaagtacgagacacaagagtttccatacgaatgaccagtgggtgcagtggatgatgaaagattcgat
ggacgctcagcctttaaaggttgggttagatgatcaaagtaggaatgtagctcactcgttacataactgcgtagtcaaaatcgat
tcaaagaaggctgatactatgtcttaccatgtagagccgatagaggacgcgtcaaagggatgtttgcatacgagaaccatgatgt
ggaaccacctggtacgaatagaaacatttcatgcggcgcaggaggtggcatatactcttaaacctacttatgacatcgtggtcca
cgctgaaaggagagatcgtagtcaaccgtttaggccaggggatcagacattaattaattttgggagaggtcagaaggtggcaatg
aaccacaattcatatgataagatggttgagggattaacacatttagtgattagagggaaaactcctgaggtgattagagatgata
ttgcgagcttggatgagatatgtaataggtggatacagagtaggcacgaccccggagagataaaagcatatgaattatgtaaaat
attatcaacgattggtcggaaagtcctcgatcgagagaaagaaccagaggacgaggcgaatctatcgatccgatttcaagaggca
atcgacaataagttccgacaacatgatcctgagcgcctgaagatatttgagcataggaatcaacgtagagatgaggaccgattct
atattctgttgatgattgcagcctccgatacttttaatacacgagtgtggtggtcgaacccatatccatgtttaagaggaacctt
aatcgcgtcagaaacgaagctaggtgacgtttattcgatgatgcgttcatggtatgattggagtgttcgaccaacctatacgcct
tacgagaaaacgagagaacaggaaaaatatatttatggacgggttaacctgtttgactttgtcgcggaacctgggattaaaattg
ttcattgggaatataggctgaatcattccacccgggagataacctatgcgcaagggaacccatgtgatttatacccagaggatga
tgatgtaatagtcacaaagttcgatgatgtcgcgtatggccaaatgatcaatgagatgataaatgggggttggaatcaagaacag
ttcaagatgcataaaattttaaaatcggaaggtaatgttctaacgatagattttgaaaaagatgcaaagctaacaaccaatgaag
gcgtaacgatgccagaatatttcaataagtggataatcgctccgatgttcaacgctaagctgcgtataaaacatgaagagattgc
gcagcgtcaaagtgatgatccgatggtaaaacgtactttatcacctattaccgcagatccaatcgaattgcaaaggttgactttg
gcgcggttttacgacattcgtcccgctttaagaggacaggcgctttcgcggcaacaggcacagtccacttacgatgaagaaatat
cgaaacagcgggattatgcggaaatattgaaacgtcgtggaattgtgcaaatcccaaagaaaccttgcccaactgtgacagctca
gtatacgctggagcgttatgctttgttcattataaacatcttacaacagcatgtagcacgagactgcgacgaggaggcgatatac
gagcatccgaaagcagattatgaacttgaaatatttggcgagagcattgtggatatctctcaagtgatcgttctagtttttgact
tgatatttgagagaagaaggagggtaagagatgtgtatgaatcgcggtacataattgcgcgcattaggaggatgcgaggtaaaga
gagattgaacgtgatcgcggagtttttcccaacctatgggagtcttctaaatggattaaacagcgctaccgtagtacaggatatt
atgtatttgaactttctcccattgtattttttagcaggcgataacatgatatactctcataggcagtggtctattcctttacttc
tatacactcatgaagtgatggtggtcccattagaagttggttcatacaatgatcggtgcggattaattgcgtacctggaatacat
ggttttctttccctccaaggcgattcgacttagcaaactaaatgaagcgcagcccaagattgcgcgcgagatgcttaagtactac
gctaatactgcggtatatgatgggggagtcaactacaacgttgtgacgacgaagcagcttctatatgagacataccttgcttcgt
tatgtgggggtatttctgacggtattgtctggtatttgccgatcacacatccgaacaaatgcatcgtagcgatcgaggtatctga
tgaaagagttccggctagcattagagcggggcgtataaggctaagatttccgctaagcgcgcgacatctaaagggggttgtaatc
atacaaattgacgaggagggcgaatttacagtgtatagcgagggaattgtgtctcatcgggtgtgtaaaaagaatttactcaagt
atatgtgcgatattatattactgaagttttcggggcacgtttttggtaacgacgagatgctgacaaaacttctcaacgtatgagc
gcagacgcaccctccgtccaaatcattaattaaacatcgcccgccagtattataaaaaacttaggacgaaaggtcaatcaccatg
tccgcacaaagggaaaggatcaatgccttctacaaagacaatcttcataataagacccatagggtaatcctggatagggaacgct
taactattgaaagaccctacatcttacttggagtcctactggtaatgtttctgagtctaatcgggctgctggccattgcagggat
caggcttcaccgagccaccgttgggactgcggagatccagagtcggctgaataccaacattgagttgaccgaatccattgatcat
caaactaaggatgtcttaactcccctgtttaaaatcattggtgatgaagtcggcatcagaattccacagaagttcagtgatcttg
tcaagttcatctccgataagattaagttcctcaaccctgacagagaatatgattttagggatctccggtggtgtatgaatccccc
tgagagagtcaaaattaactttgaccagttttgtgaatacaaagccgcagtcaagtcagttgaacatatatttgagtcatcactc
aacaggtcagaaaggttgcgattattgactcttgggcccggaacaggctgtctcggcaggacagtaacaagagctcagttctcag
agcttacgctgaccctgatggacctggatctcgagataaagcacaacgtgtcctcagtgtttaccgtagtcgaagagggattatt
cggaagaacatatactgtctggagatccgacaccggaaaaccgagcaccagtccaggtattggccattttttaagagtcttcgag
atcgggctggtgagagatctcgagctgggtgcccctattttccatatgaccaactacctcacagtaaacatgagtgatgactatc
ggagctgtcttttagcagtaggggagttgaagctgacagccctatgcaccccatctgagactgtgactctgagtgagagtggagt
tccaaagagagagcctcttgtggttgtgatactcaacctagctgggcctactctagggggcgaactatacagtgtattgcctacc
actgaccccacggtggagaaactctatttatcctcacatagggggattatcaaagataacgaggccaattgggtagtaccgtcga
ccgatgttcgtgatcttcaaaacaaaggagaatgtctggtggaagcatgcaagactcgacctccttcattttgcaatggcacagg
aataggcccatggtcagaggggagaatccctgcctacggggtgatcagggtcagtcttgacttagctagtgacccgggtgtagtt
atcacttcagtgtttggcccattgatacctcacctatccggtatggatctttacaacaatccgttttcaagagctgcatggttgg
ctgtaccaccttatgagcagtcatttctaggaatgataaatacaattggcttcccggacagagcagaggttatgccgcacatttt
gaccacagagatcagagggcctcgaggtcgttgtcatgttcctatagagttgtccagcaggattgatgatgatatcaagatcggg
tccaacatggttgtattgccgacgaaggacctgaggtacataacagccacttatgatgtttccaggagcgagcatgcaatcgtgt
actatatctatgacacgggtcgctcatcatcttacttctacccagtccgattgaatttcaggggcaatcctctctctctgaggat
agagtgttttccctggtatcataaggtgtggtgctaccatgattgtcttatatacaacaccataacaaacgaagaagtccacacg
agagggctgaccggtatagaggtaacatgtaatccagtctgagtagagctgcaaccatcgctcgaggcggccgccgagccatccc
ctagtccaagcagcataccctgggacactcagcagcacaacccagccaacaatgttataaaaaacttaggagccaaggttgtagg
agccatggactcactatcagtcaatcaggtcttgtaccctgaggtccatctagatagccctattgtcacaaacaaactagttgcc
atccttgaatactcggggatcgaccacaactatgttcttgaagaccagacccttatcaagaatattagatatagactggggtgcg
gtttttcaaatcaaatgatcatcaataataggggggtaggtgaaacagtcaattccaaacttaaaagttacccccgtaattgtca
tatcatatacccagactgcaataaggatttgttttgtatcaaagatagctgcatatctaggaagctctcggagctattcaagaag
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ggtaattccttgtactctaagataagtcacaaggtactggattgtcttaagagagtcaacgggaaattaggcctgggcacagatc
ttactcacggcctgaaggagggtatcctcgacttggggttgcacatgcatagctctcaatggttcgagacctttctgttctggtt
cactatcaagacagagatgagatcaatgatcaaagaacagtcccatatatgccacaagaggaggtataacccaatttttgtgtcg
ggggatgcattcgaggtgctcgtatcacgagacctcgttgtgataattgataagaacacccagtatgtcttctacctgacatttg
agttggtccttatgtattgtgatgtcatagagggcagacttatgacggagacagccatggctatagaccagagatattcagagct
cctaaaccgggtcagatacttgtgggatcttattgatgggttcttcccaacactgggtaacaccacataccaagttgttgctctg
cttgaaccactgtcgttggcttatcttcaacttcaggatgtcactctagagttaagaggtgcttttttggaccactgcttcaaag
aactttatgagatactggagcattgtggcattgacacggaaggtacctacaattccatcactgaaggattggattacgtatttat
cacccacgatatacacttaactggggagattttttcattttttcggagtttcggacacccccgcctcgaagcggtcaccgctgca
gagaatgtcagaaaacatatgaaccaaccgaaggtaatcagttatgagactatgatgaaagggcatgcagtattttgcgggataa
tcataaatggttttagggaccggcacggcggcagctggccccctgttgcattgccagaacatgcttctgctgcgatccggaatgc
gcaggcatccggtgaaggactgacccatgacctgtgtatagacaactggaagtcctttgttggattcagatttggctgcttcatg
ccgctcagcctagatagtgatttgaccatgtacctcaaagacaaagcactggctgcactgaagaatgagtgggattcagtttacc
cgaaagaatacctccgttataatccacctagagggacagagtcaaggcgactggtagaggtgttcctgaatgactccagctttga
tccttataacatgataatgtacgtggtgaatggctcctaccttaaagaccctgagtttaatctctcatacagcctaaaggagaaa
gagataaaagagacagggcgattgtttgccaaaatgacctacaagatgcgggcctgtcaggtaattgctgaaaatctgatatcaa
atggtgttgggaagtatttccgagacaatgggatggcaaaagacgagcatgacctaacaaaagcccttcacactctagcagtctc
aggtgttcctaagaataacaaagataaccaccgaggtgggcctcccagaaggaccacaagccgagagatgagatcaagccaagac
atcaacacacaaaatagagacaagatccaagggggccctatgtacaactacttgcgatgccaaccgaccggccctgatcagggtg
agtcatacgagactgttagtgcattcatcactgctgaccttaagaagtattgcctaaattggagatacgagacaatcagcatatt
tgcacagagactgaatgaaatatatgggttgccatccttctttcaatggttacacagggtattggaaaaatccgtgctctacgtc
agtgatccgcattgccctcccgacttagatgatcatatccctctggacagtgtccctaatgcccaaatattcatcaagtacccaa
tgggcggagtagaaggttattgtcaaaaactatggacaatcagtactataccttacttgtatctggcagcctatgagagcggagt
aagaatcgcctcactagtgcaaggtgacaatcagacaattgcagtgacaaaaagagttccaagttcttggccttattcactaaaa
aagagggaggcatccaaagcagctcaaaattacttcgtggtcctaaggcaaaggttgcacgatgtaggtcatcacttaaaggcta
atgagaccatagtatcttctcacttttttgtatactctaaagggatttattatgacggcctgttagtctcacaatcactaaagag
catcgccagatgtgtcttctggtccgagactattgtggatgaaaccagagcggcctgcagcaatattgcaacaactatcgccaag
agtatagagaggggttatgataggtacctcgcatactctttgaatatcctcaaaattttccaacagatccttatatctcttgact
tcacgattaacacaacaatgactcaagatgtcgtggcaccgatcatcgagaacggtgatttactaataaggatggcactcttgcc
agcacccattgggggtctcaattatcttaacatgagcaggttatttgtgagaaatatcggtgacccggtcacttcctccatagcc
gacctgaagaggatgatagccgctgggctaatgcctgaagaaacattgcatcaagtgatgacccagaccccgggagaatcatcct
acctcgattgggcaagtgacccttattctgccaacctaacctgcgtacagagtataactcgccttctcaagaacatcactgcacg
gtatattttaatcagcagcccaaatccgatgctgaaaggattgtttcatgaggggagtagagatgaagacgaagagcttgcgagt
ttcttgatggatcggcatataattgttccgagagctgcacatgaaatcttagaccatagcataaccggagcaagagaagctatag
ccgggatgttggacaccaccaagggtctgattagaacaagtatgaagcggggtggcctcacccctcgagtattagcccgcctttc
caattatgattatgaacaattcagatccggaataacattattgacaaagaaagggcagtgttatctcattgacaaggactcgtgc
tcggtgcagctcgctatagccctgagggaccacatgtgggccaggttagctcgcgggagacctatctatgggttggaggtgcctg
atatactggaatcgatgaacggctaccttatcaaacgccatgagtcctgtgccatctgtgaaacgggctcaagtcactacgggtg
gtttttcgtccctgcagggtgccagcttgacgatgtctcaagagagacttcggctcttcgtgtaccttatgtcggatcaaccact
gaggaaaggacagatatgaaacttgctttcgttagatctccaagccgagccctcaaatcagcagtcagaattgccacagtttact
catgggcctacggggatgatgagaaatcatggagtgaagcttggatgctagctaggcagagagctgatatcaccttagatgaatt
gagaatgatcactccagtctctacatccaccaacctagcccatcggttgagggatcggagcacccaggtgaaatattcggggaca
tcccttgtgagggttgcaagatacacaaccatctccaatgacaatttgtcatttgtgatatctgagaaaaaagtagataccaact
tcatttaccagcaagggatgctgctcggtcttgggatccttgagaatctcttcagattagaggccaccacaggggtatccaacac
agtgctacacctacacgtggaaacagaatgttgtgttgtacccatggttgatcacccaaggataccgagtctccgtaatattaaa
gttacgaatgagctatgcacaaaccctctgatctacgacaggtcccccatcatagaacacgatgcaactcgattatactcacaaa
gccacaggagacatttggtggagtttgttacctggtcaacaagccagctttatcatatactggccaaatctacagcaatgtccat
gattgagttgatcacaagatttgagaaagatcacatgaatgaaatagccgccctgattggcgatgacgacatcaacagtttcatc
acagaatttttgctagtagagcccagattgtttatagtttaccttggccagtgtgctgccatcaattgggcttttgatatacatt
atcatcggccctcggggaagtaccagatgggggaactcctctactccttactctctcggatgagcaaaggagtatataagatctt
cactaatgctctgagtcaccctaaagtttacaagaaattttggcgaagtggtgtaattgagccgattcatggcccatccctagat
acacagaatttacatgtcactgtctgtgacatgatatacggatcatacgtcacctatctggatcttttgctgaatgatgagctag
atgattacccgtatttgctctgcgagagtgatgaggacgtggtcacagacaggttcgacaacattcaagccaaacatctctgtgt
actggccgatgtctactgcagctccaagagatgtccctcgatcatcgggatgtctcctatagaaaaatgcaccatcctcacacat
tacatcaagggagaatcggtacaatccccgtccgggatctcatggaacactgatccccttgtagtagatcattactcatgctctc
tgacctaccttcgccgcggttccatcaaacaaatcaggttgagagtggatcctgggtttgtattcgaggcgttgacagacatcga
cttcaaacagcctcgcaaggctaagttggatgtatcggttgtggggttgactgatttttctcccccttgggataacgtcggtgat
tttctagggactatcaacacattgaggcacaatctgcccgtcaccggaaccggggtctcgaactatgaagtccacgcttatcgta
gaatcggcctgaattcatcagcatgttataaagctgtagagatctccacgttaatcaagtcatctttagaagtcggagagaatgg
gttgttcttaggagaaggttccggttctatgctggctgcgtacaaggaagttcttaaattggcaaactgttattacaacagcggg
gtaacagcggagggcagagccggacagagggaaatctctccctatccctcagagatgagcctagtagagaatcagatggggatag
agaggagtgttaaagtgctgttcaatggcaaacctgaagtaacctgggtagggaccaccgattgctacaagtatataatcagtaa
cattcagacctctagtctgggtttcatacactcggatattgagacactcccaaccaaggatgccgttgagaagttagaagaattt
gcctctatcctatccctatccctaattttgggaaaaatcggctctattacagttgtcaaaattatgcccattagcggagatttta
cccaaggcttcatagcctatgccattcaatattttagagagagcctgcttgcctacccgagatatagtaacttcatctcgactga
gtgttaccttattatgataggattaaaggccaatcggttgataaacccagaagccattaagcaaagcataatcagagtggggact
aggactgcaccaggacttgtgagccacatattatcagagaaacagaaaggttgtattcaatcttttctgggtgatccttatatcc
233 
 
aaggagacttcaataagcaccttaaagctctaacccctattgagaaaatcctagtaaattgtggtctctcgatcaatggcacaaa
aatctgtagggatctaatccaccatgatatcgcctccggtccagacggtctgatgagctccacaattattttgtatagggaactg
gcccatttcaaagacaatataagaagtcagcacggtatgttccacccctatccagtattggccagtagcaggcaacgtgaattaa
tccttcgaatagccaagaaattctgggggtatgtcttgctatattcagatgacccggcactaatcaaacaaacgatcaagaactt
gaagcggaatcacctaacctttgacttacacagtaatccgtttattaagggcttatccaaagctgagaaactgctagtgcggaca
agttcactcagaagggaatggttgttcactctcaatacgaaagaagtgaaagagtggttcaaattggtgggttacagtgcactcg
tcagaggttaaatcgatatacatctgcccccttctcctccgccatgagactctactggcaatctaaaagattaaagaaaactaca
tattggataagtatctattcccagctttgtctggtggccggcatggtcccagcctcctcgctggcgccggctgggcaacattccg
aggggaccgtcccctcggtaatggcgaatgggacgatgcagcccaagctgatccggctgctaacaaagcccgaaaggaagctgag
ttggctgctgccaccgctgagcaataactagcataaccccttggggcctctaaacgggtcttgaggggttttttgctgaaaggag
gaactatatccggatcgaattgatccggctgctaacaaagcccgaaaggaagctgagttggctgctgccaccgctgagcaataac
tagcataaccccttggggcctctaaacgggtcttgaggggttttttgcccccactgtcattagcaactccttgtccttcgatctc
gtcaacaacagcttgcagttcaaatacaagacccagaaggcgactattctggaagcgagcttgaagaaattgattccggcctggc
aattcaccatcatcccatacaatggccagaagcatcagtctgacatcaccgacattgtttcgtatagcgtgcaattagaattgga
tcgcttatccgggcgcgcggccgatggcgcaagctccatgacgcggctagacatgcacgaccagggctacaatgaactcgaaacg
accggggcgcgctcggcctagagatccgtactgtactttgttgttcaattggcgcatagcggccgtttgggtcttacggtcccca
ctagaggcccggcctagagaataggaacttccctatagagtcgaataagggcgacaccccctaattagcccgggcgaaaggccca
gtctttcgactgagcctttcgttttatttgatgcctggcagttccctactctcgcatggggagtccccacactaccatcggcgct
acggcgtttcacttctgagttcggcatggggtcaggtgggaccaccgcgctactgccgccaggcaaacaaggggtgttatgagcc
atattcaggtataaatgggctcgcgataatgttcagaattggttaattggttgtaacactgacccctatttgtttatttttctaa
atacattcaaatatgtatccgctcatgagacaataaccctgataaatgcttcaataatattgaaaaaggaagaatatgagccata
ttcaacgggaaacgtcgaggccgcgattaaattccaacatggatgctgatttatatgggtataaatgggctcgcgataatgtcgg
gcaatcaggtgcgacaatctatcgcttgtatgggaagcccgatgcgccagagttgtttctgaaacatggcaaaggtagcgttgcc
aatgatgttacagatgagatggtcagactaaactggctgacggaatttatgccacttccgaccatcaagcattttatccgtactc
ctgatgatgcatggttactcaccactgcgatccccggaaaaacagcgttccaggtattagaagaatatcctgattcaggtgaaaa
tattgttgatgcgctggcagtgttcctgcgccggttgcactcgattcctgtttgtaattgtccttttaacagcgatcgcgtattt
cgcctcgctcaggcgcaatcacgaatgaataacggtttggttgatgcgagtgattttgatgacgagcgtaatggctggcctgttg
aacaagtctggaaagaaatgcataaacttttgccattctcaccggattcagtcgtcactcatggtgatttctcacttgataacct
tatttttgacgaggggaaattaataggttgtattgatgttggacgagtcggaatcgcagaccgataccaggatcttgccatccta
tggaactgcctcggtgagttttctccttcattacagaaacggctttttcaaaaatatggtattgataatcctgatatgaataaat
tgcagtttcatttgatgctcgatgagtttttctaaaagctt 
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